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General Protocol 
 
 
 
1. 1H NMR spectra were recorded on Bruker avance II 400 MHz NMR 
spectrometer using TMS as an internal reference.  
 
2. Mass spectra were recorded on GC-MS QP-2010 spectrometer. 
 
3. IR spectra were recorded on Schimadzu FR-IR-8400 spectrometer. 
 
4. Elemental analysis was carried out on Vario EL III Carlo Erba 1108. 
 
5. Thin layer chromatography was performed on Silica Gel (Merck 60 F254). 
 
6. The chemicals used for the synthesis of compounds were purchased from 
Spectrochem, Merck, Thomas-baker and SD fine chemical. 
 
7. MPs were taken in open capillary and are uncorrected. 
 
8. Microwave assisted reaction were carried out in QPro-M microwave 
synthesizer.  
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1.1 Biginelli Reaction 
 
P. Biginelli reported the synthesis of functionalized 3,4-dihydropyrimidin-(1H)-ones 
(DHPMs) via three component condensation reactions of an aromatic aldehyde, urea, and 
ethyl acetoacetate. In the past decade, this multicomponent reaction has experienced a 
remarkable revival, mainly due to the interesting pharmacological properties associated with 
this dihydropyrimidine scaffold.1  
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Biginelli Dihydropyrimidine Synthesis 
 
The reaction was carried out by simply heating a mixture of the three components dissolved 
in ethanol with a catalytic amount of HCl at reflux temperature. The product of this novel 
one-pot, three-component synthesis that precipitated on cooling of the reaction mixture was 
identified correctly by Biginelli as 3,4-dihydropyrimidin-2(1H)-one. Apart from a series of 
publications by the late Karl Folkers in the mid 1930s, the “Biginelli reaction” or “Biginelli 
Chapter 1 
Synthesis and characterization of novel n-butyl 6-
methyl-4-phenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-
5-carboxylate derivatives using conventional method 
and microwave synthetic approach under solid support  
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condensation” as it was henceforth called was largely ignored in the early part of the 20th 
century. The synthetic potential of this new heterocycle synthesis therefore remained 
unexplored for quite some time. In the 1970s and 1980s, interest slowly increased, and the 
scope of the original cyclocondensation reaction was gradually extended by variation of all 
three building blocks, allowing access to a large number of multifunctionalized 
dihydropyrimidines.2-4   
 
1.2 Mechanistic Studies of Biginelli Reaction 5-9 
 
The mechanism of the Biginelli reaction has been the subject of some debate over the past 
decades. Early work by Folkers and Johnson suggested that bisureide, i.e. the primary 
bimolecular condensation product of benzaldehyde and urea, is the first  
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intermediate in this reaction. In 1973, Sweet and Fissekis proposed a different pathway and 
suggested that carbenium ion, produced by an acid-catalyzed aldol reaction of benzaldehyde 
with ethyl acetoacetate, is formed in the first and limiting step of the Biginelli condensation. 
Kappe et al reinvestigated the mechanism in 1997 using 1H/13C NMR spectroscopy and 
trapping experiments and have established that the key step in this sequence involves the 
acid-catalyzed formation of an N-acyliminium ion intermediate from the aldehyde and urea 
precursors. Interception of the iminium ion by ethyl acetoacetate, presumably through its enol 
tautomer, produces an open-chain ureide which subsequently cyclizes to 
 3
hexahydropyrimidine. Acid-catalyzed elimination of water ultimately leads to the final 
DHPM product. The reaction mechanism can therefore be classified as an R-amidoalkylation, 
or more specifically as an R-ureidoalkylation. The alternative “carbenium ion mechanism” 
does not constitute a major pathway; however, small amounts of enone are sometimes 
observed as byproduct. Although the highly reactive N-acyliminium ion species could not be 
isolated or directly observed, further evidence for the proposed mechanism was obtained by 
isolation of intermediates, employing sterically bulky or electron-deficient acetoacetates 
respectively. The relative stereochemistry in hexahydropyrimidine was established by an X-
ray analysis. In fact, a number of hexahydropyrimidines could be synthesized by using 
perfluorinated 1,3-dicarbonyl compounds or α-keto esters as building blocks in the Biginelli 
condensation. 
 
1.3 Alternative synthetic routes for better yield, 
shorter reaction time and to synthesize new 
analogs  
 
 
Various modifications have been applied to Biginelli reaction to get better yield and to 
synthesize biologically active analogs. Different catalysts have been reported to increase the 
yield of the reaction. Microwave synthesis strategies have also applied to shorten the reaction 
time. Solid phase synthesis and combinatorial chemistry has made possible to generate 
library of DHPM analogs.  
 
1.3.1 Catalysts  
 
Essa H. Hu et al reported Biginelli reaction catalyzed with BF3OEt2, transition metal salt, and 
proton source to yield 80-90% Biginelli product. We propose a mechanism similar to that of 
Folkers and Johnson and to that of Kappe for the Biginelli reaction wherein formation of acyl 
imine intermediate  formed by reaction of the aldehyde with urea and stabilized by either BF3 
or the transition metal, is the key, rate limiting step. Subsequent addition of the α-keto ester 
enolate, followed by cyclization and dehydration, would afford the dihydropyrimidinone.10  
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Brindaban C. Ranu et al reported Indium (III) Chloride as an efficient catalyst for Biginelli 
reaction. A wide range of structurally varied α-dicarbonyl compound, aldehyde and urea were 
coupled together by this procedure to produce the corresponding dihydropyrimidinones. A 
variety of substituted aromatic, aliphatic, and heterocyclic aldehydes have been subjected to 
this condensation very efficiently. Thiourea has been used with similar success to provide the 
corresponding dihydropyrimidin-2(1H)-thiones.11 
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Bose et al used CeCl3 as a catalyst and reported solvent free synthesis of Biginelli compounds 
using this new catalyst. This procedure provides higher yield, shorter reaction time and 
simple work up methods. Solvent free reactions using this catalyst gave about 70% yield and 
reaction time was about 10 hrs. If ethanol is used as solvent, 90% yield was obtained with 
this catalyst. 25 mol % amount of CeCl3.7H2O was found to be sufficient to push the reaction 
forward. The increased amount did not build further advantage.12 
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Enantioselective one pot synthesis of Biginelli reaction is reported with use of lanthanide 
triflates ytterbium triflates.  These catalyst leads to highly enantioselectivity and up to 99% 
enantioselective Biginelli reaction can be carried out.13 
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Entry Ar R X Yield, % ee, % Config. 
1 C6H5 Et O 87 90 R 
2 C6H5 Et S 81 99 R 
3 3-(NO2)-C6H4 iPr O 90 >99 R 
4 3-(NO2)-C6H4 iPr S 88 87 R 
5 3-(F)-C6H4 Et O 80 97 R 
6 2-(Cl)-C6H4 Et S 73 98 R 
7 2-(Cl)-C6H4 Et O 78 89 R 
8 2-(Br)-C6H4 Et O 82 95 R 
9 3-(OH)-C6H4 Et O 81 91 R 
10 3-(OH)-C6H4 Et S 80 99 R 
11 2-(OH)-C6H4 Et O 86 98 R 
12 
 
Et O 81 80 R 
13 
 
Et O 82 82 R 
14 
O  
Et O 87 93 R 
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entry Lewis acid solvent yield, % ee, % config. 
1 La(OTf)3 THF 83 81 R 
2 Sm(OTf)3 THF 81 85 R 
3 Yb(OTf)3 THF 87 90 R 
4 Yb(OTf)3 CH2Cl2 80 83 R 
5 Yb(OTf)3 CH3CN 86 82 R 
6 Yb(OTf)3 CH3OH 88 80 R 
7 Yb(OTf)3 THF 84 85 R 
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Very recently, chiral phosphoric acid is reported as highly enantioselective catalyst for 
Biginelli reaction. Reaction is reported in presence of 10 mol % of chiral phosphoric acid to 
produce desired enantioselective product. This is the first organocatalytic asymmetric 
Biginelli reaction. The optimal chiral phosphoric acid afforded the reaction in high yields 
with excellent enantioselectivities of up to 97% ee. A wide variety of substrates, including 
aldehydes and α-keto esters, could be tolerated. This reaction has an advantage of avoiding 
the contamination of transition metals in the manufacture of the medicinally relevant chiral 
3,4-dihydropyrimidin-2-(1H)-ones.14 
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Recently Jiang and Chen reported Yb(III)-Resin catalyzed Biginelli reaction Under Solvent-
free Conditions.15 
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Heravi et. al. recently reported synthesis of dihydropyrimidones using 12-molybdophosphoric 
acid in refluxing acetic acid to catalyze this three-component condensation reaction to afford 
the corresponding pyrimidinones in good yields.16 
 
An improved approach has been found to carry out the Biginelli reaction for the synthesis of 
3,4- dihydropyrimidine- 2(1H)-one derivatives. This synthesis was performed in the presence 
of hydrochloric acid and β-cyclodextrin in ethanol solution. Compared with the classical 
Biginelli reaction conditions, this new approach has the advantage of excellent yields and 
short reaction time.17   
 
 8
An efficient synthesis of 3,4-dihydropyrimidinones from the aldehyde, β-keto ester and urea 
in ethanol, using ferric chloride hexahydrate or nickel chloride hexahydrate as the catalyst, is 
described. Compared with the classical Biginelli reaction conditions, this new method has the 
advantage of excellent yields (53-97%) and short reaction time (4-5 hours).18  
 
5-Alkoxycarbonyl-4-aryl-3,4-dihydropyrimidin-2-ones are synthesized by the one-pot 
reactions of aldehydes, β-ketoesters and urea using a catalytic amount of phosphotungstic 
acid (PTA) in ethanol. The modified Biginelli cyclocondensation not only shortens the 
reaction period and simplifies the operation, but also improves the yields.19 
Ruthenium (III) chloride efficiently catalyzes the three-component Biginelli reaction of an 
aldehyde, a β-keto ester, and urea or thiourea under solvent-free conditions to afford the 
corresponding 3,4-dihydropyrimidine-2-(1H)-ones in excellent yields.20 
The Biginelli reaction, a one-pot condensation of aldehydes, urea or thiourea, and -
dicarbonyl compounds, is efficiently catalyzed by samarium diiodide. The biologically active 
dihydropyrimidinones are easily synthesized in moderate to excellent yields under solvent-
free conditions.21 
Hydroxyapatite doped with ZnCl2, CuCl2, NiCl2 and CoCl2 efficiently catalyses the three 
components Biginelli reaction between an aldehyde, ethyl acetoacetate and urea in refluxing 
toluene to afford the corresponding dihydropyrimidinones in high yields.22 
Sc(III)triflate efficiently catalyzes the three-component condensation reaction of an aldehyde, 
a β-ketoester, and urea in refluxing acetonitrile to afford the corresponding 3,4-
dihydropyrimidin-2(1H)-ones in excellent yields. The catalyst can be recovered and reused, 
making this method friendly and environmentally acceptable.23 
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Shailaja et al have demonstrated experimentally a simple and straightforward protocol 
(combination system of SnCl2–LiCl) which provides dihydropyrimidin-2-one system in high 
yield and high purity while retaining the simplicity of the Biginelli concept.24 
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Magnesium bromide efficiently catalyzes the three-component condensation reaction of 
aldehyde, β-diketone and urea/thiourea under solvent free conditions to afford the 
corresponding dihydropyrimidinones in high yields and short reaction time.25  
R2 CHO
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Bismuth nitrate pentahydrate catalyzes the three component condensation reaction of an 
aromatic aldehyde, urea and a β-ketoester or a β-diketone under solvent-free conditions to 
afford the corresponding dihydropyrimidinones (DHPMs) in high yields. The present method 
is also effective for the selective condensation of aryl aldehydes in the presence of aliphatic 
aldehydes.26 
NO2
CHO
CHO Bi(NO3)3 . 5H2O (0.1 mmol)
Urea, Ethylacetoacetate
Reflux, 35 min.
NO2
N
H
NH
O
EtO
O
N
H
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O
EtO
O
78 % 0 %
+ +
 
 
Sharma et al reported a simple, efficient, mild and green method has been developed for the 
synthesis of 3,4-dihydropyrimidin-2-ones employing dodecyl sulfonic acid as an excellent 
surfactant-type Bronsted acid catalyst in aqueous media at room temperature.27  
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Yadav et al reported that Ceric ammonium nitrate efficiently catalyzes the three component 
Biginelli reaction in methanol to afford the corresponding dihydropyrimidinones in excellent 
yields under sonication.28a 
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More recently, copper (II) sulfamate,28b ferric perchlorate,28c alumina-supported 
trifluoromethane sulfonic acid,28d Al2O3/MeSO3H,28e cellulose sulfuric acid28f and CsF-
Celite28g were reported as an efficient catalyst for one-pot Biginelli reaction. 
 
 
1.3.2 Solid Phase Synthesis  
 
 
Solid-phase organic synthesis (SPOS) exhibits several advantages compared with classical 
protocols in solution. Reactions can be accelerated and driven to completion by using a large 
excess of reagents, as these can easily be removed by filtration and subsequent washing of the 
solid support. In addition, SPOS can easily be automated by using appropriate robotics and 
applied to “split-and-mix” strategies, useful for the synthesis of large combinatorial 
libraries29-30 
 
A study published in 2001 demonstrated that high temperature microwave heating (200 8C) 
can be effectively employed to attach aromatic carboxylic acids to chloromethylated 
polystyrene resins (Merrifield and Wang) by the cesium carbonate method. Significant rate 
accelerations and higher loadings were observed when the microwave-assisted protocol was 
compared to the conventional thermal method. Reaction times were reduced from 12–48 
hours with conventional heating at 80 ºC to 3–15 minutes with microwave heating at 200 ºC 
in NMP in open glass vessels31-32. 
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Kappe et al33 have reported microwave assisted synthesis of bicyclic systems derived from 
Biginelli DHPM derivatives.  
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In recent years, various methods have been examined for the synthesis of DHPM on solid 
phase. Li and Lam describe a convenient traceless solid-phase approach to synthesize3,4-
dihydropyrimidine-2-ones. Key steps in the synthesis are (i) sulfinate acidification, (ii) 
condensation of urea or thiourea with aldehydes and sulfinic acid, and (iii) traceless product 
release by a one-pot cyclization-dehydration process. Since a variety of reagents can be used 
in steps (ii) and (iii), the overall strategy appears to be applicable to library generation.34 
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Very recently, Gross et al developed a protocol for based on immobilized α-ketoamides to 
increase the diversity of DHPM. The resulting synthetic protocol proved to be suitable for the 
preparation of a small library using different building blocks. They found that the expected 
DHPM derivatives were formed in high purity and yield if aromatic aldehyde- and α-
ketoamide building blocks were used. The usage of an aliphatic aldehyde leads to an isomeric 
DHPM mixture. Purities and yields were not affected if thiourea was used instead of urea.35 
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Lusch et al reported a direct, Lewis acid-catalyzed Biginelli synthesis of 3,4-
dihydropyrimidinones on high-capacity polystyrene macrobeads with a polymer O-silyl-
attached N-(3-hydroxypropyl)urea. Resin-urea was first reacted separately with either 4-
bromo- or 4-chlorobenzaldehyde or LiOTf in MeCN at 80 °C. After washing, the beads were 
pooled and reacted with ethyl acetoacetate and LiOTf in MeCN at 80 °C. Formation of only 
one kind of Biginelli product per bead demonstrated the feasibility of a solid-phase non-
Atwal two-step split-and-pool synthesis of 3,4-dihydropyrimidinones.36  
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1.3.3 Microwave assisted synthesis  
 
The major limitations of Biginelli reaction are lower yield and longer reaction time. When 
thiourea is used for synthesis, yield obtained is very low and reaction completion takes longer 
time. Similar disadvantages are observed when different 1,3-diketone and aldehyde other 
than aromatic are used for the synthesis of designed molecules. Moreover, product separation 
and work up also cause problem and needed special techniques. Thus, three main 
disadvantages are lower yield, longer reaction time and work up in Biginelli reaction when 
different building blocks are used to synthesize library of compound. 
The use of microwave as energy source in organic synthesis for better yield and 
shorter reaction time has been extensively investigated.37-42 Most of the early pioneering 
experiments in MAOS were performed in domestic, sometimes modified, kitchen microwave 
ovens; the current trend is to use dedicated instruments which have only become available in 
the last few years for chemical synthesis. The number of publications related to MAOS has 
therefore increased dramatically since the late 1990s to a point where it might be assumed 
that, in a few years, most chemists will probably use microwave energy to heat chemical 
reactions on a laboratory scale. Not only is direct microwave heating able to reduce chemical 
reaction times from hours to minutes, but it is also known to reduce side reactions, increase 
yields, and improve reproducibility. Therefore, many academic and industrial research groups 
are already using MAOS as a forefront technology for rapid optimization of reactions, for the 
efficient synthesis of new chemical entities, and for discovering and probing new chemical 
reactivity. A large numbers of review articles provide extensive coverage of the subject.43-48 
Microwave-enhanced chemistry is based on the efficient heating of materials by “microwave 
dielectric heating” effects. This phenomenon is dependent on the ability of a specific material 
(solvent or reagent) to absorb microwave energy and convert it into heat. The electric 
component of an electromagnetic field causes heating by two main mechanisms: dipolar 
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polarization and ionic conduction. Irradiation of the sample at microwave frequencies results 
in the dipoles or ions aligning in the applied electric field. As the applied field oscillates, the 
dipole or ion field attempts to realign itself with the alternating electric field and, in the 
process, energy is lost in the form of heat through molecular friction and dielectric loss. The 
amount of heat generated by this process is directly related to the ability of the matrix to align 
itself with the frequency of the applied field. If the dipole does not have enough time to 
realign, or reorients too quickly with the applied field, no heating occurs. The allocated 
frequency of 2.45 GHz used in all commercial systems lies between these two extremes and 
gives the molecular dipole time to align in the field, but not to follow the alternating field 
precisely.49-50 
The heating characteristics of a particular material (for example, a solvent) under 
microwave irradiation conditions are dependent on its dielectric properties. The ability of a 
specific substance to convert electromagnetic energy into heat at a given frequency and 
temperature is determined by the so-called loss factor tanδ. This loss factor is expressed as 
the quotient tanδ=e’’/e’, where e’’ is the dielectric loss, which is indicative of the efficiency 
with which electromagnetic radiation is converted into heat, and e’ is the dielectric constant 
describing the ability of molecules to be polarized by the electric field. A reaction medium 
with a high tanδ value is required for efficient absorption and, consequently, for rapid 
heating.51 
 
 
 
 
 
 
 
 
 
 
In general, the standard procedure for the Biginelli condensation involves one-pot 
condensation of the three building blocks in a solvent such as ethanol using a strongly acidic 
catalyst, that is, hydrochloric acid. One major drawback of this procedure, apart from the long 
reaction times involving reflux temperatures, are the moderate yields frequently observed 
when using more complex building blocks. Kappe et al recently described a high yielding and 
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rapid microwave-assisted protocol that allows the synthesis of gram quantities of DHPMs 
utilizing controlled single-mode microwave irradiation. As the first model reaction for our 
scale-up experiments, they selected the standard Biginelli cyclocondensation, where in a one-
pot process equimolar amounts of benzaldehyde, ethyl acetoacetate, and urea react under 
Lewis acid (FeCl3) catalysis to the corresponding dihydropyrimidine. Utilizing single-mode 
microwave irradiation, the reaction can be carried out on a 4.0 mmol scale in AcOH/EtOH 
3:1 at 120 °C within 10 min, compared to 3-4 h using conventional thermal heating, 
providing DHPM in 88% isolated yield and high purity (>98%).52  
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Dihydropyrimidines were synthesised in high yields by one-pot cyclocondensation reaction 
of aldehydes, acetoacetates and urea using various acid catalysts like Amberlyst-15, Nafion-
H, KSF clay and dry acetic acid under microwave irradiation.53 
 
The antimony (III) chloride impregnated on alumina efficiently catalyses a one-pot, three-
component condensation reaction among an aldehyde, a β-ketoester, and urea or thiourea to 
afford the corresponding dihydropyrimidinones in good to excellent yields. The reactions are 
probed in microwave (MW), ultrasonic, and thermal conditions and the best results are found 
using MW under solvent-free conditions.54 
Cupric chloride dihydrate catalyzes the three-component Biginelli condensation between an 
aldehyde, a β-ketoester and urea or thiourea under microwave irradiation in the absence of 
solvent to yield various substituted 3,4-dihydropyrimidin-2(1H)-ones. The reaction is also 
effective when performed at room temperature in acetonitrile or at 100 °C in a solvent free 
approach, without any side reactions as observed by Biginelli and others.55  
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The publications by Gupta56 and Dandia57 describe 26 examples of microwave-enhanced 
solution-phase Biginelli reactions employing ethyl acetoacetate, (thio)ureas  (X O, S), and a 
wide variety of aromatic aldehydes as building blocks. Upon irradiation of the individual 
reaction mixtures (ethanol, catalytic HCl) in an open glass beaker inside the cavity of a 
domestic microwave oven the reaction times were reduced from 2–24 hours of conventional 
heating (80 ºC, reflux) to 3–11 minutes under microwave activation (ca. 200–300 W). At the 
same time the yields of DHPMs obtained by the authors were markedly improved compared 
to those reported earlier using conventional conditions.  
 
Kappe reinvestigated above reactions using a purpose-built commercial microwave reactor 
with on-line temperature, pressure, and microwave power control. Transformations carried 
out under microwave heating at atmospheric pressure in ethanol solution show no rate or 
yield increase when the temperature is identical to conventional thermal heating. In the case 
of superheating by microwave irradiation at atmospheric pressure the observed yield and rate 
increases are rationalized as a consequence of a thermal (kinetic) effect. Under sealed vessel 
conditions (20 bar, 180 ºC) the yield of products is decreased and formation of various 
byproducts observed. The only significant rate and yield enhancements are found when the 
reaction is performed under “open system” conditions where the solvent is allowed to rapidly 
evaporate during microwave irradiation. However, the observed rate and yield enhancements 
in these experiments are a consequence of the solvent-free conditions rather than caused 
specifically by microwave irradiation. This was confirmed by control experiments of the 
solvent less Biginelli reaction under microwave and thermal heating.58a 
 
N. Foroughifar et al had reported some tert-Butyl-6-methyl-4-phenyl-2-oxo-1,2,3,4-
tetrahydro Pyrimidine-5-carboxylate derivatives by microwave irradiation using 
polyphosphate ester (PPE) as a reaction moderator in ceramic bath.58b 
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1.3.4 Ionic liquid  
Wang et al reported the Biginelli reaction between an aromatic aldehyde, ethyl acetoacetate, 
and urea - catalyzed by polymer-supported, re-usable, room-temperature ionic liquids (RTIL) 
was shown to efficiently proceed in glacial AcOH at 100°C to afford the corresponding 
pyrimidine-5-carboxylates in yields up to 99% within 2 h. The catalyst(s) could be reused at 
least five times, basically without loss of activity, which makes this transformation not only 
straight-forward, but also considerably less expensive compared to methods involving 
classical RTIL catalysts.59 
 
1.4 Reported dihydropyrimidones bearing versatile 
biological activities  
4-Aryl-1,4-dihydropyridines (DHPs, e.g. nifedipine, ) are the most studied class of organic 
calcium channel modulators. More than 30 years after the introduction of nifedipine many 
DHP analogs have now been synthesized and numerous second-generation commercial 
products have appeared on the market.60, 61  
 
In recent years interest has also focused on aza-analogs such as dihydropyrimidines (DHPMs) 
which show a very similar pharmacological profile to classical dihydropyridine calcium 
channel modulators.62-69 Over the past few years several lead-compounds were developed 
(i.e. SQ 32,926) that are superior in potency and duration of antihypertensive activity to 
classical DHP drugs, and compare favorable with second-generation analogs such as 
amlodipine and nicardipine.70 
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Barrow et al reported in vitro and in vivo Evaluation of Dihydropyrimidinone C-5 Amides as 
Potent and Selective r1A Receptor Antagonists for the Treatment of Benign Prostatic 
Hyperplasia. R1 Adrenergic receptors mediate both vascular and lower urinary tract tone, and 
R1 receptor antagonists such as terazosin are used to treat both hypertension and benign 
prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been 
identified, with the R1A receptor being most prevalent in lower urinary tract tissue. Barrow et 
al reported 4-aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C-
5 amide as selective R1A receptor subtype antagonists. In receptor binding assays, these 
types of compounds generally display Ki values for the R1a receptor subtype <1 nM while 
being greater than 100-fold selective versus the R1b and R1d receptor subtypes. Many of 
these compounds were also evaluated in vivo and found to be more potent than terazosin in 
both a rat model of prostate tone and a dog model of intra-urethral pressure without 
significantly affecting blood pressure. While many of the compounds tested displayed poor 
pharmacokinetics, one compound was found to have adequate bioavailability (>20%) and 
half-life (>6 h) in both rats and dogs. Due to its selectivity for the R1a over the R1b and R1d 
receptors as well as its favorable pharmacokinetic profile, it has the potential to relieve the 
symptoms of BPH without eliciting effects on the cardiovascular system.71-75 
 
 
 
 
 
 
 
 
The 4-aryldihydropyrimidinone heterocycle attached to an aminopropyl-4-arylpiperidine via 
a C-5 amide has proved to be an excellent template for selective R1A receptor subtype 
antagonists. These types of compounds are exceptionally potent in both cloned receptor 
binding studies as well as in in vivo pharmacodynamic models of prostatic tone. 
 
Compounds exhibited high binding affinity and subtype selectivity for the cloned human R1a 
receptor. Systematic modifications led to identification of highly potent and subtype-selective 
compounds with high binding affinity (Ki ) 0.2 nM) for R1a receptor and greater than 1500-
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fold selectivity over R1b and R1d adrenoceptors. The compounds were found to be functional 
antagonists in human, rat, and dog prostate tissues. They exhibited excellent selectively to 
inhibit intraurethral pressure (IUP) as compared to lowering diastolic blood pressure (DBP) 
in mongrel dogs (Kb(DBP)/Kb(IUP))suggesting uroselectivity for R1a-selective 
compounds.76 
 
 
 
 
 
 
 
Cho et. al. reported 3-N-substituted-3,4-dihydropyrimidine and 3-N-substituted-
dihydropyrimidin-2(1H)-ones  as calcium channel antagonist. Compounds [especially  
[R1=(CH2)2N(benzyl)(2-naphthylmethyl) R2= i-Pr, X=o-N02] and [R'= (CH2)2N(benzyl)(3,4-
dichlorobenzyl) R2= i-Pr, X=o-NO2]] exhibited not only more potent and longer lasting 
vasodilative action but also a hypertensive activity with slow onset as compared with 
dihydropyridines. Moreover, some dihydropyrimidines [R' =(CH2)2N(benzyl)(3-
phenylpropyl), R2 = CH2(cyclopropyl), X = o-NO2] were weaker in blocking atrioventricular 
conduction in anesthetized open-chest dogs and less toxic than the dihydropyridines.77 
 
 
 
 
 
 
Atwal et al examined a series of novel dihydropyrimidine calcium channel blockers that 
contain a basic group attached to either C5 or N3 of the heterocyclic ring. Structure-activity 
studies show that  l-(phenylmethyl)-4-piperidinyl carbamate moiety at N3 and sulfur at C2 are 
optimal for vmrelaxant activity in vitro and impart potent and long-acting antihypertensive 
activity in vivo. One of theae compounds was identified as a lead, and the individual 
enantiomers were synthesized. Two key steps of the synthesis were (1) the efficient 
separation of the diastereomeric ureido derivatives and (2) the high-yield transformation of 2-
methoxy intermediate to the (p-methoxybenzy1)thio intermediates. Chirality was 
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demonstrated to be a significant determinant of biological activity, with the dihydropyridine 
receptor recognizing the enamino ester moiety but not the carbamate moiety. 
Dihydropyrimidine is equipotent to nifidepine and amlodipine in vitro. In the spontaneously 
hypertensive rat, dihydropyrimidine is both more potent and longer acting than nifidepine and 
compares most favorably with the long-acting dihydropyridine derivative amlodipine. 
Dihydropyrimidine has the potential advantage of being a single enantiomer.78 
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In order to explain the potent antihypertensive activity of the modestly active (ICw = 3.2 pM) 
dihydropyrimidine calcium channel blocker, Atwal et al carried out drug metabolism studies 
in the rat and found it is metabolized. Two of the metabolites (ICw = 16 nM) and (ICw = 12 
nM), were found to be responsible for the antihypertensive activity of compound. Potential 
metabolism in vivo precluded interest in pursuing compounds related to it. Structure-activity 
studies aimed at identifying additional aryl-substituted analogues led to comparable potential 
in vivo, though these compounds were less potent in vitro. To investigate the effects of 
absolute stereochemistry on potency, authors resolved via diastereomeric ureas, prepared by 
treatment with (R)-α-methylbenzylamine. The results demonstrate that the active R-(-)-
enantiomer is both more potent and longer acting than nifedipine as an antihypertensive agent 
in the SHR. The in vivo potency and duration is comparable to the long-acting 
dihydropyridine amlodipine. The superior oral antihypertensive activity compared to that of 
previously described carbamates (R2 = COOEt) could be explained by its improved oral 
bioavailability, possibly resulting from increased stability of the urea functionality.79 
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Authors modified the structure of previously described dihydropyrimidine i.e. 3-substituted 
1,4-dihydropyrimidines. Structure- activity studies using potassium-depolarized rabbit aorta 
show that ortho,meta-disubstituted aryl derivatives are more potent than either ortho- or 
meta-monosubstituted compounds. While vasorelaxant activity was critically dependent on 
the size of the C5 ester group, isopropyl ester being the best, a variety of substituents 
(carbamate, acyl, sulfonyl, alkyl) were tolerated at N3. The results show dihydropyrimidines  
are significantly more potent than corresponding 2- heteroalkyl-l,4-dihydropyrimidines and 
only slightly less potent than similarly substituted 2-heteroalkyl-1-4-dihydropyridines. Where 
as dihydropyridine enantiomen usually show 10-15-fold difference in activity, the 
enantiomers of dihydropyrimidine show more than a 1000-fold difference in activity. These 
results strengthen the requirement of an enamino ester for binding to the dihydropyridine 
receptor and indicate a nonspecific role for the N3-substituent. 
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2-Heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5-pyrimidinecarboxylic esters, which lack 
the potential symmetry of dihydropyridine calcium channel blockers, were prepared and 
evaluated for biological activity. Biological assays using potassium-depolarized rabbit aorta 
and radio ligand binding techniques showed that some of these compounds are potent mimics 
of dihydropyridine calcium channel blockers.80 
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1.5 Nanoparticles   
 
 
Nanoparticles are of great scientific interest as they are effectively a bridge between bulk 
materials and atomic or molecular structures. The properties of materials change as their size 
approaches the nanoscale and as the percentage of atoms at the surface of a material becomes 
significant. Nanoparticles exhibit a number of special properties relative to bulk material.  
 
Nanoparticle characterization is necessary to establish understanding and control of 
nanoparticle synthesis and applications. Characterization is done by using a variety of 
different techniques, mainly drawn from materials science. Common techniques are electron 
microscopy [TEM,SEM], atomic force microscopy [AFM], dynamic light scattering [DLS], 
x-ray photoelectron spectroscopy [XPS], powder x-ray diffractometry [XRD], Fourier 
transform infrared spectroscopy [FTIR], Matrix-Assisted Laser-Desorption Time-of-flight 
mass spectrometry [MALDI-TOF], and Ultraviolet-visible spectroscopy. Whilst the theory 
has been known for over a century (see Robert Brown), the technology for Nanoparticle 
tracking analysis (NTA) allows direct tracking of the Brownian motion and this method 
therefore allows the sizing of individual nanoparticles in solution. 
 
Nanoparticles of organic compounds may have interesting applications from pharmaceutical 
application point of view. Nanoparticles are used, nowadays, in some formulations for their 
capacity for drug vacterization, to reduce the amount of drug delivered and hence to reduce 
its secondary effects. 
 
Out of synthesized dihydropyrimidine derivatives in this chapter, the nanoparticles of n-butyl 
4-(3,4-dimethoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate was 
prepared using Microemulsion Technique and their characterization was carried out using 
Transition Electron Microscopy (TEM), powder XRD, TGA and FTIR spectroscopy by Mr. 
Poorvesh M. Vyas (Research Fellow, Department of Physics, Saurashtra University, Rajkot). 
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1.6 Current work   
 
 
Our group is involved in the synthesis of modified 1,4-DHP and DHPM skeleton derivatives 
for last few years. Introduction of n-butyl carboxylic ester moiety at C-5 position in DHPM 
skeleton may show diverse activity profile. Very promising results may obtain with these 
modifications to DHPM skeleton. This concept prompted us to introduce n-butyl carboxylic 
ester at C-5 position in DHPM skeleton. For this modification n-butyl acetoacetate was 
required as a precursor which was obtained by transesterification of ethyl or methyl 
acetoacetate. A few methods for transesterification of β-keto ester are reported in literature.81-
83  
 
In extension of work, the same molecules when synthesized through green chemistry 
approach by utilizing Fuller’s earth as solid support through microwave irradiation technique, 
resulted in formation of all newly synthesized compounds with higher yields and also 
reaction hours are reduced to a great extent in comparison with conventional synthetic 
methods as mentioned in literature. Fuller’s earth is prior coated with ZnCl2, acidic in nature 
which fulfills the requirement of the Biginelli condensation. As a result we found increased 
yield about 10-15% more than conventional method. All newly synthesized compounds were 
characterized by IR, Mass, 1H NMR, 13C NMR spectroscopy and elemental analysis. 
Reaction schemes are illustrated in section 1.7. Scheme 1 and 2 displays the synthesis of n-
butyl acetoacetate by transesterification of ethyl acetoacetate and n-Butyl 6-methyl-4-phenyl-
2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate derivatives. Physical data of all 
synthesized compounds is reported in section 1.10 and spectral data is discussed in section 
1.11. The anti viral screening of the compounds synthesized with this modification to DHPM 
skeleton is under investigation. 
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1.7 Reaction Scheme 
 
1.7.1 Scheme 1.  
 
    Transesterification of ethyl acetoacetate 
 
 
 
 
 
 
1.7.2 Scheme 2.  
 
 
      Synthetic approaches towards dihydropyrimidine 
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1.8 Reaction Mechanism: 
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1.9 Experimental  
 
 
1.9.1  n-Butyl acetoacetate:  
A mixture of ethyl acetoacetate (0.1 M) and n-butyl alcohol (0.11 M) in toluene (50 ml) was 
taken in a round bottom flask provided with a distillation condenser to remove methanol or 
ethanol. Sodium ethoxide (1 mmol) was added to the mixture as a catalyst. The mixture was 
heated at 100-110 °C for 5-6 hrs. After completion of reaction (TLC), the catalyst was 
filtered and the filterate was concentrated to get crude product. n-Butyl acetoacetate was 
distilled off at 92-98 ° C/20 mm Hg. Yellowish viscous oil. 
 
1.9.2 n-Butyl 6-methyl-4-aryl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5- 
         carboxylate:  
Method-1 
A mixture of n-butyl acetoacetate (10 mmol), appropriate aldehyde (10 mmol) and thiourea 
(15 mmol) was dissolved in absolute EtOH (20 mL) and refluxed until clear solution is 
obtained. Few drops of con. HCl were added to reaction mixture as a catalyst  and was 
refluxed for 8-12 hrs. The reaction was monitored with thin layer chromatography and after 
completion of the reaction, the mixture was allowed to cool at room temperature. The solid 
separated was filtered, washed with hot methanol and recrystallized from ethanol. (Yield – 
45-60%).  
 
Method-2 
In 50 ml microwave flask containing 2.5 equivalent of Fuller’s earth, a mixture of n-butyl 
acetoacetate (10 mmol), appropriate aldehyde (10 mmol) and thiourea (15 mmol) was added 
and stirred for 5 minutes to make a homogeneous mixture. It was subjected to microwave 
irradiation (300 W) for 5 - 7 minutes. After cooling at room temperature 50 mL water was 
added to it and extracted with 25 mL CHCl3. The organic phase was separated and washed 
successively with H2O, saturated NaHSO3 solution and H2O until free from unreacted 
aldehyde. After drying over anhydrous Na2SO4, the solvent was removed by vaccuo under 
reduced pressure. The obtained solid was crystallized from EtOH to give a pure compound as 
pale yellow crystals. 
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1.10 Physical data  
 
 
 
 
 
 
Yield % 
Comp. R M.F. M.W. 
Method-1 Method-2 
Rf 
AP-1 H C16H20N2O2S 304.40 60 85 0.48 
AP-2 4-OCH3 C17H22N2O3S 334.43 60 84 0.45 
AP-3 3,4-(OCH3)2 C18H24N2O4S 364.45 62 89 0.41 
AP-4 2,5-(OCH3)2 C18H24N2O4S 364.45 62 85 0.42 
AP-5 2-Cl C16H19ClN2O2S 338.85 52 75 0.54 
AP-6 3-Cl C16H19ClN2O2S 338.85 56 79 0.56 
AP-7 4-Cl C16H19ClN2O2S 338.85 55 79 0.61 
AP-8 3-NO2 C16H19N3O4S 349.40 61 81 0.54 
AP-9 4-NO2 C16H19N3O4S 349.40 59 83 0.48 
AP-10 2-OH C16H20N2O3S 320.40 57 80 0.49 
AP-11 4-OH C16H20N2O3S 320.40 55 78 0.55 
AP-12 4-F C16H19FN2O2S 322.39 50 68 0.50 
AP-13 4-CH3 C17H22N2O2S 318.43 53 70 0.45 
AP-14 4-dimethylamino C18H25N3O2S 347.47 61 78 0.51 
AP-15 [2,3] Benzo C20H22N2O2S 354.46 58 80 0.62 
 
TLC Solvent system: Ethyl acetate : Hexane – 3:7 
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1.11 Spectral discussion 
 
 
1.11.1  Mass spectral study 
 
Instrument                : SHIMADZU GCMS-QP-2010 
Sample technique    : EI technique 
M/z range                  : 40-500 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection 
Probe technique. Systematic fragmentation pattern was observed in mass spectral analysis. 
Peaks for specific fragments were identified in each mass spectrum. Molecular ion peak was 
observed in agreement with molecular weight of respective compound. Mass fragmentation 
for compound AP-1 is discussed below. 
 
Molecular ion peak M+ was observed at 304 and M++1 peak was also observed with very low 
intensity. Then four peaks were observed due to cleavage of alkyl chain at 289, 276, 261 and 
247 as M+-CH3, M+-C2H5, M+-C3H7 and M+-C4H9 respectively as per shown in figure 1. 
Another very intense peak observed at 203 due to cleavage of carboxylic ester group at C-5 
position. After this cleavage another two cleavages occurs at C-4 position with removal of 
methyl group and at C-2 position with removal of sulfur atom which shows the peak at 188 
and 171 respectively. 
 
1.11.2  IR spectral study 
 
Instrument                 : Shimadzu FT-IR-8400 
Sample technique     : KBr pellet 
Frequency range       : 400-4000cm-1 
As per IR spectral study of newly synthesized dihydropyrimidine derivatives, the stretching 
vibration of secondary amine (>NH) appears around 3100-3200 cm-1. The carbonyl (>C=O) 
stretching vibration of ester group is observed around 1700 cm-1. The symmetric and 
asymmetric C-H stretching vibration of methyl and methylene group of alkyl chain was 
observed between 2850-2990 cm-1. Methyl and methylene gives C-H bending vibration 
around 1380 and 1450 cm-1 respectively. The ring skeleton vibration is observed between 
1500-1600 cm-1 due to the presence of phenyl ring system.  
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1.11.3  1H NMR spectral study 
 
Instrument                  : BRUKER AC 400 MHz FT-NMR 
Internal reference       : TMS 
Solvent                        : CDCl3 
 
 
 
 
 
 
 
 
Number of protons and their chemical shifts were found to support the structure of the 
synthesized compounds. Protons of n-butyl chain ‘a’, ‘b’ and ‘c’ were observed at 0.82-0.86 
δ ppm, 1.15-1.25 δ ppm and 1.45-1.55 δ ppm respectively. Protons ‘d’ were observed at 3.96-
4.08 δ ppm due to neighboring attachment of hetero atom. Protons ‘e’ of methyl group 
attached at C-4 position were observed at 2.34-2.35 δ ppm as singlet and very intense peak. 
Asymmetric carbon proton ‘f’ was observed at 5.0-5.9 δ ppm as singlet. Protons ‘h’ and ‘i’ of 
>NH gave singlet peak at 8.0-9.8 δ ppm. The aromatic ring protons ‘g’ were observed at 
6.50-7.80 δ ppm and J value were found according to substitution on phenyl ring.  
 
1.11.4  13C NMR spectral study 
 
Instrument                  : BRUKER AC 400 MHz FT-NMR 
Internal reference       : TMS 
Solvent                        : CDCl3 
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13C NMR spectrum data for compound AP-1 is given below. δ ppm values are listed along 
with corresponding carbon atom number given in bracket and displayed in the structure. 
 
13C NMR δ ppm:  13.66 (C1), 18.29 (C2), 19.12 (C3), 30.54 (C4), 56.12 (C5), 64.34 (C6), 
102.81 (C7), 126.78 (C8), 126.78 (C9), 128.37 (C10), 128.91 (C11), 128.91 (C12), 142.31 
(C13), 143.03 (C14), 165.38 (C15), 174.29 (C16). 
 
1.11.5  Elemental Analysis 
 
Elemental analysis of the all the synthesized compounds was carried out on Elemental Vario 
EL III Carlo Erba 1108 model and the results are in agreements with the structures assigned. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 31
Figure 1. Mass fragmentation of Mass spectrum of n-Butyl 6-methyl-4-
phenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
(AP-1). 
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Spectral data of synthesized compounds (AP 1-15) 
 
n-Butyl 6-methyl-4-phenyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (AP-1) 
Pale-yellow solid; mp 206-208 ˚C; IR (KBr): 1180, 1427, 1456, 1707, 2868, 2976, 3215 cm-
1; 1H NMR (400 MHz, CDCl3): δ ppm = 0.84 (t, 3 H, CH3), 1.20 (m, 2 H, CH2), 1.47 (m, 2 
H, CH2), 2.34 (s, 3 H CH3), 4.02 (m, 2 H, CH2), 5.35 (s, 1 H, CH), 7.29 (m, 5 H, Ph), 8.17 (s, 
1 H, NH), 8.76 (s, 1 H, NH).; 13C NMR (400 MHz, CDCl3): 13.66, 18.29, 19.12, 30.54, 
56.12, 64.34, 102.81, 126.78, 126.78, 128.37, 128.91, 128.91, 142.31, 143.03, 165.38, 
174.29; MS: m/z = 304 (53, [M+]), 247 (95), 227 (100).; Anal. Calcd for C16H20N2O2S: C, 
63.13; H, 6.62; N, 9.20. Found: C, 63.04; H, 6.59; N, 9.15. 
 
n-Butyl 4-(4-methoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (AP-2) 
Pale-yellow solid; mp 186-188 ˚C; IR (KBr): 1462, 1560, 1599, 2877, 2955, 3319 cm-1; 1H 
NMR (400 MHz, CDCl3): δ ppm = 0.85 (t, 3 H, CH3), 1.21 (m, 2 H, CH2), 1.50 (m, 2 H, 
CH2), 2.35 (s, 3 H, CH3), 3.76 (s, 3 H, OCH3), 4.01 (m, 2 H, CH2), 5.28 (s, 1 H, CH), 6.83 (d, 
2 H, Ph), 7.20 (d, 2 H, Ph), 8.91 (s, 1 H, NH), 9.54 (s, 1 H, NH); MS: m/z = 334 (44, [M+]), 
277 (100); Anal. Calcd for C17H22N2O3S: C, 61.05; H, 6.63; N, 8.38. Found: C, 61.17; H, 
6.51; N, 8.32. 
 
n-Butyl 4-(3,4-dimethoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (AP-3) 
Pale-yellow solid; mp 202-204 ˚C; IR (KBr): 1454, 1562, 1602, 2958, 2999, 3282 cm-1; 1H 
NMR (400 MHz, CDCl3): δ ppm = 0.85 (t, 3 H, CH3), 1.21 (m, 2 H, CH2), 1.50 (m, 2 H, 
CH2), 2.35 (s, 3 H, CH3), 3.76 (s, 3 H, OCH3), 3.77 (s, 3 H, OCH3), 4.01 (m, 2 H, CH2), 5.28 
(s, 1 H, CH), 6.74-6.88 (m, 3 H, Ph), 8.91 (s, 1 H, NH), 9.54 (s, 1 H, NH); MS: m/z = 364 
(81, [M+]), 307 (100); Anal. Calcd for C18H24N2O4S: C, 59.32; H, 6.64; N, 7.69. Found: C, 
59.38; H, 6.59; N, 7.62. 
 
n-Butyl 4-(2,5-dimethoxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (AP-4) 
Pale-yellow solid; mp 198-200 ˚C; IR (KBr): 1451, 1538, 1668, 2855, 2957, 3224 cm-1; MS: 
m/z = 364 (M+); Anal. Calcd for C18H24N2O4S: C, 59.32; H, 6.64; N, 7.69. Found: C, 59.30; 
H, 6.57; N, 7.79. 
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n-Butyl 4-(2-chlorophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (AP-5) 
Pale-yellow solid; mp 190-192 ˚C; IR (KBr): 1447, 1588, 1689, 2847, 2976, 3258 cm-1; MS: 
m/z = 338 (M+); Anal. Calcd for C16H19ClN2O2S: C, 56.71; H, 5.65; N, 8.27. Found: C, 
56.60; H, 5.55; N, 8.19. 
 
n-Butyl 4-(3-chlorophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (AP-6) 
Pale-yellow solid; mp 204-206 ˚C; IR (KBr): 1450, 1489, 1694, 2847, 2976, 3285 cm-1; MS: 
m/z = 338 (M+); Anal. Calcd for C16H19ClN2O2S: C, 56.71; H, 5.65; N, 8.27. Found: C, 
56.64; H, 5.58; N, 8.21. 
 
n-Butyl 4-(4-chlorophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (AP-7) 
Pale-yellow solid; mp 214-216 ˚C; IR (KBr): 1478, 1551, 1703, 2865, 2956, 3214 cm-1; MS: 
m/z = 338 (M+); Anal. Calcd for C16H19ClN2O2S: C, 56.71; H, 5.65; N, 8.27. Found: C, 
56.67; H, 5.61; N, 8.20. 
 
n-Butyl 6-methyl-4-(3-nitrophenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (AP-8) 
Yellow solid; mp 190-192 ˚C; IR (KBr): 1416, 1648, 2829, 2960, 3252 cm-1; MS: m/z = 349 
(M+); Anal. Calcd for C16H19N3O4S: C, 55.00; H, 5.48; N, 12.03. Found: C, 54.89; H, 5.39; 
N, 12.08. 
 
n-Butyl 6-methyl-4-(4-nitrophenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (AP-9) 
Yellow solid; mp 202-204 ˚C; IR (KBr): 1528, 1598, 1671, 2812, 2934, 3319 cm-1; MS: m/z 
= 349 (M+); Anal. Calcd for C16H19N3O4S: C, 55.00; H, 5.48; N, 12.03. Found: C, 54.94; H, 
5.43; N, 12.11. 
 
n-Butyl 4-(2-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (AP-10) 
Pale-yellow solid; mp 208-210 ˚C; IR (KBr): 1494, 1507, 1680, 2845, 2981, 3200 cm-1; MS: 
m/z = 320 (M+); Anal. Calcd for C16H20N2O3S: C, 59.98; H, 6.29; N, 8.74. Found: C, 59.91; 
H, 6.33; N, 8.72. 
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n-Butyl 4-(4-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (AP-11) 
Pale-yellow solid; mp 216-218 ˚C; IR (KBr): 1539, 1708, 2921, 2989, 3216 cm-1; MS: m/z 
= 320 (M+); Anal. Calcd for C16H20N2O3S: C, 59.98; H, 6.29; N, 8.74. Found: C, 60.08; H, 
6.39; N, 8.67. 
 
n-Butyl 4-(4-fluorophenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (AP-12) 
Pale-yellow solid; mp 195-197 ˚C; IR (KBr): 1459, 1528, 1572, 1660, 2801, 2937, 3222 cm-
1; MS: m/z = 322 (M+); Anal. Calcd for C16H19FN2O2S: C, 59.61; H, 5.94; N, 8.69. Found: 
C, 59.58; H, 5.87; N, 8.65. 
 
n-Butyl 6-methyl-4-(4-methylphenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate (AP-13) 
Pale-yellow solid; mp 187-189 ˚C; IR (KBr): 1555, 1669, 2850, 2971, 3201 cm-1; MS: m/z 
= 318 (M+); Anal. Calcd for C17H22N2O2S: C, 64.12; H, 6.96; N, 8.80. Found: C, 64.03; H, 
70.11; N, 8.65. 
 
n-Butyl 4-[4-(dimethylamino)phenyl]-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-
5-carboxylate (AP-14) 
Yellow solid; mp 234-236 ˚C; IR (KBr): 1459, 1488, 1659, 2861, 2968, 3281 cm-1; MS: m/z 
= 347 (M+); Anal. Calcd for C18H25N3O2S: C, 62.22; H, 7.25; N, 12.09. Found: C, 62.17; H, 
7.29; N, 12.04. 
 
n-Butyl 6-methyl-4-(1-naphthyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate 
(AP-15) 
Yellow solid; mp 239-241 ˚C; IR (KBr): 1509, 1550, 1667, 2889, 2970, 3217 cm-1; MS: m/z 
= 354 (M+); Anal. Calcd for C20H22N2O2S: C, 67.77; H, 6.26; N, 7.90. Found: C, 67.70; H, 
6.18; N, 7.76. 
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1H NMR spectrum of AP-1 
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13C NMR spectrum of AP-1 
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Mass Spectrum of AP-1 
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Mass Spectrum of AP-3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass Spectrum of AP-15 
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IR spectrum of AP-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR spectrum of AP-2 
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IR spectrum of AP-3 
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2.1 Scaffold decoration of DHPM ring, methods of 
synthesis and their biological profile  
 
In chapter one, importance of DHPM moiety and various modifications applied to Biginelli 
reaction for better yield, shorter reaction time and to synthesize various analogs is surveyed 
in detail. The biological profile of this heterocyclic moiety is also briefly reported in chapter 
one.  
Biginelli reaction is not only important to synthesize analogs of DHPM ring using different 
building block as potent bioactive heterocycles, but also various scaffolds can be synthesized 
from this heterocyclic scaffold.  
 
2.1.1 Various scaffolds derived from DHPMs 
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Synthesis & characterization of n-butyl 3,7-dimethyl-5-
phenyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate 
derivatives  
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As displayed in above figure, it cab be understood that a number of scaffolds can be 
developed from DHPM ring.  
 
2.1.2 N3-Acylated and C5-substituted DHPMs and their biological 
importance  
 
Kappe et al reported that N3-acylated DHPMs can be rapidly synthesized in a highthroughput 
fashion by combining microwave-assisted acylations with microwave-assisted scavenging 
techniques. Scavenging experiments can be carried out employing either supported 
nucleophilic amine sequestration reagents or water2. 
 
N-acylated DHPMs are pharmacologically very important scaffolds as most of bioactive 
DHPMs are N-acylated. N-acylation of DHPM can be performed as shown below.  
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N3-substituted DHPMs have been identified to possess potent pharmacological profiles. 
Following compound exhibited high binding affinity and subtype selectivity for the cloned 
human R1a receptor3.  
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N
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N
Ph
R
O
NO2
 
 
 
Systematic modifications of above compounds led to identification of highly potent and 
subtype-selective compounds with high binding affinity (Ki ) 0.2 nM) for R1a receptor and 
greater than 1500-fold selectivity over R1b and R1d  adrenoceptors. The compounds were 
found to be functional antagonists in human, rat, and dog prostate tissues. 
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Modifications to the C5 position also play important role in potency of DHPM ring. 4-
aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C-5 amide as 
selective R1A receptor subtype antagonists. In receptor binding assays, these types of 
compounds generally display Ki values for the R1a receptor subtype <1 nM while being 
greater than 100-fold selective versus the R1b and R1d receptor subtypes. Many of these 
compounds were also evaluated in vivo and found to be more potent than terazosin in both a 
rat model of prostate tone and a dog model of intra-urethral pressure without significantly 
affecting blood pressure4.  
 
 
 
 
 
 
 
2.1.3 Intramolecular Heck cyclization of DHPMs 
 
The intramolecular Heck reaction can be observed in DHPM skeleton. The starting material 
for the intramolecular Heck reaction, DHPM was prepared by selective N3-acylation of 4-(o-
bromophenyl)-dihydropyrimidone with acryloyl chloride5 
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Applying intramolecular Heck reaction, tricyclic ring system can be obtained as shown 
below.6 
 
 
 
 
 
The computational experiments reveal that the formation of a tricyclic ring system did not 
flatten out the overall geometry. On the contrary, the aryl ring was still locked in a 
pseudoaxial position, resembling other nonfused 4-aryl-dihydropyrimidines.7,8 In fact, here, 
the intramolecular Heck strategy allows locking of the aryl ring in the proposed bioactive, 
that is, the pseudoaxial, orientation.9 
 
 
 
 
 
 
 
 
2.1.4 N3-Arylation of DHPMs 
 
N3-arylated DHPM analogues cannot be obtained by classical Biginelli condensation 
strategies involving N-arylureas. Here, the corresponding N1-substituted derivates will be 
formed exclusively10,11.  
Wannberg et al reported protocol using concentrated mixture of 20 mol % of CuI as catalyst, 
1.5 equiv of Cs2CO3 as base, and 5 mol equiv of DMF as solvent. The reactions were 
conducted at 180 °C for 40 min with a set of eight differently substituted aryl iodides. 
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2.1.5 Bicyclic systems derived from DHPMs  
 
Many bicyclic systems can be synthesized from DHPM scaffold. Pyrazolo[4,3-d]pyrimidine 
derivatives synthesized by reacting sodium azide with N-Me, 6-Br-Me DHPM. The possible 
mechanism of this transformation is shown in below and involves decomposition of the 
diazide  to vinyl diazo derivative, which undergoes spontaneous 1,5-electrocyclization to 3H-
pyrazole. Subsequent migration of the ester substituent from the tetrahedral carbon to N2 
(thermal van Alphen-Hüttel rearrangement) yields pyrazolo[4,3-d]pyrimidine. The structure 
confirming the position of the ester group at N2 was established by an X-ray analysisa.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Use of the 4-chloroacetoacetate building block 1 in a Biginelli-type condensation is very 
useful to get variety of bicyclic systems. The resulting functionalized DHPM appeared to be 
an ideal common chemical template for the generation of a variety of interesting bicyclic 
scaffolds such as furo[3,4-d]- pyrimidines, pyrrolo[3,4-d]pyrimidines, and pyrimido[4,5-
d]pyridazines . 
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Solid-phase and solution-phase protocols for the synthesis of furo[3,4-d]pyrimidines, 
pyrrolo[3,4-d]-pyrimidines, and pyrimido[4,5-d]pyridazines are reported. The multistep 
solid-phase sequence involves the initial high-speed, microwave-promoted acetoacetylation 
of hydroxymethylpolystyrene resin with methyl 4-chloroacetoacetate. The immobilized 4-
chloroacetoacetate precursor was subsequently subjected to threecomponent Biginelli-type 
condensations employing urea and a variety of aromatic aldehydes. The resulting 6-
chloromethyl-functionalized resin-bound dihydropyrimidones served as common chemical 
platforms for the generation of the desired heterobicyclic scaffolds using three different 
traceless cyclative cleavage strategies. The corresponding furo[3,4-d]pyrimidines were 
obtained by microwave flash heating in a rapid, thermally triggered, cyclative release. 
Treatment of the chloromethyl dihydropyrimidone intermediates with a variety of primary 
amines followed by high-temperature microwave heating furnished the anticipated 
pyrrolo[3,4-d]pyrimidine scaffolds via nucleophilic cyclative cleavage. In a similar way, 
reaction with monosubstituted hydrazines resulted in the formation of pyrimido[4,5-
d]pyridazines. All compounds were obtained in moderate to good overall yields and puritiesb.  
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2.1.6 Chemistry and biological importance of thaizolo[3,2-a]pyrimidine and 
pyrimido[2,1-b][1,3]thiazines scaffolds 
 
Preparation of thiazolo[3,2-a]pyrimidine derivatives is very well reported in literature. Two 
approaches is generally employed for synthesis.  
1. Azole approach: various methods for synthesis of thiazolo[3,2-a]pyrimidine 
derivatives using thiazole as starting material.  
Chart 1 
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Literature survey on synthetic methodology for thiazolo[3,2-a]pyrimidine derivatives can be 
summarized in chart 1 & 2 where various methods are illustrated for synthesis of this class of 
compounds.  
 
Chart 1: Thiazolo[3,2-a]pyrimidine 2 was prepared in 30% yield by the reaction of 2-
aminothiazole 1 with ethyl cyanoacetate  in a sodium ethoxide/ethanol mixture or using 
polyphosphoric acid or acetic acid. However, oxothiazolopyrimidine 3 was obtained upon 
treatment with phosphorous pentoxide and methanesulfonic acid. 
 
The reaction of 1 with ethyl acetoactate  at 140-150°C resulted in the formation of compound 
that was then converted to the Z-isomer upon heating at 250°C and cyclized to give 4. 2-
Aminothiazole 5 cyclized with acetylacetone at lOO"C, in the presence of methanesulfonic 
acid-phosphorus pentoxide or formic acid-phosphorus pentoxide, followed by treatment with 
70% perchloric acid, to give the thiazolopyrimidin-4-ium salt 5. The ester 6 was obtained 
from 2-aminothiazole 1 with an excess of methyl methanetricarboxylate in 61 % yield. 
Cyclocondensation of 1 with diethyl ethoxymethylene malonate in acetic acid followed by 
hydrolysis of the ester gave 7. Similarly, 2-aminothiazole 1 reacted with benzylidine in 
ethanol to give 8. Stanovink et al., [13-171 reported the synthesis of a series of 
thiazolopyrimidine derivatives upon reacting 2-aminothiazole with a variety of different 
reagents. Thus, dimethylaminobut- 2-enoate (or pentenoate), reacted with 1 to give 
thiazolopyrimidines 23. (Ref. 12-25) 
 
Chart 2: The reaction of 2-aminothiazole 1 with 2-hydropolyfluoroalk-2-enoate in basic 
medium gave two isomers, 7-oxo 2 and its isomeric 5-0x0 3. The structure of both 2 and 3 
was established through 'H NMR, 19F NMR and mass spectra26. 2-Aminothiazole 
derivatives, (R' = H, C02Et; R2 = Ph, aryl, Me), reacted with the acetylenic derivative  and 
ester derivative in ethanol and polyphosphoric acid, respectively, to give the isomeric 
oxothiazolopyrimidine derivatives 4 and 5, in 5-32% and 8-97 % yield, respectively27. 
Condensation of 2-aminothiazole 1 in absolute ethanol with the sodium salt of ethyl 
oximinocyanoacetate gave after acidification (pH 6) with diluted hydrochloric acid, the 
nitroso derivative 6 in 92% yield28. Treatment of the 2-aminothiazaole derivatives 5 with the 
hydrazone derivatives  gave the oxothiazolo [3,2-a] pyrimidine derivatives 7.29 
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Chart 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2-Amino-2-thiazoline reacted with 2-acylamino-3-dimethylamino-propenoates in acetic acid 
to yield 6-acylamino-5-oxo-2,3-dihydro-5~-thiazolo[3,2-a]pyrimidines in 73 and 12% yields, 
respectively30.  
 
 
 
 
 
 
Moreover, 2-amino-2-thiazoline reacted with an aromatic aldehyde and diethyl malonate, to 
give a mixture of thiazolidino[3,2-a]pyrimidines. Furthermore, malononitrile reacted to give 
following product.31-32  
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2-Amino-Zthiazoline reacted with potassium 2-ethoxycarbonyl-2-fluorovinyl alcoholate in a 
sodium methoxide/methanol mixture to give 6-fluoro-2,3-dihydro-5-oxothiazolo[3,2-
a]pyrimidine33.  
 
 
 
 
 
 
2-(Methylthio)-24hiazoline reacted with /3-alanine to give a 5-oxothiazolo[3,2-a]-pyrimidine 
derivative  in 23% yield34. 
 
 
 
 
 
 
2. Azine approache 
 
Pyrmidinethione derivatives were alkylated with monochloroacetic acid or chloroacetyl 
chloride and then cyclized to give thiazolopyrimidine derivatives.35-48 Thus, pyrimidinethione 
reacted in DMF35 or in an acetic anhydride/pyridine mixture37 to give thiazolo-pyrimidines. 
Alkylation in the presence of an aromatic aldehyde gave the ylidene. Similarly, 
pyrimidinethione derivatives reacted with monochloroacetic acid in acetic acid/acetic 
anhydride/sodium acetate mixture or with chloroacetyl chloride in dry dioxane to give the 
corresponding thiazolopyrimidines39,40.  
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Treatment of mercaptopyrimidine derivative with 2-chloroethanol in DMF gave the 
asymmetrical thioether which underwent cyclization on refluxing with a mixture of acetic 
anhydride-pyridine, to give the oxothiazolopyrimidine49.  
 
 
 
 
 
 
 
1,3-Dibromopropan-2-ol reacted with mercaptopyrimidine derivative to give product through 
the non isolated intermediates. The same reaction product was obtained by reacting with I-
bromomethyloxirane.50 
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Several derivatives of 4,5-disubstituted imidazole, 2,4,5-trisubstituted pyrimidine, 2-
substituted purine, thiazolo[3,2-a]purine, [1,3]thiazino[3,2-a]purine, thiazolo[2,3-i]purine, 
[1,3]thiazino-[2,3-i]purine, and 6-substituted pyrazolo[3,4-d]pyrimidine were synthesized and 
tested as inhibitors of the xanthine oxidase enzyme51. 
    
 
 
 
 
Dihydropyrimidines are well-known calcium channel blockers. According to the literature 
analogous derivatives are anti-inflammatories. Thus Bo´szing and co-workers decided to 
synthesize the pyrimidothiazines and assay these compounds for the same profile. Acute anti-
inflammatory activity was tested by inhibition of the carrageenan-induced paw edema in 
rats52. 
 
 
 
 
 
Adam et al filed US patent for phenyl substituted thiazolo pyrimidine derivatives synthesized 
from DHPM. These compounds and their slats are novel and are distinguished by valuable 
therapeutic properties. Specifically it has been found that the compounds of general formula 
given below are metabotropic glutamate receptor antagonists. These compounds are capable 
of high affinity binding to group II mGluR receptors53.  
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Compounds displayed by general formulae given below exhibit excellent adenosine A3 
receptor antagonism where A is an optionally substituted benzene ring. B may be substituted 
and R1 is optionally substituted cyclic group54.  
 
 
 
 
 
 
Amr, A. E. G. E. and Maigali, S. S. described the analgesic and antiparkinsonian activity of 
some thiazolopyrimidine derivatives as shown below. Out of them compound of type III are 
potent antiparkinsonian agents.55 
 
 
 
 
 
 
  
CDC25 phosphatases play critical roles in cell cycle regulation and are attractive targets for 
anticancer therapies. Several small non-peptide molecules are known to inhibit CDC25, but 
many of them appear to form a covalent bond with the enzyme or act through oxidation of the 
thiolate group of the catalytic cysteine. Matthieu Montes et al reported thiazolopyrimidine 
structure based compound as CDC25 phosphatases inhibitor.56 
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2.2 Current work   
 
 
Importance of DPHM ring to develop variety of bicyclic systems is briefly surveyed in 
section 2.1. N3-substitution in DHPM ring is reported to enhance activity profile.3,4 Similarly, 
substitutions at C5 position may plays key role in activity profile. In our work, n-butyl 
carboxylic ester side chain is introduced at C5 position of DHPM ring. Further, thiazolo 
pyrimidine derivatives with n-butyl carboxylic ester moiety at C5 position are synthesized 
and characterized. 
 
Thiazolo pyrimidine and pyrimido thiazine are very important bicyclic system in medicinal 
chemistry.51-56 Various synthetic routes have been reported in literature to synthesize these 
bicyclic systems. Utility of DHPM ring to synthesize different bicyclic system is discussed. 
Derivatives of these bicyclic systems with n-butyl carboxylic ester as side chain on 
pyrimidine ring of bicyclic system can be synthesized using this methodology. 
 
DHPM ring, substituted with n-butyl carboxylic ester side chain at C5 position, was 
synthesized as described in Chapter 1. This DHPM ring was reacted with α-halo ketone to get 
bicyclic systems. In synthesis of thiazolo pyrimidine system, mono chloroacetone was used 
as α-halo ketone. Various solvents were utilized as reaction media to get better results. 
Among them glacial acetic acid with sodium acetate as catalytic amount was succeeded to 
give better yield with shorten reaction time and easy in isolation of product. All newly 
synthesized compounds were characterized by IR, Mass, 1H NMR, 13C NMR spectroscopy 
and elemental analysis. Reaction schemes are illustrated in section 2.3. Physical data of 
synthesized compounds is reported in section 2.6 and spectral data is discussed in section 2.7. 
The antiviral screening of compounds is under investigation. 
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2.3 Reaction Scheme 
 
2.3.1 Scheme 1 
 
   Transesterification of ethyl acetoacetate 
 
 
 
 
 
 
 
2.3.2  Scheme 2 
 
 
      Synthetic approaches towards dihydropyrimidine 
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 2.3.3 Scheme 3 
 
 
Synthetic approach towards thiazolopyrimidine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4 Reaction Mechanism 
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2.5 Experimental  
 
 
2.5.1 n-Butyl acetoacetate: 
A mixture of ethyl acetoacetate (0.1 M) and n-butyl alcohol (0.11 M) in toluene (50 ml) was 
taken in a round bottom flask provided with a distillation condenser to remove methanol or 
ethanol. Sodium ethoxide (1 mmol) was added to the mixture as a catalyst. The mixture was 
heated at 100-110 °C for 5-6 hrs. After completion of reaction (TLC), the catalyst was 
filtered and the filterate was concentrated to get crude product. n-Butyl acetoacetate was 
distilled off at 92-98 ° C/20 mm Hg. Yellowish viscous oil. 
 
2.5.2 n-Butyl 6-methyl-4-aryl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-
carboxylate: 
A mixture of n-butyl acetoacetate (10 mmol), appropriate aldehyde (10 mmol) and thiourea 
(15 mmol) was dissolved in absolute EtOH (20 mL) and refluxed until clear solution is 
obtained. Few drops of con. HCl were added to reaction mixture as a catalyst  and was 
refluxed for 8-12 hrs. The reaction was monitored with thin layer chromatography and after 
completion of the reaction, the mixture was allowed to cool at room temperature. The solid 
separated was filtered, washed with hot methanol and recrystallized from ethanol. (AP 1-15) 
(Yield – 45-60%). 
  
2.5.3 n-Butyl 3,7-dimethyl-5-phenyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-
carboxylate: 
Compound AP(1-15) (10 mmol) and mono chloroacetone (10 mmol) were dissolved in 
glacial acetic acid with sodium acetate and refluxed for 6 hrs. The reaction was monitored 
with thin layer chromatography and after completion of the reaction, the reaction mixture was 
poured on crushed ice and was extracted with chloroform. The chloroform was removed in 
vacuum. The residue was dried and recrystallized from ethanol. (ATP 1-15) (Yield: 55-65%).  
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2.6 Physical data  
 
 
 
 
 
 
 
Comp. R M.F. M.W. Mp °C Yield % Rf 
ATP-1 H C19H22N2O2S 342.45 240-242 75 0.48 
ATP-2 4-OCH3 C20H24N2O3S 372.48 225-227 74 0.62 
ATP-3 3,4-(OCH3)2 C21H26N2O4S 402.50 235-237 79 0.41 
ATP-4 2,5-(OCH3)2 C21H26N2O4S 402.50 238-240 75 0.42 
ATP-5 2-Cl C19H21ClN2O2S 376.90 242-244 65 0.56 
ATP-6 3-Cl C19H21ClN2O2S 376.90 235-236 69 0.56 
ATP-7 4-Cl C19H21ClN2O2S 376.90 238-240 69 0.61 
ATP-8 3-NO2 C19H21N3O4S 387.45 239-240 71 0.54 
ATP-9 4-NO2 C19H21N3O4S 387.45 243-244 73 0.58 
ATP-10 2-OH C19H22N2O3S 358.45 240-242 70 0.49 
ATP-11 4-OH C19H22N2O3S 358.45 228-230 68 0.56 
ATP-12 4-F C19H21FN2O2S 360.44 244-245 58 0.54 
ATP-13 4-CH3 C20H24N2O2S 356.48 251-253 60 0.47 
ATP-14 4-dimethylamino C21H27N3O2S 385.52 244-246 68 0.59* 
ATP-15 [2,3] Benzo C23H24N2O2S 392.51 241-243 70 0.60* 
 
TLC Solvent system: Ethyl acetate : Hexane – 4:6, *CHCl3 : MeOH – 9:1 
MPs were taken in open capillary and are not corrected. 
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2.7 Spectral discussion  
 
2.7.1  Mass spectral study 
Instrument                : SHIMADZU GCMS-QP-2010 
Sample technique    : EI technique 
M/z range                  : 40-500 
Systematic fragmentation pattern was observed in mass spectral analysis. Peaks for specific 
fragments were identified in each mass spectrum. Molecular ion peak was observed in 
agreement with molecular weight of respective compound. Mass fragmentation for 
compound ATP-1 is discussed below. 
 
Molecular ion peak M+ was observed at 342 and M++1 peak was also observed with very low 
intensity. The three peaks were observed due to cleavage of alkyl chain at 327, 314, and 285 
as M+-CH3, M+-C2H5, and M+-C4H9 as per shown in figure 1. One low intense peak was 
observed at 269 due to cleavage of n-butoxy group from carboxylic ester group at C-6 
position as M+-OC4H9. This fragment was further undergone to cleavage from both methyl 
groups at C3 and C7 position of thiazolo pyrimidine moiety and gave very intense peak at 
241. A base peak was observed at 265 due to cleavage of phenyl ring from thiazolo 
pyrimidine moiety as M+-C6H5.  This fragment was further undergone to cleavage of ethyl 
and butyl group from alkyl chain of carboxylic ester at C6 of thiazolo pyrimidine moiety and 
gave two intense peaks at 237 and 209 respectively. 
2.7.2  IR spectral study 
 
Instrument                 : Shimadzu FT-IR-8400 
Sample technique     : KBr pellet 
Frequency range       : 400-4000cm-1 
As per IR spectral study of synthesized thiazolopyrimidine derivatives, there was not 
observed NH stretching vibration around 3200-3500 cm-1, which revealed the complete 
transformation of dihydropyrimidine to thiazolopyrimidine. Alkyl chain of carboxylic acid 
ester showed C-H stretching vibration between 2800-2900 cm-1 while C-H bending vibration 
was observed at near 1450 and 1375 cm-1. Ring skeleton vibration was shown between 1500 
to 1600 cm-1.  
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2.7.3  1H NMR spectral study 
 
Instrument                  : BRUKER AC 400 MHz FT-NMR 
Internal reference       : TMS 
Solvent                        : CDCl3 
 
 
 
 
 
 
 
Number of protons and their chemical shifts were found to support the structure of the 
synthesized compounds. Protons of n-butyl chain ‘a’, ‘b’ and ‘c’ were observed at 0.90-0.95 
δ ppm, 1.32-1.42 δ ppm and 1.58-1.67 δ ppm respectively. Protons ‘d’ were observed at 4.06-
4.18 δ ppm due to neighboring attachment of hetero atom. Protons ‘e’ and ‘h’ of methyl 
group attached at C-7 and C-3 position respectively were observed at 2.36-2.40 δ ppm and 
2.06-2.08 δ ppm as singlet and very intense peak. Asymmetric carbon proton ‘f’ was 
observed at 5.0-5.9 δ ppm as singlet. Proton of thiazole ring ‘g’ was observed at 6.1-6.2 δ 
ppm. The aromatic ring protons ‘i’ were observed at 6.50-7.80 δ ppm. 
 
2.7.4  13C NMR spectral study 
 
13C NMR spectrum data for compound ATP-1 is given below. δ ppm values are listed along 
with corresponding carbon atom number given in bracket and displayed in the structure. 
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13C NMR δ ppm:  13.78 (C1), 14.02 (C2), 19.38 (C3), 23.51 (C4), 30.87 (C5), 57.87 (C6), 
63.98 (C7), 100.35 (C8), 126.52 (C9), 126.52 (C10), 128.36 (C11), 128.36 (C12), 128.80 
(C13), 128.80 (C14), 128.80 (C15), 135.52 (C16), 142.76 (C17), 166.29 (C18), 166.86 (C19). 
 
2.7.5  Elemental Analysis 
 
Elemental analysis of the all the synthesized compounds was carried out on Elemental Vario 
EL III Carlo Erba 1108 model and the results are in agreements with the structures assigned. 
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Figure 1. Mass fragmentation of Mass spectrum of n-butyl 3,7-dimethyl-
5-phenyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate 
(ATP-1). 
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Spectral data of synthesized compounds (ATP 1-15) 
 
n-butyl 3,7-dimethyl-5-phenyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate (ATP-1) 
Yellow solid; mp 240-242 ˚C;  
IR (KBr): 3032, 2947, 2875, 2775, 1681, 1521, 1492, 1442, 1342 cm-1; 1H NMR (400 MHz, 
CDCl3): δ ppm = 0.92 (t, 3H, CH3), 1.37 (m, 2H, CH2), 1.63 (m, 2H CH2), 2.07 (s, 3H, CH3), 
2.40 (s, 3H, CH3), 4.11 (m, 2H, CH2), 6.02 (s, 1H, CH), 6.17 (s, 1H, CH), 7.24–7.33 (m, 5H, 
Ph); 13C NMR (400 MHz, CDCl3): δ ppm = 13.78, 14.02, 19.38, 23.51, 30.87, 57.87, 63.98, 
100.35, 126.52, 126.52, 128.36, 128.36, 128.80, 128.80, 128.80, 135.52, 142.76, 166.29, 
166.86; MS: m/z = 342 (M+); Anal. Calcd for C19H22N2O2S: C, 66.64; H, 6.48; N, 8.18. 
Found: C, 66.56; H, 6.39; N, 8.01. 
 
n-butyl 5-(4-methoxyphenyl)-3,7-dimethyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-
carboxylate (ATP-2) 
Yellow solid; mp 225-227 ˚C; 
IR (KBr): 3006, 2924, 2875, 1674, 1556, 1521, 1468, 1338 cm-1; MS: m/z = 372 (M+); 
Anal. Calcd for C20H24N2O3S: C, 64.49; H, 6.49; N, 7.52. Found: C, 64.58; H, 6.31; N, 7.43. 
 
n-butyl 5-(3,4-dimethoxyphenyl)-3,7-dimethyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-
carboxylate (ATP-3) 
Yellow solid; mp 235-237 ˚C; 
IR (KBr): 2958, 2914, 2859, 1690, 1445, 1371 cm-1; 1H NMR (400 MHz, CDCl3): δ ppm = 
0.93 (t, 3H, CH3), 1.39 (m, 2H, CH2), 1.63 (m, 2H CH2), 2.08 (s, 3H, CH3), 2.38 (s, 3H, 
CH3), 3.83 (s, 6H, OCH3), 4.11 (m, 2H, CH2), 5.96 (s, 1H, CH), 6.11 (s, 1H, CH), 6.74–6.88 
(m, 3H, Ph); MS: m/z = 402 (M+); Anal. Calcd for C21H26N2O4S: C, 62.66; H, 6.51; N, 6.96. 
Found: C, 62.71; H, 6.45; N, 7.23. 
 
n-butyl 5-(2,5-dimethoxyphenyl)-3,7-dimethyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-
carboxylate (ATP-4) 
Yellow solid; mp 238-240 ˚C; 
IR (KBr): 2944, 2898, 2832, 1672, 1416, 1345 cm-1; MS: m/z = 402 (M+); Anal. Calcd for 
C21H26N2O4S: C, 62.66; H, 6.51; N, 6.96. Found: C, 62.46; H, 6.37; N, 7.01. 
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n-butyl 5-(2-chlorophenyl)-3,7-dimethyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-
carboxylate (ATP-5) 
Yellow solid; mp 242-244 ˚C; 
IR (KBr): 2875, 2821, 1645, 1596, 1446 cm-1; MS: m/z = 376 (M+); Anal. Calcd for 
C19H21ClN2O2S: C, 60.55; H, 5.62; N, 7.43. Found: C, 60.38; H, 5.56; N, 7.33. 
 
n-butyl 5-(3-chlorophenyl)-3,7-dimethyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-
carboxylate (ATP-6) 
Yellow solid; mp 235-236 ˚C; 
IR (KBr): 2970, 2845, 1689, 1450, 1381 cm-1; MS: m/z = 376 (M+); Anal. Calcd for 
C19H21ClN2O2S: C, 60.55; H, 5.62; N, 7.43. Found: C, 60.69; H, 5.34; N, 7.19. 
 
n-butyl 5-(4-chlorophenyl)-3,7-dimethyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-
carboxylate (ATP-7) 
Yellow solid; mp 238-240 ˚C; 
IR (KBr): 2865, 1696, 1556, 1460, 1551, cm-1; MS: m/z = 376 (M+); Anal. Calcd for 
C19H21ClN2O2S: C, 60.55; H, 5.62; N, 7.43. Found: C, 60.44; H, 5.75; N, 7.32. 
 
n-butyl 3,7-dimethyl-5-(3-nitrophenyl)-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate 
(ATP-8) 
Yellow solid; mp 239-240 ˚C; 
IR (KBr): 2968, 2875, 1682, 1416, 1346 cm-1; MS: m/z = 387 (M+); Anal. Calcd for 
C19H21N3O4S: C, 58.90; H, 5.46; N, 10.85. Found: C, 58.76; H, 5.36; N, 10.71. 
 
n-butyl 3,7-dimethyl-5-(4-nitrophenyl)-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate 
(ATP-9) 
Yellow solid; mp 243-244 ˚C; 
IR (KBr): 2925, 2881, 1674, 1535, 1378 cm-1; MS: m/z = 387 (M+); Anal. Calcd for 
C19H21N3O4S: C, 58.90; H, 5.46; N, 10.85. Found: C, 58.86; H, 5.38; N, 10.81. 
 
n-butyl 5-(2-hydroxyphenyl)-3,7-dimethyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-
carboxylate (ATP-10) 
Yellow solid; mp 240-242 ˚C; 
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IR (KBr): 3405, 2974, 2945, 1681, 1507, 1464, 1328 cm-1; MS: m/z = 358 (M+); Anal. 
Calcd for C19H22N2O3S: C, 63.66; H, 6.19; N, 7.82. Found: C, 63.73; H, 6.32; N, 8.05. 
 
n-butyl 5-(4-hydroxyphenyl)-3,7-dimethyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-
carboxylate (ATP-11) 
Yellow solid; mp 228-230 ˚C; 
IR (KBr): 3488, 2934, 2889, 1708, 1545, 1447, 1361 cm-1; MS: m/z = 358 (M+); Anal. 
Calcd for C19H22N2O3S: C, 63.66; H, 6.19; N, 7.82. Found: C, 63.47; H, 6.11; N, 7.68. 
 
n-butyl 5-(4-fluorophenyl)-3,7-dimethyl-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-
carboxylate (ATP-12) 
Yellow solid; mp 244-245 ˚C; 
IR (KBr): 2901, 2827, 1674, 1459, 1328 cm-1; MS: m/z = 360 (M+); Anal. Calcd for 
C19H21FN2O2S: C, 63.31; H, 5.87; N, 7.77. Found: C, 63.17; H, 5.73; N, 7.80. 
 
n-butyl 3,7-dimethyl-5-(4-methylphenyl)-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-
carboxylate (ATP-13) 
Yellow solid; mp 251-253 ˚C; 
IR (KBr): 2850, 2971, 1669, 1453, 1357 cm-1; MS: m/z = 356 (M+); Anal. Calcd for 
C20H24N2O2S: C, 67.38; H, 6.79; N, 7.86. Found: C, 67.32; H, 6.70; N, 7.95. 
 
n-butyl 3,7-dimethyl-5-[4-(dimethylamino)phenyl]-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-
carboxylate (ATP-14) 
Yellow solid; mp 244-246 ˚C; 
IR (KBr): 2962, 2908, 1683, 1478, 1364 cm-1; MS: m/z = 385 (M+); Anal. Calcd for 
C21H27N3O2S: C, 65.42; H, 7.06; N, 10.90. Found: C, 65.50; H, 6.89; N, 11.17. 
 
n-butyl 3,7-dimethyl-5-(1-napthyl)-5H-[1,3]thiazolo[3,2-a]pyrimidine-6-carboxylate 
(ATP-15) 
Yellow solid; mp 241-243 ˚C; 
IR (KBr): 2969, 2944, 2889, 1691, 1554, 1518, 1461, 1373 cm-1; MS: m/z = 392 (M+); 
Anal. Calcd for C23H24N2O2S: C, 70.38; H, 6.16; N, 7.14. Found: C, 70.73; H, 6.25; N, 7.02. 
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1H NMR spectrum of ATP-1 
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1H NMR spectrum of ATP-3 
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13C NMR spectrum of ATP-1 
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Mass spectrum of ATP-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of ATP-3 
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IR spectrum of ATP-1 
 
IR spectrum of ATP-2 
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3.1 Introduction 
 
Spiro compounds can be defined as cyclic molecules containing at least two rings joined 
together by a single carbon atom. This unique structural feature has been observed in natural 
products and has also been the target of methodological studies and synthesis. 
 
A number of 2-spiroquinazolinones have been reported to possess biological and 
pharmaceutical activities. Tranquilizing activity has been observed in 1'N-substituted spiro 
[cyclohexane-1,2'(1H)-quinazolin]-4'(3'H)-one1 1. Compound 2 was found to be a potent 
inhibitor of inosine 5'-monophosphate dehydrogenase type II.2 As a ligand of the nociceptin 
receptor, cis-spiropiperidine 3 exhibited a 20-fold higher affinity than that of its trans 
stereoisomer.3 Spiro-cyclic carbamate 4 has been tested as a novel, highly selective4 nitric 
oxide synthase inhibitor. Some spiro[heterocycloalkyl-2'(1'H)quinazolin]-4'(3'H)-ones 
demonstrate antiamebic activity in vitro5 and had been investigated as central nervous system 
depressants. The plant-growth regulator agent octahydroquinazoline-2-spirocyclohexane 56 
increases the height and green mass of barley and wheat.7 2-Spiroquinazolinones are also key 
intermediates for the synthesis of cycloalkanone-2-carboxamides,8 acridin-9-ones9 and cis-3-
azacepham analogs.10 
 
Böhme et. al. reported11 that the room-temperature treatment of anthranilamide with 
cyclohexanone or cyclopentanone in ethanol saturated with hydrogen chloride provided a 
facile synthesis of spiro [cycloalkane-1,2'(1'H)-quinazolin]-4'(3'H)-ones. Heating of 
monosubstituted anthranilamides with cyclic ketones without solvents12 was an effective 
method for the preparation of spiroquinazolinones. The cyclization of anthranilamide with 
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ketones in absolute ethanol,13 in refluxing trifluoroethanol14 or under microwave irradiation15 
is also known. Other methodologies too have been employed, for example with isatoic 
anhydride16,17 or anthranylhydrazide18 as starting compound. For the preparation of spiro-1,2-
dihydroquinazolin-4(3H)ones, a new method, the reductive cyclization of 2-nitrobenzamides 
with carbonyl compounds, was introduced by Shi et al.19,20 Ferenc Miklós21 reported the 
synthesis of methylene- and epoxy-bridged spiroquinazolinones. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
NH2
O
NH2
X
O
n
NH
O
N
H
X
n
+
EtOH, Reflux
2 h
X = CH2, O
n = 1,2,3,4,8  
 
It has been found that coumarin is one of the most interesting molecules since it shows a wide 
spectrum of chemical reactivity. The reported antibacterial and the antibiotic novobiocin of 
many heterocyclic compounds containing coumarin moiety encourages to use a 
benzopyrano[2,3-c]pyrazol-3-one as a building block for the synthesis of poly fused 
heterocycles containing pyran, oxazine, pyrazole, thienyl, thiophene and substituted benzene 
derivatives. A. Khodairy22 reported synthesis of such type of spiro compounds having 
coumarin core. 
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V. V. Mulwad and Abid Ali Mir23 had reported the synthesis of N-[coumarin-6-yl] spiro-
indoloazetidin-2-ones/thiazolidin-4-one derivatives and evaluated in vitro antimicrobial 
activity. 
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A. M. El-Snyed24 synthesized some novel pyrano, oxazino, triazolo, oxazolo, furano, and 3-
substituted (1,5) benzodiazepines from thereaction of lH(alkyl)-2,3-dihydro-4-methyl1, 5-
benzodiazepin-2-ones with the proper reagents. 
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Diego Armesto25 synthesized cyclobutenes by the photochemical ring contraction of 
4-substituted 2-amino-3,5-dicyano-6-phenyl-4H-pyrans. 
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An efficient one-pot synthesis of novel 8,9-dihydrospiro[chromeno[2,3-d]pyrimidine-5,3′-
indoline]-2,2′,4,6(1H,3H,7H)-tetraone derivatives by a three-component condensation 
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reaction of barbituric acids, isatins and cyclohexane-1,3-diones in refluxing water in the 
presence of p-TSA for 10 h is reported.26 Reaction of 5,5-dimethyl-cyclohexane-1,3-dione 
and acenaphthylene-1,2-dione with barbituric acids resulted in the formation of 
spiro[acenaphthylene-1,5′-chromeno[2,3-d]pyrimidine] derivatives. 
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Ramin Ghahremanzadeh et al27 described a simple, clean and efficient method for the 
synthesis of spiro[pyrimido[4,5-b]quinoline-5,5’-pyrrolo[2,3-d]pyrimidine]-pentaone 
derivatives by condensation reaction of 6-amino-uracils and isatins in aqueous media. These 
products were evaluated in vitro for their antibacterial activities. 
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A simple, clean and efficient method for the synthesis of spiro[indoline-3,9’-xanthene]trione 
derivatives and spiro[acenaphthene-1,9’-xanthene]-1’,2,8’(2’H,5’H)-trione by condensation 
reaction of dimedone and isatins or acenaphthene in aqueous media using p-TSA is reported 
by Somayeh Ahadi.28 
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A. T. Soldatenkov29 reported one-pot synthesis of spiro-N-
methylhexahydrobenzo[f]isoquinoline-1,2’-(tetrahydro-1’-napthalenone) by the condensation 
of α-tetralone with formaldehyde and methylamine. 
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Regio- and stereoselective methods for the synthesis of substituted  2-amino-4-aryl-3-cyano-
4H-pyrans are under extensive development because of biological activities of these 
compounds.30-38 2-Amino-4-aryl-3-cyano-4H-pyrans fused with fragments of coumarin39 and 
substituted benzenes,40 quinolines,41 naphthalenes,42 and pyrazolones,43,44 which exhibit 
anticoagulating, antisclerotic, anticancer, and other practically important properties, are of the 
greatest interest as biologically active compounds. 
 
A. M. Shestopalov et al45 synthesized spiro pyrano[2´,3´:4,5]thieno[2,3-b]pyridines by the 
reaction of 4,6-dimethyl-2H-thieno[2,3-b]pyridine-3-one with cyclic ketone and 
malanonitrile. 
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A.K. El-Shafei46 reported the the reaction of cycloalkylidenemalononitriles with some active 
methylene reagents as well as cycloalkanones in boiling ethanol containing piperidine 
catalyst affords a series of new spiro heterocyclic systems. 
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The indole moiety is probably the most well-known heterocycle, a common and important 
feature of a variety of natural products and medicinal agents.47 Spiro compounds represent an 
important class of naturally occurring substances characterized by highly pronounced 
biological properties. The spirooxindole system is the core structure of many 
pharmacological agents and natural alkaloids.48–51 For example, spirotryprostatin A, a natural 
alkaloid isolated from the fermentation broth of Aspergillus fumigatus, has been identified as 
a novel inhibitor of microtubule assembly,51 and pteropodine and isopteropodine have been 
shown to modulate the function of muscarinic serotonin receptors.48 
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Fused chromenes have been found to have a wide spectrum of activities such as 
antimicrobial,52 antiviral,53 mutagenicity,54 antiproliferative,55 sex pheromone,56 antitumor,57 
and central nervous system activities.58 Many research group had investigated spirooxindoles. 
Gnanamani Shanthi et al59 reported  new InCl3-catalyzed, facile and efficient method for the 
synthesis of spirooxindoles under conventional and solvent-free  microwave conditions. 
 
N
H
O
O NC CN
OH
OH2N
NC
N
H
O+ +
InCl3/SO2/ MW
(or)
InCl3/CH3CN
Reflux
 88
Michail N. Elinson60 described facile and convenient way to functionalized spirocyclic 
(5,6,7,8-tetrahydro-4H-chromene)-4,3’-oxindole system by electrocatalytic  multicomponent 
transformation of cyclic 1,3-diketones, isatins, and malononitrile. 
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A key compound in the synthesis (Scheme 1) of warfarin (rodenticide, a blood anticoagulant) 
is 2-amino-3-cyano-5-oxo-4-phenyl-4,5-dihydropyrano[3,2-c]chromene 3 prepared by 
heating of 4-hydroxycoumarin 1 with benzylidenemalononitrile 2 in pyridine61 or water.62 
Acid hydrolysis of substituted pyrano[3,2-c]chromene 3 gives compound 4, which is used to 
synthesize warfarin 5.61–65 2-Amino-4-aryl-3-(thiocarbamoyl, alkoxycarbonyl, or cyano)-5-
oxo-4,5-dihydropyrano[3,2-c]chromenes were also obtained63,66 by morpholine catalyzed 
reactions of 4-hydroxycoumarin with arylidenecyanothioacetamide, alkyl 
arylidenecyanoacetates, or arylidenemalononitrile in hot benzene or ethanol. 
 
A. A. Shestopalov67 described the three component reactions of 4-hydroxycoumarin, 
carbonyl compounds, and malononitrile or alkyl cyanoacetates in ethanol in the presence of 
Et3N as a catalyst give substituted 2-amino-5-oxo-4,5-dihydropyrano[3,2-c]chromenes. 
 
O
OH
O N
H
O
O
NC CN
O
O
O
NH2
NH
CN
O
+ +
 
 89
 
3.2 Current work   
 
 
In view of marked importance of spiro heterocyclic compounds in the field of organic 
chemistry as well as medicinal chemistry, we sought to develop some diversified spiro 
heterocycles. As per mentioned above, 2-amino-3-cyano-5-oxo-4-phenyl-4,5-
dihydropyrano[3,2-c]chromene has attained great importance in the field of medicinal 
chemistry. Despite some achievements attained in recent years in the synthesis of 2-amino-3-
cyano-5-oxo-4,5-dihydropyrano[3,2-c]chromene type compounds with other substituents in 
position 4, preparation and isolation of unsaturated nitriles,  which are analogs of toxic agents 
CS,68 substantially complicated the synthesis of pyrano[3,2-c]chromene. In some cases, the 
condensation does not yield the target unsaturated nitrile at all: in the reaction of pyridine-4-
carbaldehyde with malononitrile, 1-amino-2,4,4,6,6-pentacyano-3,5-di(4-pyridyl)cyclohex-1-
ene was obtained instead.69 In further investigations of cross reactions of malononitrile with 
carbonyl compounds with the aim of developing one-step syntheses of functionalized spiro-
heterocycles, we studied three-component reactions of 4-hydroxycoumarin, malononitrile and 
carbonyl compounds. 
 
The brief heating of 4-hydroxy coumarin with cyclic aliphatic ketone (cyclopentanone, 
cyclohexanone, and cycloheptanone) and malononitrile in boiling ethanol in the presence of 
morpholine as a catalyst gave 2-amino-3-cyano pyrano[3,2-c]chromene derivatives in high 
yields. The three component reaction between 4-hydroxy coumarin, malononitrile and 
various substituted acetphenone as the carbonyl compound under analogous condition didn’t 
follow the same pathway. Substituted acetophenone reacts with malononitrile to give 
unsaturated nitrile, which does not undergo Michael addition reaction with coumarin anion. 
Thus coumarin remains out of the process. 
 
All newly synthesized compounds were characterized by IR, Mass, 1H NMR, 13C NMR 
spectroscopy and elemental analysis. Reaction scheme is illustrated in section 3.3. The 
plausible reaction mechanism is demonstrated followed by reaction scheme. Spectral data is 
discussed in section 3.6 which is consistent with proposed structure. The anti viral screening 
of the synthesized compounds is under investigation. 
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3.3 Reaction Scheme  
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3.4 Reaction Mechanism  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Apparently, the initial Knoevenagel  condensation of cyclic ketone 2 with malononitrile 3 
gives unsaturated nitrile 4, which, when at the “reaction intersection”, enters into the Michael 
reaction with coumarin anion 5. The resulting Michael adduct 6 undergoes intramolecular 
cyclization into annelated iminopyran 7. Subsequent tautomeric [1,3]sigmatropic shift gives 
compound 8 . 
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3.5 Experimental  
 
 
3.5.1  Preparation of spiro pyrano[3,2-c]chromene derivatives: 
 General Procedure  
A stirred mixture of 4-hydroxy coumarin (10 mmol), carbonyl compound (cyclopentanone, 
cyclohexanone, and cycloheptanone) (10 mmol), malononitrile (10 mmol), and morpholine 
(0.5 mmol) in anhydrous EtOH (50 mL) was refluxed for 15 to 20 min and allowed to 
crystallize at 4 °C for 12 h. The precipitate that formed was filtered off, washed with ethanol 
and hexane, and recrystallized from 1,4-dioxane to give desired compound as a white solid 
powder in good to excellent yield. 
 
 
 
 
3.6 Spectral discussion 
 
3.6.1  Mass spectral study 
Instrument                : SHIMADZU GCMS-QP-2010 
Sample technique    : EI technique 
M/z range                  : 40-500 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection 
Probe technique. Systematic fragmentation pattern was observed in mass spectral analysis. 
Molecular ion peak was observed in agreement with molecular weight of respective 
compound. 
3.6.2  IR spectral study 
Instrument                 : Shimadzu FT-IR-8400 
Sample technique     : KBr pellet 
Frequency range       : 400-4000cm-1 
As per IR spectral study of newly synthesized spiro pyrano[3,2-c]chromene derivatives, the 
stretching vibration of primary amine (-NH2) appeared around 3200-3300 cm-1. Methylene 
groups of cycloalkane ring showed C–H stretching vibration between 2850 to 2990 cm-1. The 
carbonyl (>C=O) stretching vibration of lactone ring was observed around 1720 cm-1. Nitrile 
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group attached to pyran ring showed C≡N stretching vibration around 2180–2280 cm-1. 
Methylene group also gave C-H bending vibration around 1450 cm-1. The benzenoid part 
showed C=C ring skeleton vibration around 1500-1600 cm-1. 
 3.6.3  1H NMR spectral study 
Instrument                  : BRUKER AC 400 MHz FT-NMR 
Internal reference       : TMS 
Solvent                        : CDCl3 
 
 
 
 
 
 
Number of protons and their chemical shifts were found to support the structure of the 
synthesized compounds. Benzenoid protons of coumarin ring ‘a’ were found between 7 to 8 δ 
ppm with its characteristic pattern. Methylene protons of cycloalkane ring ‘b’ were observed 
between 2 to 2.5 δ ppm. Proton ‘c’ of primary amine attached to pyran ring was  observed at 
5.5-6.0 δ ppm as a singlet and very intense sharp peak. 
3.6.4  13C NMR spectral study 
Instrument                  : BRUKER AC 400 MHz FT-NMR 
Internal reference       : TMS 
Solvent                        : CDCl3 
13C NMR spectrum data for compound AS-1 is given below. δ ppm values are listed along 
with corresponding carbon atom number given in bracket and displayed in the structure. 
 
 
 
 
 
 
 
13C NMR δ ppm: 27.6 (C1, C2), 41.0 (C3), 43.1 (C4, C5), 70.9 (C6), 109.3 (C7), 113.0 (C8), 
116.5 (C9), 119.2 (C10), 122.3 (C11), 124.3 (C12), 132.3 (C13), 152.2 (C14), 152.4 (C15), 
154.6 (C16), 159.7 (C17). 
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3.6.5  Elemental Analysis 
Elemental analysis of the all the synthesized compounds was carried out on Elemental Vario 
EL III Carlo Erba 1108 model and the results are in agreements with the structures assigned. 
 
Spectral data of synthesized compounds (AS 1-3) 
 
Spiro(2–amino–3–cyano pyrano[3,2–c]chromene–4,1’–cyclopentane) (AS–1) 
White solid; mp 230–232 ˚C;  
IR (KBr): 3308 (NH2), 2962, 2947, 2872 (CH2), 2187 (C≡N), 1730 (C=O), 1602, 1492 
(ArC=C), 1450 (CH2), 1030 (C–O) cm-1; 1H NMR (400 MHz, CDCl3): δ ppm = 1.84–1.90 
(m, 2H, CH2), 1.93–2.06 (m, 4H, CH2), 2.33–2.39 (m, 2H, CH2), 5.78 (s, 2H, NH2), 7.30–
7.34 (m, 2H, ArH), 7.55–7.60 (m, 1H, ArH), 7.82–7.84 (m, 1H, ArH); 13C NMR (400 MHz, 
CDCl3): δ ppm = 27.6, 41.0, 43.1, 70.9, 109.3, 113.0, 116.5, 119.2, 122.3, 124.3, 132.3, 
152.2, 152.4, 154.6, 159.7; MS: m/z = 294 (M+); Anal. Calcd for C17H14N2O3: C, 69.38; H, 
4.79; N, 9.52. Found: C, 69.22; H, 4.65; N, 9.41. 
 
Spiro(2–amino–3–cyano pyrano[3,2–c]chromene–4,1’–cyclohexane) (AS–2) 
White solid; mp 230–232 ˚C; 
IR (KBr): 3400 (NH2), 2887 (CH2), 2279 (C≡N), 1714 (C=O), 1614, 1556, 1523 (ArC=C), 
1415 (CH2), 1031 (C–O) cm-1; MS: m/z = 308 (M+); Anal. Calcd for C18H16N2O3: C, 70.12; 
H, 5.23; N, 9.09. Found: C, 69.99; H, 5.10; N, 9.02. 
 
Spiro(2–amino–3–cyano pyrano[3,2–c]chromene–4,1’–cycloheptane) (AS–3) 
White solid; mp 225–226 ˚C; 
IR (KBr): 3314 (NH2), 2956, 2872 (CH2), 2196 (C≡N), 1718 (C=O), 1545 (ArC=C), 1442 
(CH2) cm-1; MS: m/z = 322 (M+); Anal. Calcd for C19H18N2O3: C, 70.79; H, 5.63; N, 8.69. 
Found: C, 70.64; H, 5.51; N, 8.54. 
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Mass spectrum of AS-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of AS-2 
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1H NMR spectrum of AS-1 
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13C NMR spectrum of AP-1 
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IR spectrum of AS-1 
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4.1 Introduction to Coumarin 
 
Heterocycles containing Oxygen and Nitrogen possess many biological and pharmacological 
properties. Besides, these they are also known to exhibit properties and applications such as 
anti-oxidants, heat stabilizers, photo sensitizers, indicators, lubricants and many more. 
 
Six membered oxygen heterocycles constitute a group of compounds, which occur widely 
throughout the plant kingdom. Coumarin (2H-1-benzopyran-2-one) is one of the naturally 
occurring heterocycles in many natural products. It is widely distributed in plant world either 
in free state or in combined state. It was first isolated from tonka beans (Dipteryx odorata). It 
also occurs in sweet clover (Melilotus Officinalis and Melilotus Alba) and woodruff (Aperula 
odorata). It is the parent substance of a very large group of derivatives and fused compounds, 
many of which occur naturally and are of economic importance for example, Umbelliferone, 
Aesculetin and Herniarin etc. 
 
O O O O
O O O O
HO
HO
HO MeO
Coumarin Umbelliferone
Aesculetin Herniarin  
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Coumarin chemistry has become important because of the discovery of varied biochemical 
properties, industrial uses and analytical applications. Coumarins have been found to be 
physiologically active for animals as well as humans. It acts as narcotics for rabbits, frogs and 
many other animals. 3-Chlorocoumarin have been proved to be sedative as well as hypnotic 
for mice and humans. However, it is toxic to dogs and humans.1 Werder synthesized over 
hundred derivatives of coumarin-3-carboxilic acids – they were found to be sedative in small 
doses and hypnotic in large doses.2 Coumarin also shows various other biological activities 
such as antifungal,3 anticoagulants,4 anti-psoriasis,5 anti-carcinogen,6 antibacterial7 and 
insecticidal.8 
 
Some of the commercial drugs having an application as vasodialators such as Chromonar and 
Visnadin, Antithelmintics like Haloxon, diuretics like mercumallylic acid, and systemic 
insecticide like Hymercromone. Antibiotic novobiocin produced by Streptomyces Spheroids 
and Sreptomyces Niveus has been marketed as antibacterial or antimicrobial preparations. 
O O
CH3
NEt2O(EtO)2 O OO
OO
O O
ClO
P
(ClCH2CH2O)2
O O O
OH
OMe
HOHg
O O
O
OH
CH2CH(CH3)2
O
O
MeO
O
OH
H2N
O
O OHO
Chromonar
Visnadin
Haloxan
Mercumallylic Acid
Hymercromone
Novobiocin  
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Coumarin is also used as synthetic intermediates for preparation of many heterocyclic 
compounds of biological and pharmacological importance.9-12 Some biological activities such 
anti-HIV13 and antitumor agents14 are also reported. 
 
4-Hydroxy coumarin is a metabolite of coumarin oxygen heterocycles, which are studied for 
their tautomeric structures.12 It can exist in 2 forms as shown below. Chemically, it is acidic 
in nature and therefore reacts easily at 3rd position. 
 
O
OH
O O
O
OH
4-Hydroxy-2H-chromen-2-one 2-Hydroxy-4H-chromen-4-one  
 
 
4.1.1 Preparation of coumarin  
 
There are many synthetic approaches for the preparation of coumarin skeleton. 
1. The biosynthesis of coumarin in plants is via hydroxylation, glycoysis and cyclization 
of cinnamic acid. Coumarin can be prepared in laboratory with the help of Perkin 
reaction between salicylaldehyde and acetic anhydride.15 
CHO
OH O
OO
O O
CH3COONa+
 
2. One of the most reliable method for preparation of coumarin and its derivatives is 
Pechmann condensation. It was discovered by the German chemist Hans von 
Pechmann.16 It is a condensation starting from phenol and a carboxylic acid or ester 
containing a β-carbonyl group under acidic conditions. 
HO OH
+
OEt
O O H2SO4
O
CH3
OHO  
3. Cyclization of 3-amino-3-phenyl propanoic acid in presence of HBr results in 58% 
yield of coumarin.17 
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COOH
NH2
O O
HBr
 
4. O-demethylation and lactonisation of E-cinnamic acid in presence of pyridine and 
HCl gives 55% yield of coumarin.18 
O
COOH
O O
C5H5N, HCl
 
5. Malonic acid diethyl ester condenses with salicylaldehyde to give coumarin.19 
CHO
OH EtO OEt
OO
O O
+
 
6. Manimaran et al synthesized coumarins, thiocoumarins and carbostyrils in the 
presence of AlCl3.20 
OH
O
AlCl3
O O  
7. Substituted coumarins and benzocoumarins were prepared by esterification of 2-furan 
acrylic acid with substituted phenols in presence of POCl3 and pyridine. Further, 
cyclization of furan acrylates were effected in presence of AlCl3 to yield 73% of 
coumarin.21 
O COOH O
OPh
O
O O
Phenol AlCl3
POCl3
 
8. Coumarin was also prepared via cyclization-elimination followed by cyclo 
condensation reaction between 2-hydroxybenzaldehyde and trimethylsilylketene in 
presence of NaH.22 
CHO
OH
CSi
O
NaH
O O
+
 
9. 3-Ethoxy acrolyl chloride with phenol in presence of triethyl amine and diethyl ether 
yielded phenyl ester, which on treatment with H2SO4 and SO3 cyclised to give 
coumarins in good yields (69%).23 
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Cl
O
OEt
Phenol
N-(Et)3, Et2O O
Ph
O
OEt
O O
H2SO4
SO3
 
10. Koepp Erich et al used Cs(OAc)2 instead of NaOAc in Perkin synthesis of cinnamic 
acid to yield coumarin 79%.24 
CHO
OH O O
Ac2O
Cs(OAc)2
 
The same group discussed a new approach of using aroamatic metallation reaction of 
aldehydes such as 2-(methoxymethoxy)benzaldehyde with LiCH2-CO-NMe2 and 
deblocking and cyclization of the adducts with AcOH.25 
CHO
O OMe
+ N
O
Li THF
AcOH
O O  
11. An European patent disclosed preparation of coumarin by cayalytivally 
dehydrogenation followed by cyclization of the cyclohexanoyl propionic acid esters at 
100-300 °C in presence of catalyst comprising of a carrier having Pd supported either 
on CrO3 or Cr(OH)3.26 
O
OMe
O
Pd
O O O O
42 % 26 %  
12. Zhou, Chengdong et al described an improved synthesis of coumarin by using 
salicylaldehyde. Salicylaldehyde was heated with Ac2O and PEG at 185 °C for 1 hour 
to give 2-acetoxy benzaldehyde. It was further heated with Ac2O and KF at 180-190 
°C for 4-5 hours to give 76% of coumarin.27 
CHO
OH
Ac2O
CHO
OAc
Ac2O
KF
O O  
13. Flash Vacuum Pyrolysis of salicylaldehyde and triphenyl phosphine adduct in 
presence of methylendichloride gave coumarin in 87% yield.28 
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OH
MeO
O
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Ph3
CH2Cl2
CHO
OMe
O
O O  
 
 
4.1.2 Preparation of 4-Hydroxy coumarin  
 
1. Zeigler and coworkers cyclised malonic acid diphenyl ester in presence of AlCl3 using 
Friedal Craft’s alkylation to give 4-hydroxy coumarin in 85% yield.29 
 
PhO OPh
O O
O
OH
O
AlCl3
 
 
2. Shah et al synthesized 4-hydroxy coumarin by fusion of Equimolar amount of 
malonic acid and phenol with 2-3 moles of POCl3 and ZnCl2 admixture which gave 
64% yield.30 
 
HO
O O
OH
OH
ZnCl2
POCl3
O
OH
O
+
 
 
3. Sheikh et al synthesized trimethoxy and tetramethoxy substituted 4-hydroxy 
coumarins by Friedal Craft’s acylation.31 
 
4. Selenium catalyzed carbonylation of 2-hydroxy acetophenone in THF containing 
nitrotoluene under carbon monoxide atmosphere at 90 °C for 30 hours giving 68% 
yield.32 
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O
OH
CO
Se, THF O
OH
O  
 
5. A facile synthesis of 4-hydroxy coumarin in presence of sulfur from 2-hydroxy 
acetophenone with carbon monoxide in presence of triethylamine and THF yielded 
96% of 4-hydroxy coumarin.33 
 
O
OH
CO
S, N(Et)3, THF O
OH
O  
 
6. Coumarins were also prepared by treating malonic acid diesters with MgCl2 and 
acetylsalicylic chloride and further cyclasation of resulting dialkyl 2-(2-
acetoxybenzoyl)malonate by alkali. Diethylmalonate, MgCl2 and acetylsalicylic 
chloride were treated with acetonitrile and triethylamine mixture at 0 °C for one hour. 
The product obtained was heated with KOH in methanol at 50 °C for 3 hours to give 
77% target compound.34 
 
OAc
O
Cl
EtO
O O
OEt
MgCl2, N(Et)3
MeCN, KOH, MeOH
O
OH
O  
 
7. Intraolecular Claisen condensation of methylacetylsalicylate with NaOMe in liquid 
paraffin at 160-260 °C for 5 hours gave 20% of 4-hydroxy coumarin.35 
 
OAc
O
OMe
Liq. paraffin
O
OH
O
NaOMe
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8. Substituted 4-hydroxy coumarin was synthesized via new Bakew-Venkatraman 
rearrangement.36 
 
N
O
OPh
Et
Et AcCl
BuLi, THF
Ac
O
O
Bu
NaH, THF
CF3COOH
PhMe O
OH
O  
 
9. One-pot synthesis of coumarin and 4-hydroxucoumarin by acylation followed by 
internal ring closure.37 
 
OAc
OH O
OH
O
Et2CO3+
NaH
PhMe
 
 
10. Salicylic acid was esterified and acetylated. It was further cyclized with metallic 
sodium in dry toluene.38a 
 
COOH
OH O
OH
O
+
MeOH
Na, Toluene
Ac2O
 
 
 
 
4.1.3 3-Substituted 4-Hydroxy coumarin  
 
V. V. Mulwad et. al. had synthesized 4-hydroxy coumarin-3-carbaldehyde and used to 
construct thiazolidinone and azetidinone ring system at 3 position of 4-hydroxy coumarin. All 
the compounds were screened for antimicrobial activity and shown good activity against S. 
typhi and S. aureus.38b 
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O
OH
O
CHO
NH2
R
O
OH
O
N
R
O
OH
O
N
S
R
O
O
OH
O
N
R
O Cl
+
SHCH2COOH ClCH2COCl
 
 
V. V. Mulwad et. al. synthesized some 4-hydroxy coumarin substituted at 3-position with 
oxazole, pyrimidine and thiazepine derivatives by condensation of 4-hydroxy-3-coumarinyl 
chalcon with ammonium hydroxide, urea and 2-aminothiophenol respectively and reported as 
good antibacterial agents.38c 
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In further investigation 4-hydroxy-3-coumarinyl chalcon was condensed with pyridinium salt 
of phenacyl bromide and ammonium acetate in acetic acid  to afford 4-hydroxy-3-pyridyl 
coumarin derivatives. All the compounds were screened for their antimicrobial activity and 
shown good activity.38d 
 
O
OH
O
O
RR
N
O
Br-
+
NH4OAc
AcOH
O
OH
O
N
RR
 
 
D. S. Satwe et. al. synthesized 4-hydroxy-3-coumarinylidene oxazolone by the reaction of 4-
hydroxy coumarin-3-carbaldehyde and 2-benzamidoacetic acid in acetic anhydride. It was 
further reacted with various hydrazine and various aromatic amines to give corresponding 
trazine and imidazol derivatives.38e,f 
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4-hydroxy-3-pyrazoline coumarin reacted with chloroacetylchloride to give corresponding N-
chloracetylpyrazoline which resulted into hydrazine derivative with hydrazine hydrate. This 
hydrazine derivative was utilized to prepare a number of thiazolidinine and azetidinone 
derivatives.38g 
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4.2 Introduction to Diazete 
 
Summary of the general chemistry of four-membered heterocycles: 
• The stability and reactivity of the compounds are determined by the ring strain and the 
nature of the heteroatom or heteroatoms. While azete, as an antiaromatic system, is 
extremely reactive, the aromatic systems 1,2-dithiete and l,2-dihydro-l,2-diazete are 
hardly any more stable and are very reactive. 
• Ring-opening by nucleophiles proceeds more slowly than with three-membered 
heterocycles and is catalyzed by acids. 
• Special ring-openings are [2+2] cycloreversions (oxetan-2-ones, 1,2-dioxetanes, l,2-
dioxetan-3-ones, 1,2-diazetidines, l,2-diazetidin-3-ones) and valence isomerizations 
(1,2-dithiete, 1,2-dihydro-1,2-diazete). 
• Oxetan-2-ones, azetidin-2-ones and l,2-diazetidin-3-ones are more reactive than five- 
and six membered homologues. They are attacked by nucleophiles on the C-atom of 
the carbonyl group. Ring-opening occurs to give γ-substituted carboxylic acids or 
carboxylic acid derivatives. 
• An important synthetic principle is the intramolecular nucleophilic substitution of a γ-
substituted leaving group 
— by an O-atom (oxetanes, oxetan-2-ones, 1,2-dioxetanes, 1,2-dioxetan-2-ones) 
— by an S-atom (thietanes) 
— by an N-atom (azetidines, azetidin-2-ones) 
The rate of reaction is greater than that of the three-membered heterocycles because 
of the smaller ring strain of the products. At the same time, however, the entropy gain 
is smaller, because two degrees of freedom of inner rotation are lost en route to the 
activated complex. 
• [2+2] Cycloadditions are of great importance for synthetic purposes 
— carbonyl compounds + alkenes -> oxetanes 
— aldehyde + ketenes -> oxetan-2-ones 
— imine + ketenes —> azetidin-2-ones 
— isocyanates + alkenes —> azetidin-2-ones 
— singlet oxygen + alkenes —> 1,2-dioxetanes 
— alkenes + azo compounds —» 1,2-diazetidines 
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— ketene + azo compounds —» l,2-diazetidin-3-ones 
• The importance of four-membered heterocycles for organic synthesis is limited. 
Examples are the alkene synthesis involving oxetan-2-ones and the /?-
aminocarboxylic acid synthesis involving azetidin-2-ones. 
 
1,2-Diazetines are a class of strained four membered ring azo compounds.39,40 Their 
properties remain largely unexplored presumably as a result of the difficulty of  their 
synthesis. Even though the first member of this family of compounds was described in 1962, 
fewer than a dozen diazetines are currently known.41 Despite the propensity for 
decomposition of diazetines to ultimately afford nitrogen and the corresponding alkene, 
diazetines are quite thermally robust.39,42 This has prompted questions concerning the 
mechanism of decomposition of these compounds with advocacy of concerted (both [2s + 2s] 
and [2s + 2a] retrocycloadditions being suggested) and nonconcerted (i.e., via diradical 
intermediates) processes.39,43 Detailed studies on the decomposition process have been 
hampered by the inaccessibility of diazetine substrates.39a,44 
 
4.2.1 Aromaticity  
 
Aromaticity continues to be an actively investigated area of chemistry.45 The simplest criteria 
for aromatic compounds are that they possess cyclic conjugated π-systems 
containing the proper number of π-electrons (i.e., the Huckel rule). While these criteria are 
robust enough to predict the aromaticity of a host of neutral and charged ring systems, it is 
not always a clear indicator of aromaticity for more complex systems. For instance, 
applying these criteria to the cyclobutadienyl dianion (1) one would predict an aromatic 
compound since it contains six π-electrons akin to that of benzene and the cyclopentadienyl 
anion. 
 
N N
H H
::::
1 2  
 
 115
Early computational studies suggested that 1 adopted a folded structure and was therefore not 
aromatic.46 More recent studies, however, suggested that the dianion is planar but adopts a 
structure with C2h symmetry rather than the D4h symmetry that would be expected for a fully 
delocalized aromatic structure.47 The failure to adopt a D4h structure was attributed to 
repulsive interaction of the negative charges within the ring. Indeed, only when two Li+ 
cations were added to the model system to stabilize the charges did the ring adopt the 
expected D4h symmetry.47 Recently, the synthesis and characterization of a cyclobutadienyl 
dianion substituted at each of the four carbons of the ring with anion-stabilizing trimethylsilyl 
groups was reported.48 The resulting compound was planar and almost square (as determined 
by X-ray crystallography), suggesting that it may be aromatic. 
 
The charge repulsion problem in the cyclobutadienyl dianion could be minimized by 
substituting the two adjacent negatively charged carbons of the ring by nitrogen atoms to 
afford a 1,2-dihydrodiazete (2). The 1,2-dihydrodiazetes are isoelectronic with the 
cyclobutadienyl dianion, but should experience considerably less charge/ charge repulsion 
and might, therefore, exhibit aromaticity without the need for additional stabilization. Only a 
few 1,2-dihydrodiazetes have been reported in the literature. The first to be reported were 
rather highly substituted derivatives (3) and their characterization did not include 
spectroscopic data.49 Greene reported the syntheses of 4 (R = Me, Ph) as stable crystalline 
compounds.50 Neither of these investigators discussed the possibility of aromaticity of the 
ring system. Warrener synthesized compound 5, which is substituted at the nitrogen by 
carbomethoxy groups.51 This compound proved to be of limited thermal stability and 
underwent spontaneous electrocyclic ring-opening at room temperature (t1/2[20 °C] = 6.9 h). 
Warrener considered the possibility of the ring’s aromaticity but ultimately rejected it based 
on its low thermal stability, 1H NMR spectroscopic data, and theoretical arguments.51b 
 
N N
NR2
SO2PhPh
N N
NO O
R
Ar Ar
N N
CO2MeMeO2C
Ar = 2,6-dimethyl-4-
         methoxyphenyl
3
4
5
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Gary W. Breton* et al reported the synthesis of compound 6, an analogue of Greene’s 
compound 4.52 Compound 6 is a stable crystalline compound that lent itself to thorough 
structural and chemical analyses. Gary W. Breton  presently reported our experimental work 
with 6 along with additional computational studies on 6 and 1,2-dihydrodiazetes in general to 
determine whether the 1,2-dihydrodiazete ring system exhibits any characteristics that may be 
attributed to aromaticity.53 
 
 
N N
O O
CH3
6  
 
 
4.2.2 Biological Importance  
 
3,4-Dihydrodiazete 1,2-dioxides (diazetine dioxides, DD) were described for the first time 
about 20 years ago;54 however, their biological activity was studied only recently.55 These 
compounds were found to exert strong vasorelaxant and antiaggregant effects.55 Spontaneous 
decomposition of DD was considered to be a source of nitric oxide (NO),54b,55 and the rate 
constants of this reaction were measured for a series of DD in aqueous solutions.55b However, 
the rate constants were in the range of 10-7 s-1, too low to account for the strong 
vasorelaxation induced by DD.55a,d Typical concentrations of diazetine dioxides causing 
significant vasodilation were determined to be in the range of 10-6 M.2 It has been shown that 
the activity of various NO liberating compounds is considerably influenced by thiols.56 
Diazetine dioxides are known to react with various nucleophilic and reducing agents. These 
reactions can proceed via diazetine ring opening and may be accompanied by a loss of one of 
the nitrogen atoms of the heterocycle.57 
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4.3 Current work   
 
 
In view of marked importance of coumarin core attached at 3 position with four membered 
nitrogen heterocycles in the field of vast area of organic and medicinal chemistry,38b-g Our 
interest was to develop a moieties containing coumarin core attached with nitrogen 
heterocycles. The precursor 4-hydroxy coumarin was synthesized as per mentioned in 
literature methods. Further microwave technique was utilized wherein, a mixture of 4-
hydroxy coumarin and triethyl orthoformate with catalytic amount of p-toluene sulfonic acid 
(PTSA) was subjected to microwave irradiation to prepare 3-ethoxymethylene-3H-2,4-dione. 
Further, the hydrolysis of 3-ethoxymethylene-3H-2,4-dione with K2CO3 resulted into 4-
hydroxy coumarin-3-carbaldehyde.58 Subsequently treatment of the 3-ethoxymethylene-3H-
2,4-dione with excess 50% solution of hydrazine hydrate at ambient temperature afforded 4-
hydroxy-2-oxo-2H-cromene-3-carbaldehyde hydrazone (scheme 2) in excellent yield. It was 
also found that the reaction does not require any solvent or external heating. The formation of 
hydrazone was further confirmed by mass and 1H NMR spectral study. The resulted 
hydrazone was reacted with various aldehydes in DMSO to afford 4-hydroxy-2-oxo-2H 
chromene-3-carbaldehyde(arylmethylene)hydrazone. Finally afforded derivative 
arylmethylene hydrazone undergoes 4π electron cyclization to construct a four membered 
1,2-diazete ring system and resulted into 4-hydroxy-3-(4-aryl-3,4-dihydro-1,2-diazet-3-yl)-
2H-chromen-2-one derivatives AA(1-18) (scheme 2). The formation of 1,2-diazete ring 
system was confirmed by IR, Mass, and 1H NMR spectral study. Physical properties of all 
newly synthesized compounds AA(1-18) are discussed in section 4.7. 
 
The plausible mechanism of 4π electron cyclization is presented in section 4.5. 
Arylmethylene hydrazone is a hetero analog of conjugated 1,3-butadiene system containing 
4π electron system which undergoes conrotatory or disrotatory 4π electron cyclization as per 
pericyclic reaction to construct a four membered 3,4-dihydro-1,2-diazete ring system at 3 
position of coumarin core. The anti viral screening of the synthesized compounds is under 
investigation. 
 
 118
 
4.4 Reaction Scheme 
 
4.4.1 Scheme 1.  
 
    Synthesis of 4-hydroxy coumarin 
 
OH
COOH
COOH O O
OH
+
ZnCl2
POCl3
70oC  
 
 
4.4.2 Scheme 2.  
 
Synthetic approach towards 4-hydroxy-3-(4-phenyl-3,4-dihydro-1,2-diazet-
3-yl)-2H-chromen-2-one derivatives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and conditions: (a) Triethyl orthoformate, p-Toluenesulfonic acid, MW 240 
W, 2 min.; (b) NH2NH2•H2O, r.t., Stirring; (c) R–CHO, DMSO, con. HCl, 100ºC, 30 min. 
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4.5 Reaction Mechanism 
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4.6 Experimental  
 
 
4.6.1 4-hydroxy coumarin: 
Phenol (9.41g, 0.1M) and malonic acid (10.4g, 0.1M) were added to a mixture of phosphorus 
oxychloride (40 ml) and anhydrous zinc chloride (30 g) which was preheated to 60 ºC. The 
reaction mixture was heated on a water bath at 70 ºC for 10 hours. It was cooled and 
decomposed with ice and water which forms a yellow solid. It was filtered and washed with 
water. It was further triturated with 10 % sodium carbonate and filtered. The filtrate was 
slowly acidified with dilute hydrochloric acid. At the neutral point, some solid product was 
separated, which was filtered, washed with water, dried and recrystallized from ethanol. 
White solid; m.p. 210 ºC; Yield: 55%. 
 
4.6.2 3-(ethoxymethylene)-2H-chromene-2,4(3H)-dione: 
A mixture of 6.2 mmol of 4-hydroxy coumarin, 7 ml of triethyl orthoformate, and 0.02 g of 
p-toluenesulfonic acid monohydrate was placed in a 50 ml beaker. The beaker was covered 
with a stemless funnel and irradiated in a microwave oven for 1 minute at 240 W and then 1 
minute at 180 W. The resultant residue was cooled to room temperature, the solvent was 
decanted, and the residue was crystallized in a chloroform to obtain target compound as a 
yellow solid. m.p. 140 ºC; Yield: 65%. 
  
4.6.3 4-hydroxy-2-oxo-2H-cromene-3-carbaldehyde hydrazone: 
3-(ethoxymethylene)-2H-chromene-2,4(3H)-dione (20.41g, 0.1M) was added to a 50% 
hydrazine hydrate solution (50 ml). Now the reaction mixture was stirred at room temperature 
for 10-15 minutes. The solid was filtered off, washed with water until free from hydrazine 
hydrate, dried and crystallized in chloroform to give pure 4-hydroxy-2-oxo-2H-chromene-3-
carbaldehyde hydrazone as yellow solid. m.p. 138 ºC; Yield: 85%.  
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4.6.4 4-hydroxy-3-(4-aryl-3,4-dihydro-1,2-diazet-3-yl)-2H-chromen-2-
one: 
4-hydroxy-2-oxo-2H-chromene-3-carbaldehyde hydrazone (0.01M) and appropriate aryl 
aldehyde (0.01M) were dissolved in 10 ml of DMSO and 2-3 drops of con. HCl was added as 
a catalyst. The reaction mixture was heated at 100 °C for 30 min. The separated solid was 
filtered off, washed with cold methanol and dried. The obtained crude product was 
recrystallized in chloroform to give 4-hydroxy-3-(4-aryl-3,4-dihydro-1,2-diazet-3-yl)-2H-
chromen-2-one as yellow crystals.  
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4.7 Physical data  
 
 
 
 
 
Comp. R M.F. M.W. Mp ºC Yield % Rf 
AA-1 Ph C17H12N2O3 292.28 230-232 75 0.35 
AA-2 4-CH3-C6H4 C18H14N2O3 306.31 214-216 71 0.41 
AA-3 4-OCH3-C6H4 C18H14N2O4 322.31 206-208 76 0.36 
AA-4 3,4-di-OCH3-C6H4 C19H16N2O5 352.34 218-220 86 0.34 
AA-5 2,5-di-OCH3-C6H4 C19H16N2O5 352.34 210-212 79 0.39 
AA-6 2-Cl-C6H4 C17H11ClN2O3 326.73 212-214 65 0.46 
AA-7 3-Cl-C6H4 C17H11ClN2O3 326.73 217-219 71 0.45 
AA-8 4-Cl-C6H4 C17H11ClN2O3 326.73 224-226 75 0.32 
AA-9 4-F-C6H4 C17H11FN2O3 310.27 206-208 65 0.48 
AA-10 2-OH-C6H4 C17H12N2O4 308.28 210-212 70 0.49 
AA-11 3-NO2-C6H4 C17H11N3O5 337.28 223-225 80 0.30 
AA-12 4- NO2-C6H4 C17H11N3O5 337.28 214-216 80 0.33 
AA-13 2- NO2-C6H4 C17H11N3O5 337.28 224-226 76 0.29 
AA-14 3-Br-C6H4 C17H11BrN2O3 371.18 216-218 70 0.41 
AA-15 4-N,N-di-CH3-C6H4 C19H17N3O3 335.35 204-206 60 0.47 
AA-16 3-Pyridyl C16H11N3O3 293.27 228-230 62 0.50 
AA-17 2-Furyl C15H10N2O4 282.25 214-216 58 0.48 
AA-18 1-napthyl C21H14N2O3 342.34 227-229 72 0.32 
 
TLC Solvent system: Ethyl acetate : Hexane – 3.5:6.5 
 
O O
OH N N
R
AA (1-18)
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4.8 Spectral discussion 
 
 
4.8.1  Mass spectral study 
 
Instrument                : SHIMADZU GCMS-QP-2010 
Sample technique    : EI technique 
M/z range                  : 40-500 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection 
Probe technique. Systematic fragmentation pattern was observed in mass spectral analysis. 
Peaks for specific fragments were identified in each mass spectrum. Molecular ion peak was 
observed in agreement with molecular weight of respective compound. M++1 peak was also 
observed with very low intensity. Another characteristic peak M+-N2 was observed. Extrusion 
of N2 from compound in the mass spectra reveals the existence of the cyclic product, which 
is in accordance with the assigned structure. After this fragmentation another cleavage was 
observed with removal of hydroxy group. 
 
4.8.2  IR spectral study 
 
Instrument                 : Shimadzu FT-IR-8400 
Sample technique     : KBr pellet 
Frequency range       : 400-4000cm-1 
As per IR spectral study of newly synthesized 4-hydroxy-3-(4-aryl-3,4-dihydro-1,2-diazet-3-
yl)-2H-chromen-2-one derivatives, the O–H stretching vibration of hydroxy group attached at 
4 position of coumarin ring was appeared around 3100-3400 cm-1. The carbonyl (>C=O) 
stretching vibration of coumarin lactone ring was observed around 1690–1715 cm-1. The 
N=N stretching vibration was observed between 1575 to 1600 cm-1. The ring skeleton 
vibration was observed between 1500 to 1600 cm-1 due to the presence of phenyl ring system.  
 
4.8.3  1H NMR spectral study 
 
Instrument                  : BRUKER AC 400 MHz FT-NMR 
Internal reference       : TMS 
Solvent                        : CDCl3 
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Number of protons and their chemical shifts were found to support the structure of the 
synthesized compounds. Proton of hydroxy group attached with coumarin ring at 4 position 
‘a’ was observed at 14.02-14.15 δ ppm. Two methine protons of diazete ring ‘b’ and ‘c’ were 
observed as a doublet at around 8.8 and 8.6 δ ppm. The coupling constants for the splitting 
were calculated which were observed between 12 to 15 Hz. Methine protons of 1,2-diazete 
ring have been observed variable in 1H NMR spectrum depending upon the substitutions at 3 
and 4 position of 1,2-diazete ring. G. W. Breton et al.59observed methine proton of 1,2-
diazete ring between 4 to 5 δ ppm. Yutaka Ishida et al.60 observed methine proton of 1,3-
diazete ring at 8.69 δ ppm. In the proposed structure, methine proton of diazete ring were 
observed with very downfield chemical shift in 1H NMR spectrum due to attachment of 
coumarin and phenyl ring at 3 and 4 positions of diazete ring. Benzenoid protons of coumarin 
‘d’ were observed between 7.60 to8.10 δ ppm in its characteristic pattern doublet-triplet-
doublet. Protons ‘e’ of phenyl ring attached with diazete ring were observed at 6.90-7.45 δ 
ppm as a multiplate. All 1H NMR data are consistent with proposed structure. 
 
4.8.5  Elemental Analysis 
 
Elemental analysis of the all the synthesized compounds was carried out on Elemental Vario 
EL III Carlo Erba 1108 model and the results are in agreements with the structures assigned. 
 
 
 
 
 
 
 
 
O
OH
O
N N
a
b c
d e
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Spectral data of synthesized compounds (AA 1-18) 
 
4-hydroxy-3-(4-phenyl-3,4-dihydro-1,2-diazet-3-yl)-2H-chromen-2-one (AA-1) 
Yellow solid; mp 230-232 ˚C;  
IR (KBr): 3200, 1690 cm-1; 1H NMR (400 MHz, DMSO): δ ppm = 14.04 (s, 1H, OH), 8.80 
(d, 1H, CH), 8.67 (d, 1H, CH), 7.96 (t, 1H, Ar), 7.73 (d, 2H, Ar), 7.57 (t, 1H, Ar), 7.45-7.39 
(m, 3H, Ar), 7.26-7.17 (m, 2H, Ar); MS: m/z = 292 (78, [M+]), 264 (4, [M+-N2]), 188 (60), 
121 (100); Anal. Calcd for C17H12N2O3: C, 69.86; H, 4.14; N, 9.58. Found: C, 69.84; H, 
4.10; N, 9.55. 
 
4-hydroxy-3-[4-(4-methylphenyl)-3,4-dihydro-1,2-diazet-3-yl]-2H-chromen-2-one (AA-
2) 
Yellow solid; mp 214-216 ˚C; 
IR (KBr): 3190, 1690 cm-1; 1H NMR (400 MHz, DMSO): δ ppm = 14.14 (s, 1H, OH), 8.95 
(d, 1H, CH), 8.60 (d, 1H, CH), 8.05 (t, 1H, Ar), 7.69 (d, 2H, Ar), 7.67 (t, 1H, Ar), 7.64-7.60 
(m, 4H, Ar), 2.42 (s, 3H, CH3); MS: m/z = 306 (87, [M+]), 278 (4, [M+-N2]), 188 (56), 121 
(100); Anal. Calcd for C18H14N2O3: C, 70.58; H, 4.61; N, 9.15. Found: C, C, 70.53; H, 4.69; 
N, 9.16. 
 
4-hydroxy-3-[4-(4-methoxyphenyl)-3,4-dihydro-1,2-diazet-3-yl]-2H-chromen-2-one (AA-
3) 
Yellow solid; mp 206-208 ˚C; 
IR (KBr): 3140, 1716 cm-1; 1H NMR (400 MHz, DMSO): δ ppm = 14.07 (s, 1H, OH), 8.86 
(d, 1H, CH), 8.70 (d, 1H, CH), 8.02 (t, 1H, Ar), 7.73 (d, 2H, Ar), 7.62 (t, 1H, Ar), 7.31-7.23 
(m, 2H, Ar), 7.00-6.98 (m, 2H, Ar), 3.86 (s, 3H, OCH3); MS: m/z = 322 (96, [M+]), 294 (3, 
[M+-N2]), 188 (35), 134 (100); Anal. Calcd for C18H14N2O4: C, 67.07; H, 4.38; N, 8.69. 
Found: C, 67.01; H, 4.34; N, 8.74. 
 
3-[4-(3,4-dimethoxyphenyl)-3,4-dihydro-1,2-diazet-3-yl]-4-hydroxy-2H-chromen-2-one 
(AA-4) 
Yellow solid; mp 218-220 ˚C; 
IR (KBr): 3210, 1699 cm-1; MS: m/z = 352 (M+); Anal. Calcd for C19H16N2O5: C, 64.77; H, 
4.58; N, 7.95. Found: C, 64.76; H, 4.54; N, 7.96. 
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3-[4-(2,5-dimethoxyphenyl)-3,4-dihydro-1,2-diazet-3-yl]-4-hydroxy-2H-chromen-2-one 
(AA-5) 
Yellow solid; mp 210-212 ˚C; 
IR (KBr): 3200, 1690, 1654,  cm-1; 1H NMR (400 MHz, DMSO): δ ppm = 14.07 (s, 1H, 
OH), 8.96 (d, 1H, CH), 8.90 (d, 1H, CH), 8.03 (t, 1H, Ar), 7.91 (d, 2H, Ar), 7.62 (t, 1H, Ar), 
7.44 (t, 1H, Ar), 7.30 (t, 1H, Ar); 7.26 (t, 1H, Ar), 3.88 (s, 6H, OCH3); MS: m/z = 352 (M+); 
Anal. Calcd for C19H16N2O5: C, 64.77; H, 4.58; N, 7.95. Found: C, 64.78; H, 4.52; N, 7.93. 
 
3-[4-(2-chlorophenyl)-3,4-dihydro-1,2-diazet-3-yl]-4-hydroxy-2H-chromen-2-one (AA-6) 
Yellow solid; mp 212-214 ˚C; 
IR (KBr): 3221, 1702 cm-1; MS: m/z = 326 (M+); Anal. Calcd for C17H11ClN2O3: C, 62.49; 
H, 3.39; N, 8.57. Found: C, 62.47; H, 3.33; N, 8.54. 
 
3-[4-(3-chlorophenyl)-3,4-dihydro-1,2-diazet-3-yl]-4-hydroxy-2H-chromen-2-one (AA-7) 
Yellow solid; mp 217-219 ˚C; 
IR (KBr): 3180, 1715 cm-1; MS: m/z = 326 (M+); Anal. Calcd for C17H11ClN2O3: C, 62.49; 
H, 3.39; N, 8.57. Found: C, 62.53; H, 3.35; N, 8.60. 
 
3-[4-(4-chlorophenyl)-3,4-dihydro-1,2-diazet-3-yl]-4-hydroxy-2H-chromen-2-one (AA-8) 
Yellow solid; mp 224-226 ˚C; 
IR (KBr): 3240, 1717 cm-1; MS: m/z = 326 (M+); Anal. Calcd for C17H11ClN2O3: C, 62.49; 
H, 3.39; N, 8.57. Found: C, 62.46; H, 3.37; N, 8.54. 
 
3-[4-(4-fluorophenyl)-3,4-dihydro-1,2-diazet-3-yl]-4-hydroxy-2H-chromen-2-one (AA-9) 
Yellow solid; mp 206-208 ˚C; 
IR (KBr): 3088, 1716 cm-1; MS: m/z = 310 (M+); Anal. Calcd for C17H11FN2O3: C, 65.81; 
H, 3.57; N, 9.03. Found: C, 65.84; H, 3.56; N, 9.01. 
 
4-hydroxy-3-[4-(2-hydroxyphenyl)-3,4-dihydro-1,2-diazet-3-yl]-2H-chromen-2-one (AA-
10) 
Yellow solid; mp 210-212 ˚C; 
IR (KBr): 3400, 3259, 1696 cm-1; MS: m/z = 308 (M+); Anal. Calcd for C17H12N2O4: C, 
66.23; H, 3.92; N, 9.09. Found: C, 66.23; H, 3.91; N, 9.06. 
 
4-hydroxy-3-[4-(3-nitrophenyl)-3,4-dihydro-1,2-diazet-3-yl]-2H-chromen-2-one (AA-11) 
Yellow solid; mp 223-225 ˚C; 
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IR (KBr): 3565, 1693 cm-1; MS: m/z = 337 (M+); Anal. Calcd for C17H11N3O5: C, 60.54; H, 
3.29; N, 12.46. Found: C, 60.55; H, 3.29; N, 12.43. 
 
4-hydroxy-3-[4-(4-nitrophenyl)-3,4-dihydro-1,2-diazet-3-yl]-2H-chromen-2-one (AA-12) 
Yellow solid; mp 214-216 ˚C; 
IR (KBr): 3490, 1697 cm-1; MS: m/z = 337 (M+); Anal. Calcd for C17H11N3O5: C, 60.54; H, 
3.29; N, 12.46. Found: C, 60.50; H, 3.25; N, 12.44. 
 
4-hydroxy-3-[4-(2-nitrophenyl)-3,4-dihydro-1,2-diazet-3-yl]-2H-chromen-2-one (AA-13) 
Yellow solid; mp 224-226 ˚C; 
IR (KBr): 3423, 1702 cm-1; MS: m/z = 337 (M+); Anal. Calcd for C17H11N3O5: C, 60.54; H, 
3.29; N, 12.46. Found: C, 60.50; H, 3.29; N, 12.47. 
 
4-hydroxy-3-[4-(3-bromophenyl)-3,4-dihydro-1,2-diazet-3-yl]-2H-chromen-2-one (AA-14) 
Yellow solid; mp 216-218 ˚C; 
IR (KBr): 3211, 1686 cm-1; MS: m/z = 371 (M+); Anal. Calcd for C17H11BrN2O3: C, 55.01; 
H, 2.99; N, 7.55. Found: C, 55.05; H, 2.97; N, 7.53. 
 
3-{4-[4-(dimethylamino)phenyl]-3,4-dihydro-1,2-diazet-3-yl}-4-hydroxy-2H-chromen-2-
one (AA-15) 
Yellowish red solid; mp 204-206 ˚C; 
IR (KBr): 3209, 1719 cm-1; MS: m/z = 335 (M+); Anal. Calcd for C19H17N3O3: C, 68.05; H, 
5.11; N, 12.53. Found: C, 68.02; H, 5.14; N, 12.50. 
 
4-hydroxy-3-(4-pyridin-3-yl-3,4-dihydro-1,2-diazet-3-yl)-2H-chromen-2-one (AA-16) 
Yellow solid; mp 228-230 ˚C;IR (KBr): 3235, 1699 cm-1; MS: m/z = 293 (M+); Anal. Calcd 
for C16H11N3O3: C, 65.53; H, 3.78; N, 14.33. Found: C, 65.51; H, 3.72; N, 14.36. 
 
3-[4-(2-furyl)-3,4-dihydro-1,2-diazet-3-yl]-4-hydroxy-2H-chromen-2-one (AA-17) 
Yellow solid; mp 214-216 ˚C;IR (KBr): 3266, 1689 cm-1; MS: m/z = 282 (M+); Anal. Calcd 
for C15H10N2O4: C, 63.83; H, 3.57; N, 9.92. Found: C, 63.90; H, 3.53; N, 9.89. 
 
4-hydroxy-3-[4-(1-naphthyl)-3,4-dihydro-1,2-diazet-3-yl]-2H-chromen-2-one (AA-18) 
Yellow solid; mp 227-229 ˚C;IR (KBr): 3253, 1717 cm-1; MS: m/z = 342 (M+); Anal. Calcd 
for C21H14N2O3: C, 73.68; H, 4.12; N, 8.18. Found: C, 73.35; H, 4.19; N, 8.03. 
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1H NMR spectrum of Hydrazone 
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1H NMR spectrum of AA-1 
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1H NMR spectrum of AA-3  
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1H NMR spectrum of AA-2  
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1H NMR spectrum of AA-5  
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Mass Spectrum of Hydrazone 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass Spectrum of AA-1 
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Mass Spectrum of AA-2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass Spectrum of AA-3 
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Mass Spectrum of AA-4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass Spectrum of AA-12 
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IR spectrum of AA-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR spectrum of AA-2 
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IR spectrum of AA-3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IR spectrum of AA-9 
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IR spectrum of AA-11 
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5.1 Introduction to chromene-2,4-dione 
 
In earlier chapter, it was observed that coumarins from a part of many heterocyclic 
compounds with important pharmacological activity and are being evaluated for potential 
biological activities. Since coumarins are active at C-3 position, these moieties easily undergo 
C-3 substitution reactions. 
 
Biological systems easily accept the chromene nucleus of coumarin as against its tautomeric 
chromane and hence were studied extensively as antimicrobial.1-3 
 
Antimicrobial and anti-tubercular activity of 2,4-chromane dione were studied and 
established by Chavda and Shah et al.4 They observed that the introduction of electron with-
drawing group like nitro and fluoro at the benzenoid part of chromane may help in increasing 
the potency at much lower concentration. 
 
4-hydroxy coumarins frequently react with aromatic aldehydes to give 3-benzylidene-2,4-
chromandiones.5-8 
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Similarly, reaction of 4-hydroxycoumarin with acetylated aldehydohexoses in ethanol for 24 
hours gave 2,4-chromanedione as given below.9 
 
O
OH
O
OHC(CHOAc)4CH2OAc
O
O
CH(CHOAc)4CH2OAc
O  
 
Reaction between 4-hydroxycoumarin and hydroxylamine hydrochloride gave corresponding 
2,4-chromandione-3-oxime.10 However, reaction of 4-hydroxycoumarin with sodium nitrite 
afforded 2,3,4-chromantrione-3-oxime which forms a silver salt.11 
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(B) aq. NaNO2  
 
When 3-amino-4-hydroxycoumarin was reacted with nitrous acid gave 3-diazo-2,4-
chromandione. The same product was also obtained in 72% yield when sodium nitrite in 
dilute hydrochloric acid was added to 3-amino-4-hydroxycoumarin.12 
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Treatment of substituted 4-hydroxycoumarin with diazotized anilines at temperature below 
0°C gave 3-phenylhydrazone-2,3,4-chromantrione.13 
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Sureja D.14 synthesized 2,3,4-chromantrione phenylhydrazones by diazo coupling of 4-
hydroxy-6-methyl coumarin with various arylamines. The compounds were tested for 
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antitubercular activitiy and the results were very promising. In few cases, MIC was observed 
<12.5 μg/mg bearing 90% inhibition against H37Rv strain, when compared to Rifampicin 
(0.125 μg/mg). 
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When a mixture of (2-hydroxy benzoyl) acetanilide, ethyl orthoformate and acetic anhydride 
was heated at 100–110 °C for 7 minutes, 3-anilinomethylene-2,4-chromandione was isolated 
in 44% yield.15 
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Hamdi and coworkers synthesized many new compounds N-(methylene-4-oxo-coumarinyl) 
caebamates by condensation of carbamates with 4-hydroxy coumarin in the presence of 
triethylorthoformate with good yields.16 
 
O
OH
O O
O
O
N
H
COORHC(OEt)3
NH2COOR
 
 
Further, when 4-hydroxy coumarin reacted with an amino acid in the presence of excess 
triethyl orthoformate gave the compounds outlined as below with good yield. The amino 
acids like glycine, alanine, leucine, phenyl alanine, tyrosine, tryptophan, L-DOPA, serine, 
cysteine and glutamine were used.17 
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5.2 Introduction to 1,3-diazetidine  
 
 
In four-membered heterocycles, the ring strain is less than in the corresponding three-
membered compounds and is approximately equal to that found in cyclobutane.  
Nevertheless, ring-opening reactions forming acyclic products predominate. At the same 
time, analogy with the reactivity of the corresponding aliphatic compounds (ethers, 
thioethers, secondary and tertiary amines, imines) becomes more evident. 
 
1,3-Diazetidines are a class of strained four membered ring azo compounds. Their properties 
remain largely unexplored presumably as a result of the difficulty of their synthesis. Even 
though a dozen diazetines are currently known. Despite the propensity for decomposition of 
diazetines to ultimately afford nitrogen and the corresponding alkene, diazetines are quite 
thermally robust. 
 
According to the Huckel (4n + 2)/4n rule, four-membered-ring compounds should be 
aromatic with 2 or 6π-electrons and antiaromatic with 4π-electrons.18 Despite these 
predictions, few four-membered-ring 6π-systems are known. The instability of the 6π 
cyclobutadiene dianion has been attributed to the large negative charge per carbon atom19 and 
more recently also to the strong 1,3-repulsive interactions in the π-system.20,21 The 
isoelectronic neutral dioxetenes (CHO)2 and diazetines (CHNH)2 suffer less from 
electrostatic repulsions and might be expected to be more favorable. The structures of 1,3-
diazetine, 1,2-diazetine, and diazabicyclobutane have already been studied at the MIND0/3 
level by Minyaev and Minkin.22 
 
Peter H. M. Budzelaar et al23 reported that the lack of aromaticity of four-membered-ring 6π-
heterocycles can be attributed to two main factors, viz., the strongly 1,2- and/or 1,3-
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antibonding character of the higher occupied π-orbitals and the electronegativity difference 
between C and 0 or C and N. Both factors favor localization of π-electrons and ring-opening 
reactions. Presumably, 6π-aromaticity requires at least a five membered-ring system, where 
the nonbonded repulsions are much less severe. 
 
Kevin J. Gessner et al24 had calculated some fundamental properties like geometries, 
vibrations, enthalpies and other energies of 1,3-diazitidine using Gaussian-X and two 
complete basis set of methods. Most of the bonding parameters are, again, unremarkable. 
However, for the trans isomer, the minimum-energy geometry is predicted to have a planar 
backbone, giving the molecule a nominal C2v symmetry instead of the Cs symmetry of the 
puckered geometry. Because of this, the calculated dihedral angles that the hydrogen atoms 
make with the ring backbone are very different for these methods. The cis-1,3-diazetidine 
molecule has C2v symmetry even when puckered. For the 1,3-diazetidine isomers the 
predicted enthalpies of formation are lower by 60–80 kJ/mol. The diazetidines produce less 
energy per mole of oxidant, but at about 530 kJ/mol O2 they still produce more energy than 
methane on that basis. For 1,3-diazetidine, the NH groups are on opposite corners of the ring, 
so the effects on the proton affinity due to cis/trans isomerism should be minimized. 
Although the calculated proton affinity of the cis isomer is consistently higher that that of the 
trans isomer, it is only by 1–2 kJ/mol. Proton affinity calculations suggest that diazetidines 
will react strongly as bases. 
 
 
 
The normal mode frequencies and corresponding vibrational assignments of 1,3-dichloro-1,3-
diazetidine-2,4-dione were examined theoretically using the Gaussian 98 set of quantum 
chemistry codes by James O. Jensen25 Crystal structures of 1,3-dichloro-1,3-diazetidine-2,4-
dione have been determined by X-ray crystallography, and new infrared and Raman data of 
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that have been recorded in the solid state, leading to revised and complete fundamental 
frequency assignments by Ferdinand Belaj26 1,3-Diazetidine show a planar ring with a trans-
configuration of the chlorine substituent. The angles between the C-N-C plane and the 
exocyclic N-Cl bond are 32.5°. 
 
H. Ulrich et al27 found that 2-imino-4-thioxo-1,3-diazetidines (1) are formed in quantitative 
yields when isothiocyanates activated by an electron-withdrawing substituents (such as p-
nitrophenyl or alkyl- and arylsulfonyl) and carbodiimides are mixed at room temperature in a 
molar ratio of 1 : 1 with or without solvent. The reaction can be followed by infrared 
spectroscopy by the disappearance of the absorptions in the cumulative double bond region 
(4.7-4.9 μ) and by the appearance of a new C=N absorption at 6.05 μ in the case of (1a) and 
(1b), at 6.19 μ in the case of (1c) and at 6.25 μ in the case of (1d). 
 
RNCS R'N=C=NR' NN
NR'
S
RR'+ (1)
 
 
(1a) R = p-Nitrophenyl, R' = Isopropyl, m.p. 51-52°C 
(1b) R = p-Nrtrophenyl, R' = Cyclohexyl, m.p. 73-75°C 
(1c) R = Methylsulfonyl, R' = Phenyl,  m.p. 173-174°C 
(1d) R = p-Tolylsulfonyl, R' = Tolyl,  m.p. 128-129°C 
 
Henri Ulrich et al28 reprted that N-alkyl-N-arylcarbodiimides add alkyl and aryl isocyanates 
to the N-alkyl substituted CN double bond to yield 4-arylimino1,3-diazetidine-2-ones. 
 
R N C NR1 R2N C O
R2N
NR1
O
N
R
+
 
 
 
 148
Howard Alper et al29 reported the preparation of 1,3-diazetidinones by 
bis(dibenzylideneacetone)palladium(0)-catalyzed carbonylation of diaziridines having one 
substituent attached to the ring carbon atom. This regiospecific insertion into the nitrogen-
nitrogen bond also occurs for 3,3-disubstituted diaziridines, provided one uses stoichiometric 
quantities of cobalt carbonyl. 
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Yasunori Aoyama et al30 demonstrated that the 1,3-diazetidine-2,4-dione nucleus is effective 
as a scaffold for the inhibition of serine proteases. 
 
P. S. Chandrakala et al31 synthesized some mono- and bi-cyclic 1,3-diazetidin-2-ones (aza-β-
lactams), and evaluated as non-natural analogues of β-lactams. 
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Mateo Alajarın et al32 reported that Aza-Wittig reactions of bis(iminophosphorane) 1 derived 
from 2,2’-diazidobiphenyl with aromatic isocyanates provides dibenzo[d,f]-1,3-
diazetidino[1,2-a]diazepine derivatives 2 in moderate yields. 
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5.3 Current work   
 
 
In view of marked importance of chromene core and four membered nitrogen heterocycles in 
the field of vast area of organic and medicinal chemistry, four membered ring 1,3-diaztedine-
2-thione is constructed at 3 position of chromene 2,4-dione moiety. The precursor 4-hydroxy 
coumarin was synthesized as per mentioned in literature methods. A mixture of 4-hydroxy 
coumarin and triethyl orthoformate with catalytic amount of p-toluene sulfonic acid (PTSA) 
was subjected to microwave irradiation to prepare 3-ethoxymethylene-3H-2,4-dione. The 
hydrolysis of 3-ethoxymethylene-3H-2,4-dione with K2CO3 results into 4-hydroxy coumarin-
3-carbaldehyde.33 Subsequently 3-ethoxymethylene-3H-2,4-dione was reacted with various 
N-aryl thiourea in chloroform at reflux temperature for 30 minutes which results into 3-(1-
aryl-4-thioxo-1,3-diazetidin-2-yl)-2H-chromene-2,4(3H)-dione via intramolecular 
cyclization. The plausible mechanism for the cyclization is shown in section 5.5. All the 
synthesized compounds were characterized by IR, Mass, and 1H NMR discussed in section 
5.8. The anti viral screening of the synthesized compounds is under investigation. 
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5.4 Reaction Scheme 
 
5.4.1 Scheme 1.  
 
    Synthesis of 4-hydroxy coumarin 
 
OH
COOH
COOH O O
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ZnCl2
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5.4.2 Scheme 2.  
 
Synthetic approach towards 3-(1-phenyl-4-thioxo-1,3-diazetidin-2-yl)-2H-
chromene-2,4(3H)-dione derivatives 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents and conditions: (a) Triethyl orthoformate, p-Toluenesulfonic acid, MW 240 
W, 2 min.; (b) RNHCSNH2, CHCl3, Reflux, 30 min. 
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5.5 Reaction Mechanism: 
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5.6 Experimental  
 
 
5.6.1 4-hydroxy coumarin: 
Phenol (9.41g, 0.1M) and malonic acid (10.4g, 0.1M) were added to a mixture of phosphorus 
oxychloride (40 ml) and anhydrous zinc chloride (30 g) which was preheated to 60 ºC. The 
reaction mixture was heated on a water bath at 70 ºC for 10 hours. It was cooled and 
decomposed with ice and water which forms a yellow solid. It was filtered and washed with 
water. It was further triturated with 10 % sodium carbonate and filtered. The filtrate was 
slowly acidified with dilute hydrochloric acid. At the neutral point, some solid product was 
separated, which was filtered, washed with water, dried and recrystallized from ethanol. 
White solid; m.p. 210 ºC; Yield: 55%. 
 
5.6.2 3-(ethoxymethylene)-2H-chromene-2,4(3H)-dione: 
A mixture of 6.2 mmol of 4-hydroxy coumarin, 7 ml of triethyl orthoformate, and 0.02 g of 
p-toluenesulfonic acid monohydrate was placed in a 50 ml beaker. The beaker was covered 
with a stemless funnel and irradiated in a microwave oven for 1 minute at 240 W and then 1 
minute at 180 W. The resultant residue was cooled to room temperature, the solvent was 
decanted, and the residue was crystallized in a chloroform to obtain target compound as a 
yellow solid. m.p. 140 ºC; Yield: 65%. 
  
5.6.3 3-(1-aryl-4-thioxo-1,3-diazetidin-2-yl)-2H-chromene-2,4(3H)-
dione: 
In a round bottom flask, 3-propylidene-2H-chromene-2,4-dione 2 (0.01 mol), appropriate 
substituted phenyl thiourea (0.015 mol) and CHCl3 (25 mL) were placed and refluxed for 30 
minutes with stirring. Then reaction mixture was allowed to cool at ambient temperature and 
solvent was evaporated in vaccuo. The crude mixture was added 50 mL water and extracted 
with ethyl acetate (3 × 15 mL). Organic phase was dried over MgSO4 and then concentrated 
under reduced pressure to afford crude material which was crystallized in chloroform to give 
pure target compound in 75-80 % yield. 
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5.7 Physical data  
 
 
 
 
 
 
Comp. R M.F. M.W. Mp ºC Yield % Rf 
ATU-1 Ph C17H12N2O3S 324.35 230-232 75 0.48 
ATU-2 4-OCH3-C6H4 C18H14N2O4S 354.37 206-208 76 0.45 
ATU-3 2,4-di-CH3-C6H4 C19H16N2O3S 352.40 218-220 81 0.41 
ATU-4 2,5-di-CH3-C6H4 C19H16N2O3S 352.40 210-212 79 0.42 
ATU-5 3-Cl-C6H4 C17H11ClN2O3S 358.79 217-219 71 0.54 
ATU-6 4-Cl-C6H4 C17H11ClN2O3S 358.79 224-226 75 0.56 
ATU-7 3-NO2-C6H4 C17H11N3O5S 369.35 223-225 80 0.61 
ATU-8 4- CH3-C6H4 C17H12N2O3S 326.73 214-216 76 0.54 
ATU-9 3-Br-C6H4 C17H11BrN2O3S 403.24 216-218 70 0.48 
ATU-10 2-OH-C6H4 C17H12N2O4S 340.35 210-212 72 0.49 
 
TLC Solvent system: Ethyl acetate : Hexane – 3.5:6.5 
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5.8 Spectral discussion 
 
 
5.8.1  Mass spectral study 
Instrument                : SHIMADZU GCMS-QP-2010 
Sample technique    : EI technique 
M/z range                  : 40-500 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection 
Probe technique. No specific fragmentation pattern was observed in mass spectral analysis 
but molecular ion peak was observed in agreement with molecular weight of respective 
compound. In mass spectra a peak of 2,4-chromane dione was observed at 163. 
 
5.8.2  IR spectral study 
Instrument                 : Shimadzu FT-IR-8400 
Sample technique     : KBr pellet 
Frequency range       : 400-4000cm-1 
As per IR spectral study of newly synthesized compounds (ATU 1-10), the stretching 
vibration of secondary amine (>NH) was appeared around 3500-3600 cm-1. The C=O 
stretching vibration of carbonyl group of chromene ring was observed around 1680-1690 cm-
1. The C=S stretching vibration was also observed at near about 1720 cm-1. The aromatic ring 
skeleton vibration was observed between 1500 to 1600 cm-1.  
 
5.8.3  1H NMR spectral study 
Instrument                  : BRUKER AC 400 MHz FT-NMR 
Internal reference       : TMS 
Solvent                        : CDCl3 
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Number of protons and their chemical shifts were found to support the structure of the 
synthesized compounds. Protons of benzenoid part of chromene ring ‘a’ were observed 
between 7.6 to 8.1 δ ppm. Protons of phenyl ring ‘b’ were observed at 7.00-7.40 δ ppm. Two 
methine protons ‘c’ and ‘d’ were observed as a double doublet in very downfield between 9 
to 10 δ ppm with higher value of coupling constant. Proton of secondary amine ‘e’ was 
observed at 13.4 δ ppm.  
 
5.8.4  Elemental Analysis 
 
Elemental analysis of the all the synthesized compounds was carried out on Elemental Vario 
EL III Carlo Erba 1108 model and the results are in agreements with the structures assigned. 
 
Spectral data of synthesized compounds (ATU 1-10) 
 
3-(1-phenyl-4-thioxo-1,3-diazetidin-2-yl)-2H-chromene-2,4(3H)-dione (ATU-1) 
Yellow solid; mp 230-232 ˚C;  
IR (KBr): 3614, 3581, 1724, 1681, 1662, 1510, 1444, 1390, 1220, 1107, 721 cm-1; 1H NMR 
(400 MHz, DMSO): δ ppm = 7.24-7.43 (m, 5H, Ar), 7.61-8.09 (m, 4H, Ar(Coum)), 9.68-9.86 
(dd, J = 12.8, 12.1 Hz, 1H, CH), 11.99-12.23 (dd, J = 12.6, 28.0 Hz, 1H, CH), 13.42 (s, 1H, 
NH); MS: m/z = 324 (M+); Anal. Calcd for C17H12N2O3S: C, 62.95; H, 3.73; N, 8.64. Found: 
C, 62.83; H, 3.69; N, 8.55. 
 
3-[1-(4-methoxyphenyl)-4-thioxo-1,3-diazetidin-2-yl]-2H-chromene-2,4(3H)-dione 
(ATU-2) 
Yellow solid; mp 206-208 ˚C; 
IR (KBr): 3536, 2988, 1719, 1690, 1545, 1378, 1109, 714 cm-1; MS: m/z = 354 (M+); Anal. 
Calcd for C18H14N2O4S: C, 61.01; H, 3.98; N, 7.90. Found: C, 60.89; H, 3.91; N, 7.96. 
 
3-[1-(2,4-dimethylphenyl)-4-thioxo-1,3-diazetidin-2-yl]-2H-chromene-2,4(3H)-dione 
(ATU-3) 
Yellow solid; mp 218-220 ˚C; 
IR (KBr): 3535, 2916, 1718, 1687, 1452, 1384, 1219, 1107, 518 cm-1; 1H NMR (400 MHz, 
DMSO): δ ppm = 2.22 (s, 3H, CH3), 2.34 (s, 3H, CH3), 7.05-7.35 (m, 3H, Ar), 7.65-8.07 (m, 
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4H, Ar(Coum)), 9.65-9.83 (dd, J = 12.9, 12.2 Hz, 1H, CH), 11.57-12.26 (dd, J = 13.0, 35.8 Hz, 
1H, CH), 13.45 (s, 1H, NH); MS: m/z = 352 (M+); Anal. Calcd for C19H16N2O3S: C, 64.76; 
H, 4.58; N, 7.95. Found: C, 64.61; H, 4.45; N, 7.78. 
 
3-[1-(2,5-dimethylphenyl)-4-thioxo-1,3-diazetidin-2-yl]-2H-chromene-2,4(3H)-dione  (ATU-
4) 
Yellow solid; mp 210-212 ˚C; 
IR (KBr): 3581, 3018, 2984, 1706, 1681, 1654, 1527, 1460, 1384, 1217, 817 cm-1; 1H NMR 
(400 MHz, DMSO): δ ppm = 2.23 (s, 3H, CH3), 2.34 (s, 3H, CH3), 7.14-7.35 (m, 3H, Ar), 
7.67-8.06 (m, 4H, Ar(Coum)), 9.62-9.81 (dd, J = 12.8, 12.2 Hz, 1H, CH), 11.64-11.73 (dd, J = 
12.8, 37.1 Hz, 1H, CH), 13.43 (s, 1H, NH); MS: m/z = 352 (M+); Anal. Calcd for 
C19H16N2O3S: C, 64.76; H, 4.58; N, 7.95. Found: C, 64.63; H, 4.49; N, 7.88. 
 
3-[1-(3-chlorophenyl)-4-thioxo-1,3-diazetidin-2-yl]-2H-chromene-2,4(3H)-dione (ATU-
5) 
Yellow solid; mp 217-219 ˚C; 
IR (KBr): 3511, 1724, 1684, 1618, 1507, 1110, 687 cm-1; MS: m/z = 358 (M+); Anal. Calcd 
for C17H11ClN2O3S: C, 56.91; H, 3.09; N, 7.81. Found: C, 56.76; H, 3.01; N, 7.84. 
 
3-[1-(4-chlorophenyl)-4-thioxo-1,3-diazetidin-2-yl]-2H-chromene-2,4(3H)-dione  (ATU-
6) 
Yellow solid; mp 224-226 ˚C; 
IR (KBr): 3504, 1718, 1678, 1554, 1221, 821 cm-1; MS: m/z = 358 (M+); Anal. Calcd for 
C17H11ClN2O3S: C, 56.91; H, 3.09; N, 7.81. Found: C, 56.68; H, 2.87; N, 7.72. 
 
3-[1-(3-nitrophenyl)-4-thioxo-1,3-diazetidin-2-yl]-2H-chromene-2,4(3H)-dione (ATU-7) 
Yellow solid; mp 223-225 ˚C; 
IR (KBr): 3548, 3011, 1715, 1688, 1569, 1107, 796 cm-1; MS: m/z = 369 (M+); Anal. Calcd 
for C17H11N3O5S: C, 55.28; H, 3.00; N, 11.38. Found: C, 55.18; H, 2.87; N, 11.25. 
 
3-[1-(4-methylphenyl)-4-thioxo-1,3-diazetidin-2-yl]-2H-chromene-2,4(3H)-dione (ATU-
8) 
Yellow solid; mp 214-216 ˚C; 
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IR (KBr): 3528, 2967, 1701, 1678, 1377, 1221, 814 cm-1; MS: m/z = 338 (M+); Anal. Calcd 
for C18H14N2O3S: C, 63.89; H, 4.17; N, 8.28. Found: C, 63.74; H, 4.01; N, 8.14. 
 
3-[1-(3-bromophenyl)-4-thioxo-1,3-diazetidin-2-yl]-2H-chromene-2,4(3H)-dione  (ATU-
9) 
Yellow solid; mp 216-218 ˚C; 
IR (KBr): 3514, 1729, 1690, 1648, 1534, 1121, 678 cm-1; MS: m/z = 403 (M+); Anal. Calcd 
for C17H11BrN2O3S: C, 50.63; H, 2.75; N, 6.95. Found: C, 50.47; H, 2.58; N, 6.74. 
 
3-[1-(2-hydroxyphenyl)-4-thioxo-1,3-diazetidin-2-yl]-2H-chromene-2,4(3H)-dione 
(ATU-10) 
Yellow solid; mp 210-212 ˚C; 
IR (KBr): 3598, 3536, 1721, 1691, 1545, 1302, 1108 cm-1; MS: m/z = 340 (M+); Anal. 
Calcd for C17H12N2O4S: C, 59.99; H, 3.55; N, 8.23. Found: C C, 59.81; H, 3.34; N, 8.10. 
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Mass Spectrum of ATU-1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass Spectrum of ATU-2 
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Mass Spectrum of ATU-4 
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1H NMR Spectrum of ATU-1 
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1H NMR Spectrum of ATU-4 
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1H NMR Spectrum of ATU-3 
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IR Spectrum of ATU-1 
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IR Spectrum of ATU-3 
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IR Spectrum of ATU-4 
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6.1 Introduction 
 
The systematic IUPAC name benzo[c]pyrazole is not used in the Ring Index or in Chemical 
Abstract and the heterocycle is normally referred to by its trivial name indazole or more 
correctly 1H-indazole (CAS registry number 271-244-3). Alternative names for indazole such 
as 1,2-benzodiazole, are not used. Benzo-fused derivatives are known as benzoindazoles. The 
first indazoles were synthesized in 1880,1 and a systematic investigation of the heterocycle 
was performed by V. Auwers in 1924.2 Indeed, general synthetic pathways to indazoles were 
developed in the early years of the 20th century and many recent publications describe 
improvements of known methods. Methods for the synthesis of indazoles are described in 
Houben-Weyl,3 and well-tested procedures for the synthesis of 1H-indazole,4-7 2-phenyl-2H-
indazole8 and 5-nitro-1H-indazole,9 can be found in Organic Synthesis. 
 
Natural products bearing an indazole structure are rare10 and at present only two examples are 
known: nigellicine11 and nigellidine.12 However, many synthetic indazoles are known, and a 
number are important because of their pharmaceutical activity; some act as dopamine 
antagonists, anti-inflammatory, analgesic, or antipyretic agents.13-41 Others also exhibit CNS 
activity,42-45 and 6- and 7-nitroindazoles are used to study the behavior of nitric oxide in 
vivo.46-50 1-Benzyl-1H-indazole-3-carboxilic acids have antispermatogenetic and anticancer 
activity,51-56 the latter effect being shared by other indazole derivatives.57-61 1-Benzoyl-1H-
indazoles behave as antiarthritic drugs,62 and 4-nitro- and 4-amino-2-ribofuranosyl-2H-
indazole 3',5'-cyclic monophosphates act as potent mimics of adenosine-3',5'-cyclic 
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monophosphates.63 Cortivazol64 is an indazole-based drug possessing glucocorticoid 
properties. Many indazoles act as enzyme inhibitors,65-70 and some also show specific 
virucide,71 bronchodilatory,72-74 vasodilatory,75 or neuroprotectant76 activities; others are used 
in the treatment of diabetes.77-79 3-Trifluoromethyl-1H-indazoles possess trichomonacide 
properties,80 and fused indazoles with an azasteroid ring system show antimicrobial 
activity.81,82 Some 1H-indazole-4,7-quinones possess anthelmintic83 and diuretic activity.84 A 
series of indazole derivatives exhibit herbicide activity, behave as growth inhibitors,85-89 or 
are used as bactericides and fungicides in polymer based paints.90,91 Guanidino-1H-indazoles 
are used as sweeteners.92,93 
 
Certain indazoles form violet to blue azo dyes,94-96 and arylazoindazoles are used as reagents 
for the determination of vanadium.97 Indazoles act as dyes in erasable drawing inks,98 and 
others form pigments.99 In addition, some are used in photographic materials,100 as fog 
inhibitors,101 in photographic layers,102,103 in photographic developers,104-107 in instant 
photographic processes,108-110 and for preparing recording sheets with migration 
imaging.111,112 Indazoles are also used with polyisocyanates in one-component adhesives.113 
They find application in complexones,114 in polyimide films,115 and as corrosion inhibitors.116 
Patents disclose the value of preparations containing indazole for sealing gold plated metals 
as electric connectors, see ref.117,118 
 
In older reviews119-121 the structural assignment of 1H- and 2H-isomers is described in great 
detail and more recent surveys122,123 contain much spectroscopic and physical data. Although 
1H-indazole (1) has two other potential tautomers 2H-indazole (2) and 3H-indazole (3) 
(Scheme 1), these only exist as substituted derivatives. Both in the solid phase and in 
solution, N-unsubstituted indazoles exist predominantly as the 1H-tautomers. The electronic 
spectra of 1H-indazole and 1-methyl-1H-indazole are nearly identical,124-126 but differ widely 
from the spectrum of 2-methyl-2H-indazole. The favored tautomers can also be ascertained 
with care (see below)from 1H NMR spectra,127-131 but these conclusions should be refined by 
using combined NMR data, such as those from the 13C and 15N NMR spectra of fixed 1-alkyl-
1H- and 2-alkyl-2H-derivatives.132-134 X-ray crystallographic studies of indazoles confirm the 
general preference for 1H-tautomers in the solid state,23,24,135-143 as do CNDO calculations.145 
The dominance of the tautomeric 1H form can also be shown from the KT-value of indazole 
itself (KT=40).144 Microwave spectra support these conclusions.146  
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Tautomeric equilibria between 1H- and 2H-indazoles has been investigated by photophysical 
and thermochemical techniques, as well as by calculations,147-149 the results indicate, for 
example, that 1-methyl-1H-indazole is 3.2-3.6 kcal more stable than 2-methyl-2H-indazole. 
1-Unsubstituted indazole shows a high degree of association as a dimer, whereas 1-
substituted derivatives are unassociated.150 2H-Indazoles with substituents at position 2 are 
obtained in many substitution reactions; however, 3H-indazoles are not obtained in this way 
and only a few examples are known,151 they lack heteroaromatic character and are not 
described further in this contribution. 
 
Indazoles are weak bases that form, for example, sodium and silver salts. Their pK values 
have been determined by electron and photoelectron spectroscopy (pK 1.01 and 1.31 for 1H-
indazole, 0.42 for 1-methyl-1 H-indazole). 2-Methyl-2H-indazole is a much stronger base 
(pK values for this compound range between 1.72 and 2.02).144,152-156 1H-Indazole also has 
weakly acidic properties (pK 13.8).157 A theoretical study of its acidity by INDO and AM1 
calculations has been undertaken.158 Indazoles undergo electrophilic substitution reactions 
mainly at C3; further reactive positions are C5 and C7. The N1 atom resembles that of 
pyrrole, but N2 has a pyridine-like lone pair of electrons, these are available for protonation 
and thus N2 is more basic than N1. The rate of N-alkylation is lower than that of pyrazole, 
but the quaternization of 2-methyl-2H-indazole is three times faster than that of 1-methyl-1H-
indazole.159 Alkylation either at N1 or at N2 is very sensitive towards steric effects caused by 
substituents at C3 and C7.152,160 The ratio of 1- to 2-alkylation in unsubstituted indazole is 
1:1, in 3-phenyl-1H-indazole 74:26, and in 7-nitro-1H-indazole 29:70.160 A number of 
methods have been applied for the calculation of ionization potential and electron affinity, 
charge distribution, basicity and total π-energy.145,161-163 Heat capacities, entropies, and 
thermodynamic parameters for phase transitions have all been summarized.164 
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Although many derivatives of indazole show biological activity, no special toxicity has been 
reported and no special handling precautions have been recommended. The biodegradability 
of indazole is included in an ecological survey of heterocyclic compounds.165 
 
6.2 Synthetic aspect 
 
A. Methods for the preparation of substituted 1H-indazole compounds 
1. Creation of a C-N bond 
Diazotation of an o-toluidine followed by capture of the generated diazonium salt is an old 
yet common way of accessing 1H-indazoles. This can be realized following two routes : the 
first and most common proceeds by a phase transfer-catalyzed reaction from o-methyl-
benzendiazonium tetrafluoroborates (method of Bartsch and Yang);166 the second takes place 
via N-nitroso derivatives (method of Kovach and Barnes).167 These two procedures are well 
illustrated in the following example168a (Scheme 1). Several other examples are provided in 
refs.168b-i 
 
Scheme 1 
A different protocol proceeding via the intermediacy of a diazonium ion has also been 
reported. Thus, in the course of the preparation of an 1H-indazolone compound acting as 
norepiephedrine/serotonin reuptake inhibitor for the treatment of fibromyalgia, the 
construction of the 1H-indazolone core structure of precursor 2 has been accomplished via 
the decomposition of a diazonium ion and capture of the resulting aryl cation by an ortho-
disposed hydrazide (Scheme 2).169 
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Scheme 2 
Reduction of a diazonium ion, or of a N-nitroso species, to the corresponding hydrazine and 
intramolecular reaction of the latter with an ortho-disposed carbonyl functionality is another 
way to reach 3-substituted-1Hindazoles. Following this protocol, 5-bromo and 5-methoxy-3-
carboxy-1H-indazoles 3 have been prepared from properly substituted isatines (Scheme 
3).170a 
 
Scheme 3 
Another example can be found in the work of Zhang et al.170b which, in the course of a study 
aimed at preparing bicyclic benzamides as novel 5-HT1F receptor agonists, have reported the 
preparation of 1H-indazole 4 (Scheme 4). It is worth noting that this example features an 
indole to indazole conversion171 and reduction of the diazo intermediate with SO2. 
References170c-e give additional examples. 
 
Scheme 4 
One common synthetic route to 1H-indazoles is the condensation of an arylketone, 
substituted in ortho by a leaving group (halogen, OMs), with hydrazine, followed by 
cyclization of the resulting hydrazone by simple heating or in the presence of a base. For 
example172, a short and convenient synthesis of the 3-(1-piperazinyl)-1H-indazole derivative 
 172
5 has been successfully achieved. Compound 5 was obtained in 67% overall yield without the 
need for chromatographic purification (Scheme 5). 
 
Scheme 5 
Success in such an approach is greatly dependent on the phenyl ring electron density. This 
was clearly demonstrated in the following examples.173a Thus, if the cyclization of 
tosylhydrazone intermediate 6, to give the corresponding 3-(1-piperazinyl)-1H-indazole 7, 
could be easily accomplished by heating in NMP at 120°C in the presence of K2CO3 (see 
also Scheme 5), the much more electron-rich hydrazone intermediate 8 failed to cyclize, even 
at higher temperature (up to 160°C). However, the use of a catalytic amount of CuI promotes 
cyclization at reflux of isopropanol and in excellent yield (Scheme 6). Another example of 
CuI promoted cyclization of an arylhydrazone under microwave irradiation to give 1-aryl-
1H-indazoles can be found in reference.173b 
 
Scheme 6 
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Based on the same strategy, the following example174 depicts a slightly different route to 3-
amino-1Hindazoles (Scheme 7). Three other examples of preparation of 3-amino-1H-
indazoles can be found in references175; references176 give additional examples of preparation 
of differently substituted 1H-indazoles. 
 
Scheme 7 
A regioselective one-step procedure to reach 1-alkyl and 1-phenyl-1H-indazoles has been 
recently reported based on the CuO-catalyzed reaction of N-methylhydrazine with 2-
haloalkyl- or 2-halophenylketones.177 Reactions were conducted in a sealed tube at 110°C 
and were interpreted as an Ullmann-type amination followed by cyclization. The same 
protocol could also be applied to 2-haloarylcarboxylic acids to give 1-methyl-3-hydroxy-1H-
indazoles, although in quite lower yields. The reaction was also carried out with 2-
fluorophenylmethylketone and differently substituted 1-hydrazines (R3NH-NH2, R3 = t-Bu, 
Ph, CH2-CH2OH) to give differently 1-substituted-3-methyl-1H-indazoles in low to fair 
yields (Scheme 8). 
 
Scheme 8 
Several examples of preparation of 1-aryl-1H-indazoles via an intramolecular Pd-catalyzed 
amination reaction of tosylhydrazones have been reported. A recent example due to Inamoto 
et al.178 is depicted in scheme 9. 
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Scheme 9 
In the case of tosylhydrazone 13, the catalyst system that gave good results in the precedent 
example induced the formation of 1H-indazole 14 in only poor yield. Instead, extensive 
degradation of tosylhydrazone 13 was observed, even at room temperature. After having 
tested several other conditions, it was finally discovered that the use of LiHMDS or K3PO4 as 
a base allowed the cyclization to proceed at room temperature in fair yield (45-50%). 
Indazole 14 was then N-deprotected to give 15, the transformation of which to the natural 
alkaloid nigelline 16 could be achieved in two steps (Scheme 10). Other examples of 
palladium-induced formation of 1-aryl-1H-indazoles are listed in references.179 
 
Scheme 10 
Recently, Yamamoto et al.180 reported efficient procedure for synthesizing N-unsubstituted 
and 1-arylated-1H-indazoles via a [3+2] dipolar cycloaddition between arynes and 
diazomethane derivatives. Thus, treatment of o-TMS-phenyltriflate, as a benzyne precursor, 
and ethyldiazoacetate in THF at rt, in the presence of KF and a crown ether, afforded 3-
ethoxycarbonyl-1H-indazole 17 in 80% yield. Substitution of the phenyl ring and use of 
several other diazo compounds (R-CH2N2 with R = t-BuO2C, TMS, Ph) proved compatible 
with the reaction. In contrast, when o-TMS-phenyltriflate (2 equiv) was treated with 
ethyldiazoacetate in acetonitrile at rt in the presence of CsF in excess, 1-phenyl-3-
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ethoxycarbonyl-1H-indazole 18 was isolated in 79% yield (Scheme 11). Of course, 
compound 18 arised from arylation of intermediate 17 by the excess of o-TMS-phenyltriflate 
(→benzyne) in the medium. Variations in the structure of both cycloaddition reaction 
partners are possible. 
 
 
 
Scheme 11 
Almost at the same time, Larock and coll.181 reported a more exhaustive study on similar 
work. The [3+2] dipolar cycloaddition between ethyldiazoacetate (1.5 equiv) and o-TMS-
phenyl triflate (1 equiv) was accomplished in the presence of TBAF (1.2 equiv) as a fluoride 
source in THF at low temperature. In these conditions, 3-ethoxycarbonyl-1H-indazole 17 was 
formed in up to 85% yield along with small quantities (less than 5%) of 1-phenyl-3-
ethoxycarbonyl-1H-indazole 18 (Scheme 12). Subsequent exploration of the scope and 
limitations of the reaction demonstrated that, by applying the same experimental conditions 
as above, a variety of benzyne precursors and monosubstituted diazomethane derivatives 
allowed the preparation of substituted 1Hindazoles in fair to good yields. Using an excess of 
benzyne precursor (2.4 equiv) led to 1-aryl substituted 1Hindazole compounds by capture of 
the excess aryne at nitrogen N1. 
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Scheme 12 
In a second part of their work, and following the pioneering work of Shechter and coll.182, 
Larock and coll. Focused on the reaction of arynes with diazo substrates that do not have 
hydrogen on the diazo carbon. Thus, reaction of benzyne (from o-TMS-phenyl triflate) with 
diazo compounds having two carbonyl groups attached to the diazo carbon led quite 
generally to the product arising from [3+2] cycloaddition and 1,3-migration (carbon C3 to 
nitrogen N1) in good yield. When only one ester group was branched at the diazo carbon, the 
reaction led mainly, if not exclusively, to the product of cycloaddition. In contrast, when a 
ketone rather than an ester was attached at the diazo carbon, the product of cycloaddition-acyl 
migration was solely formed. Examples are shown in Scheme 13. 
 
Scheme 13 
In the course of a work aimed at discovering novel antiplatelet agents derived from 1-benzyl-
3-(5’-hydroxymethyl-2’-furyl) indazole, Lee et al.183 reported an unusual synthesis of the 1H-
indazole derivative 23 from a diaryketone. This ketone was first treated with benzylhydrazine 
to give the corresponding hydrazones (E+Z mixture). The latter mixture was then, under the 
action of lead tetraacetate, transformed to an azo compound intermediate which was 
subsequently cyclized to the desired 1H-indazole under Lewis acid activation (Scheme 14). 
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Scheme 14 
In all above examples the 1H-indazoles were prepared from a substituted phenyl precursor. In 
relation with the search for novel compounds with anti-angiogenic activity, a recent paper184 
reported the preparation of 3-aryl-1H-indazoles by aromatization of 4,5,6,7-tetrahydro-1H-
indazoles (Scheme 15). 
 
Scheme 15 
2. Creation of the N1-N2 bond 
Not surprisingly, the methods of preparation of substituted 1H-indazoles via the formation of 
the N1-N2 bond are scarce in comparison to the methods that create a C-N bond. Few 
examples have been recently reported. In order to evaluate a series of 3,5-diamino-1H-
indazoles as cyclin-dependent kinases (CDKs) inhibitors, Lee et al.185 prepared the key 
intermediate 1H-indazole 25 from 2-amino-5-nitro-benzonitrile. Their approach features the 
transformation of the starting benzonitrile into a N-hydroxylamidine followed by its 
transformation to the target 1H-indazole via the formation of a 1,2,4-oxadiazole intermediate 
(Scheme 16). 
 
Scheme 16 
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A protocol for the synthesis of 1H-indazoles from o-aminobenzoximes with creation of the 
N-N bond has been reported by Canceller et al.186 It features the selective activation of the 
oxime group by reaction with a slight excess of methanesulfonyl chloride followed by 
cyclization to the 1H-indazoles by exposure to triethylamine at rt (Scheme 17). A similar 
strategy to reach 1H-indazoles had been reported previously by Matassa et al.187 in a study 
directed at discovering potent and selective peptidoleukotriene antagonists, However, in the 
Matassa’s report (Scheme 18) the synthesis of 1H-indazole 29 was achieved following an 
indole to indazole conversion. In practice, indole 27, prepared in four steps from nitro-5-
indole, was first submitted to the action of singlet oxygen to give the C2-C3 double bond 
oxidation product 28. (E)-Oxime formation with concomitant removal of the formyl group, 
acetylation to give the corresponding oxime acetate then cyclization completed the synthesis 
of 1H-indazole 29. 
 
Scheme 17 
 
Scheme 18 
The synthesis of a series of 1H-indazol-3-ones with creation of the N-N bond has been 
achieved via the intramolecular trapping of an N-acylnitrenium intermediate by an ortho-
disposed amino group188. Starting from an o-aminobenzamide the N-acylnitrenium cation was 
best generated by action of the hypervalent iodine reagent PIFA in DCM at 0°C (Scheme 19). 
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Scheme 19 
B. Methods for the preparation of N-2 substituted 2H-indazole compounds 
1. Creation of a C-N bond 
The chemistry of 2H-indazoles has not been explored as well as the chemistry of 1H-
indazoles. However, the discovery that N-2 substituted 2H-indazole compounds may exhibit 
biological activities has generated recent interest in their simple and efficient preparation. 
A synthesis of 2-aryl-2H-indazoles via a palladium-mediated intramolecular amination 
reaction of N-aryl-N-(obromobenzyl)-hydrazines has been reported by Song and Yee.189 The 
best conditions to effect the transformation are heating in toluene at 90°C for 15h in the 
presence of Pd(OAc)2 (5 mol%), dppf (7.5 mol%), and t-BuONa (15 0 mol%). Yields were 
comprised in the 50 to 60% range. The catalytic system is equally effective for electron-rich 
and electron-deficient substituents on both phenyl rings. In a mechanistic point of view the 
formation of the sp2 C-N bond is followed by the spontaneous oxidation of the 
dihydroindazole intermediates to give the 2-aryl-2H-indazole products (Scheme 20). 
 
Scheme 20 
Molina et al.190 reported the preparation of 2,3-diamino-2H-indazoles by treatment of o-
azidobenzaldimines with tertiary phosphines followed by acidic hydrolysis. The reaction led 
first to the formation of 2H-indazole derivatives 33 whose subsequent hydrolysis furnished 
the 2,3-diamino-2H-indazoles 34. The transformation may be accounted for by an initial 
Staudinger reaction to give a reactive phosphazide intermediate 32 followed by a cyclization 
reaction or by the formation of a ketenimine through a 1,5 sigmatropic shift and subsequent 
ring closure (Scheme 21). 
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Scheme 21 
Starting from Baylis-Hillman adducts of cyclohexenone, a two-step procedure for the 
formation of N-Ph-2H-indazoles featuring DDQ oxidation of pyrazoles intermediates has 
been reported191 (Scheme 22). Moderate overall yields were obtained (c.a 35%). 
 
Scheme 22 
German scientists192 observed that several oxidation procedures, such as the Kornblum 
oxidation, applied to benzyl bromide 36, instead of giving the expected aldehyde, led in fact 
to the 2-phenyl-2H-indazole compound 37. In an other example, acidic hydrolysis of acetal 
38 failed to give the corresponding aldehyde but led instead to a mixture of 2-phenyl-2H-
indazole compound 39 and 2-phenyl-1H-indazol-3-one compound 40 (Scheme 23). 
 
Scheme 23 
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2. Creation of the N1-N2 bond 
A one-step synthesis of 3-alkoxy-2H-indazoles by heating o-nitrobenzylamines in a solution 
of 5% KOH in an alcoholic solvent has been reported by Kurth and coll.193a The starting 
amines were prepared from either o-nitrobenzylbromides or o-nitrobenzaldehydes in 
excellent yields. As shown in Scheme 24, an electron-withdrawing group in the starting o-
nitrobenzylamine has a beneficial influence on the reaction productivity. Several other 
alcohols may be employed instead of methanol. A mechanism has been proposed to account 
for these transformations.193b This synthetic strategy was subsequently applied to generate a 
library of 2-alkyl-3-alkoxy-2H-indazole-6-carboxamides (200 compounds).193c 
 
Scheme 24 
Akazome et al.194 reported the palladium-catalyzed intramolecular reductive N-
heterocyclization of (2-nitrobenzylidene) amines to give the corresponding 2H-indazole 
products in 48-75% isolated yields. Reactions were conducted in a stainless reactor at 100°C 
for 16h under 20 kg cm-2 of initial CO pressure and in the presence of a PdCl2(PPh3)2 (5 
mol%)-SnCl2 (50 mol%) system. Some examples are shown in Scheme 25. 
 
Scheme 25 
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On the basis of experimental observations and deuterium labelling experiments, a mechanism 
involving the formation of a nitrene, intermediate, strongly coordinated to the metal, was 
postulated (Scheme 26). 
 
Scheme 26 
A series of 3-cyano-2H-indazole N1-oxides has been synthesized in order to evaluate the 
trypanocidal and leishmanocidal activities of each derivative195. Following the route shown in 
Scheme 27, o-nitrobenzaldehyde was first transformed, via a Schiff base, to an α-aminonitrile 
derivative which was next cyclized to a 3-cyano-2H-indazole N1-oxide by treatment with a 
base (Et3N or NaHCO3). 
 
Scheme 27 
Nyerges et al.196 reported the synthesis of 2H-indazole-N1-oxides via a 1,7-electrocyclization 
reaction of azomethine ylides onto a nitro group. Thus, o-nitrobenzaldehyde reacted with 
sarcosine to generate, following a decarboxylative condensation process, an unstabilized 
azomethine ylide. The latter reacted with the nitro group to give, by way of a 1,7-
electrocyclization, an oxadiazepine intermediate, which then undergoes a ring contraction to 
ultimately give the 2H-indazole-N1-oxides 41 in modest yield. The formaldehyde formed 
during the contraction step is trapped by the excess of sarcosine to give an azomethine ylide, 
which, by reaction with the starting o-nitrobenzaldehyde, led to an oxazolidine by-product 
42. Reduction of 2H-indazole-N1-oxide 41 (R1,R2 = H) led to the corresponding 2H-indazole 
(Scheme 28). 
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Scheme 28 
 
 
6.3 Biological Profile 
 
 
Wolf A. D. et. al.197 reported the compounds of formula (1) as useful for the selective 
preemergence control of undesired vegetation e.g., barnyard grass, in crops such as rice, in 
particular paddy rice, wheat, and peanuts. These compounds also have utility for the post 
emergence control of weeds in certain crops, for example, rice. Furthermore, compounds of 
this invention can be used as directed treatments for the pre- or post-emergence control of 
weeds in various crops including soybeans, peanuts, cotton, garden beans and row planted 
rice. 
 
N
N
R
R1
n
n = 1,2,3
R = fluorine, chlorine, bromine or iodine
R1= fluorine, chlorine, bromine, iodine, cyano, methoxy or nitro
(1)
 
 
 
Metz, S. et. al.198 described fused pyrazolo compounds (2) for the treatment of inflammation, 
while Bauer, V. J. et. al.199 described new fused bicyclic aminopyrazoles  (3) and their 
physiologically acceptable salts possessing anti-inflammatory and analgesis properties. 
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A
NN NH2
O
H
N
A = O, NH, NCOCH3, NSO2CH3
R = o-Cl-Pyridine, o-Cl-Ph
OO
O
R
(2)  
 
 
m
n N
NR
NHR1
(3)
Where
R = H, alkyl of 1-4 carbon atoms, phenyl or
        halophenyl;
R1= alkyl of 1-4 carbon atoms, cycloalkyl of
        3-7 carbon atoms, phenyl or halophenyl;
m and n are 0 or 1.
 
 
 
Corbera A. and Esteve, S.A. et. al.200 had reported some tetrahydroindazole and fused 
pyrazole derivatives (4) having pharmacological activity towards the sigma receptor, and  
their use in particular for the treatment of psychosis or pain. 
 
 
         (4) 
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Peter J. Connolly et al201 demonstrated the synthesis of some tetrahydroindazole, 
tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds (5) and their 
use as HMG-COA reductase inhibitors. 
 
N
Y
N
Z
(CH2)p
R1
R2
R3 n
(5)
Where
R1, R2 = H, C1-C8 alkyl or aryl
R3 = H
Y   = C1-C8 alkyl or C1-C8 alkenyl
n,p = 0 to3
Z   =
O
O
OH
or
OHOH
OR
O  
 
 
Paolo Pevarello, and Menuela Villa, et. al.202 reported 4,5,6,7-tetrahydroindazole derivatives 
(6) as antitumor agents. 
 
 
N
N
R3
cR'
Rc
aR'
Ra
Ra R'a R1
R2
n
(X)
(6)  
 
Where doted line (X) is single or double bond 
 n = 0 or 1 
 R1, R2 = H, C1-C6 alkyl, C1-C6 alkoxy, amino, nitro, cyano or hydroxyl 
 R3 = O, S or NH 
 Ra, R’a, Rb, R’b, Rc, R’c = each independently H or branched C1-C6 alkyl chain 
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Zhang, T. et al203 described the synthesis of tetrahydroindole and tetrahydroindazole (7) and 
characterized their activities of inhibiting the growth of tumor cells and malignant cells, such 
as breast carcinoma, pulmonary carcinoma, cervical carcinoma, rectal carcinoma, prostatic 
carcinoma, hepatic carcinoma and leucocythaemia and the like cancer cells. 
 
N
X
R6
R5
R4
R3
OR2
(CH2)n
Y
Z
R11
R12
(7)
R7R8
 
 
Lagu, Bharat et. al.204 reported some tetrahydroindazole derivatives (8) as cannabinoid 
modulator, and a method for use in treating, ameliorating or preventing a cannabinoid 
receptor mediated syndrome, disorder or disease. 
 
N
N
X4R4
X1R1
X2R2
X3R3
R5X5
(8)  
 
Metz, S. et. al.205 had described fused pyrazolo systems (9) and methods for treating cancer, 
inflammation and inflammation-associated disorders, such as arthritis. 
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A
Z
Y
X
R4
R11
R3
R2
R12
R1
(9)  
 
Where A is (CH2)m-Q-(CH2)n, wherein each CH2 may be independently substituted with one 
or more substitution selected from the group consisting of: hydroxyl, halo, alkoxy, lower 
alkyl, amino, amino alkyl, alkenyl and alkynyl; B is a 5 or 6 membered heteroaryl, or aryl, 
optionally saturated, or optionally substituted with R1, R2, or R12; X is selected from the 
group consisting of: N, C, CH, CR3, S and O. 
 
Harada, H. et. al.206 had studied on structurally novel N-(1-benzyl-4-methylhexahydro-1H-
indazole-3-ca.rboxamide (10) as potent and selective 5-HT3 receptor antagonists. 
 
 
N
H
N
NH
O
N
N
CH2Ph
(10)
 
 
Masahiko Nagakura et.al.207 synthesized series of 1-aryl-4,5,6,7-tetrahydro-1H-indazole-5-
carboxylic acids and 2-aryl-4,5,6,7-tetrahydro-2H-indazole-5-carboxylic acids (11) and the 
anti-inflammatory activity was determined. In the carrageenan edema test, 1-aryl-4,5,6,7-
tetrahydro-1H-indazole-5-carboxylic acids exhibited fairly high anti-inflammatory activity. 
However, the 2-aryl isomer were far less active than the former. 
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N
N
HOOC
R1
N
N
HOOC
R1
(11)
R1= Aryl or Benzyl  
 
Loretta A. McQuaid et. al.208 investigated that substituted 5-Amino-4,5,6,7-
tetrahydroindazole (12) as s partial ergoline structures possessed dopaminergic activity. 
 
 
N
NH
H
NR
Where R = CH3, CH2CH3, CH2CH2CH3,
                  CH2Ph, CH2-2-Thienyl, CH2CH2SMe
(12)
 
 
 
Granisetron is an antiemetic agent to prevent the nausea and vomiting in conjunction with 
cancer chemotherapy or with radiation therapy, by blocking 5-HT3 receptors without effect 
on other receptors such as dopamine D2 receptor and 5-HT4 receptor. Chemical designation is 
endo-N-(9-methyl-9-azabicyclo [3.3.1] non-3-yl)-1-methyl-1H-indazole-3-carboxamide (13). 
 
N
N
O
NH
N
(13)  
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6.4 Current work   
 
 
Our group is involved in design, synthesis and biological screening of heterocyclic 
compounds. On conducting literature survey, it was found that tetrahydroindazole is not more 
explored though it has great importance in the field of medicinal chemistry. On the 
observation of medicinal importance of tetrahydroindazole, its derivatization is necessary.  
 
The 3-carboxamide derivatives of 1H- and 2H-indazole possess good medicinal values. We 
sought to develop some 3-carbohydrazide 4,5,6,7-tetrahydro-2H-indazole derivatives. As per 
mentioned in literature209, ethyl-2-oxo-2-(2-oxocyclohexyl)acetate was prepared by reacting 
cyclohexanone and diethyl oxalate with the help of sodium ethoxide in ethanol at 0-5 °C. 
Subsequent treatment of ethyl-2-oxo-2-(2-oxocyclohexyl)acetate with hydrazine hydrate in 
ethanol resulted into ethyl 4,5,6,7-tetrahydro-2H-indazole-3-carboxylate, while without 
solvent in excess hydrazine hydrate on reflux resulted into 4,5,6,7-tetrahydro-2H-indazole-3-
carbohydrazide as per shown in reaction scheme. The obtained hydrazide was condensed 
with various aldehydes to generate series of aryl methylene hydrazone derivatives. 
 
All newly synthesized compounds were characterized by IR, Mass, 1H NMR spectroscopy 
and elemental analysis. Reaction scheme is illustrated in section 6.5. The brief experimental 
methods are outlined in section 6.6. Physical data of all synthesized compounds is reported in 
section 6.7 and spectral data is discussed in section 6.8. The compounds synthesized with this 
modification at 3 position of 4,5,6,7-tetrahydro-2H-indazole skeleton are under investigation 
for their anti HIV activity. The anti viral screening of the synthesized compounds is under 
investigation. 
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6.5 Reaction Scheme 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O
Diethyl oxalate
NaOEt
O
O
O
O
NH2NH2
Reflux
H
N
NH2
O
NHN
R-CHO
EtOH
Reflux
H
N
N
O
NHN
R
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6.6 Experimental  
 
 
6.6.1 Ethyl 2-oxo-2-(2-oxocyclohexyl) acetate: 
To the stirred solution of sodium ethoxide (0.2 gram atom), a mixture of cyclohexanone (0.2 
mol) and diethyl oxalate (0.2 mol) was added drop wise below 5-10 ºC. Vigorous stirring is 
required to prevent complete solidification of the reaction mixture. When the addition is 
complete, the ice bath is retained for an hour, and then the mixture is stirred at room 
temperature for about six hours. The reaction mixture is then decomposed by the careful 
addition of cold dilute sulfuric acid solution. The ethyl 2-ketocyclohexylglyoxalate separates 
as heavy oil and is separated. It is sufficient pure for further reaction. Yield-60%. 
 
6.6.2 4,5,6,7-Tetrahydro-2H-indazole-3-carbohydrazide: 
Ethyl 2-oxo-2-(2-oxocyclohexyl) acetate is added into access 80% hydrazine hydrate and 
refluxed for 5 to 6 hours. The reaction mixture was allowed to cool at room temperature and 
the precipitate obtained was filtered, dried and recrystallized from ethanol. White crystals. 
Yield-65%. 
  
6.6.3 N’-arylmethylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide: 
Equimolar amount of 4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide and appropriate 
aldehyde were taken in absolute alcohol and added 2 drops of con. HCl as a catalyst. The 
reaction mixture was refluxed for 1 hour and allowed to cool at room temperature. The solid 
was filtered, dried and recrystallized from ethanol to give pure white to yellow crystals in 85-
90% yield.  
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6.7 Physical data  
 
 
 
 
 
 
Comp. R M.F. M.W. Yield % 
AH-1 
 
C15H16N4O 268.31 95 
AH-2 OCH3
 
C16H18N4O2 298.33 91 
AH-3 CH3
 
C16H18N4O 282.34 86 
AH-4 OCH3
OCH3
 
C17H20N4O3 328.36 85 
AH-5 
H3CO
OCH3  
C17H20N4O3 328.36 89 
AH-6 
Br
 
C15H15N4OBr 347.20 95 
AH-7 OH
 
C15H16N4O2 284.31 91 
AH (1-20)
H
N
N R
O
NHN
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AH-8 
HO
 
C15H16N4O2 284.31 85 
AH-9 N
 
C17H21N5O 311.38 85 
AH-10 
Cl
 
C15H15N4OCl 302.75 90 
AH-11 Cl
 
C15H15N4OCl 302.75 90 
AH-12 
Cl
 
C15H15N4OCl 302.75 90 
AH-13 F
 
C15H15N4OF 286.30 86 
AH-14 NO2
 
C15H15N5O3 313.31 80 
AH-15 
NO2
 
C15H15N5O3 313.31 80 
AH-16 
N
 
C14H15N5O 269.30 92 
AH-17 
O  
C13H14N4O2 258.27 88 
AH-18 
 
C19H18N4O 318.37 92 
AH-19 
OH
 
C15H16N4O2 284.31 93 
AH-20 
H3CO
 
C16H18N4O2 298.33 87 
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6.8 Spectral discussion 
 
 
6.8.1  Mass spectral study 
 
Instrument                : SHIMADZU GCMS-QP-2010 
Sample technique    : EI technique 
M/z range                  : 40-500 
Mass spectra were recorded on Shimadzu GC-MS-QP-2010 model using Direct Injection 
Probe technique. Systematic fragmentation pattern was observed in mass spectral analysis. 
Peaks for specific fragments were identified in each mass spectrum. Molecular ion peak was 
observed in agreement with molecular weight of respective compound. Three characteristic 
peak was observed in all mass spectrum due to specific fragmentation. First a much intense 
peak was observed at 165 due to the cleavage of N-NH single bond. Another very intense 
peak at 149 was shown due to the cleavage of single bond between C=O and NH group atom. 
A very low intense peak at 191 was also observed due to the removal of aryl ring. 
 
6.8.2  IR spectral study 
 
Instrument                 : Shimadzu FT-IR-8400 
Sample technique     : KBr pellet 
Frequency range       : 400-4000cm-1 
As per IR spectral study of newly synthesized 4,5,6,7-tetrahydro-2H-indazole derivatives, the 
stretching vibration of secondary amine (>NH) was appeared at around 3500-3600 cm-1. The 
carbonyl (>C=O) stretching vibration of amide group was observed around 1680 cm-1. The 
symmetric and asymmetric C-H stretching vibration of methylene group of cyclohexane rind 
system was observed between 2850-2990 cm-1 while C-H bending vibration of methylene 
group was appeared around 1450 cm-1. The ring skeleton vibration was observed between 
1500-1600 cm-1 due to the presence of phenyl ring system. 
6.8.3  1H NMR spectral study 
 
Instrument                  : BRUKER AC 400 MHz FT-NMR 
Internal reference       : TMS 
Solvent                        : CDCl3 
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Number of protons and their chemical shifts were found to support the proposed structure of 
the synthesized compounds. Methylene protons of cyclohexane ring ‘a’, ‘b’, ‘c’ and ‘d’ were 
observed between 1.7 to 2.9 δ ppm. Amide proton ‘f’ was observed at 10.7-11.00 δ ppm as a 
singlet, while cyclic NH protons ‘e’ was observed at very down field with 12.34-2.85 δ ppm 
value as singlet. The ethylenic proton ‘g’ was observed around the 8.3 to 8.8 δ ppm as singlet. 
The aromatic ring protons ‘h’ were observed between 6.8 to 7.80 δ ppm with splitting 
according to substitution on phenyl ring. 
 
6.8.4  Elemental Analysis 
 
Elemental analysis of the all the synthesized compounds was carried out on Elemental Vario 
EL III Carlo Erba 1108 model and the results are in agreements with the structures assigned. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H
N
N R
O
NHN
a
b
c
d
e
f
g
h
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Spectral data of synthesized compounds (AH 1-20) 
 
N’-phenylmethylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide (AH-1) 
White solid; mp 230-232 ˚C;  
IR (KBr): 3626, 3593, 2889, 2947, 2852, 1666, 1554, 1492, 1448, 1261, 709, 630 cm-1; 1H 
NMR (400 MHz, DMSO): δ ppm = 12.36 (S, 1H, NH), 10.78 (S, 1H, NH), 8.34 (s, 1H, 
=CH), 7.76-7.67 (m, 2H, Ar), 7.40-7.37 (m, 3H, Ar), 3.15-2.78 (m, 4H, CH2), 1.81-1.75 (m, 
4H, CH2); MS: m/z = 268 (M+); Anal. Calcd for C15H16N4O: C, 67.15; H, 6.01; N, 20.88. 
Found: C, 67.10; H, 6.12; N, 20.84. 
 
N'-(4-methoxyphenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide (AH-2) 
White solid; mp 216-218 ˚C; 
IR (KBr): 3628, 2989, 2966, 2943, 2033, 1905, 1680, 1627, 1605, 1508, 1460, 1251, 835 
cm-1; MS: m/z = 298 (M+); Anal. Calcd for C16H18N4O2: C, 64.41; H, 6.08; N, 18.78. Found: 
C, 64.58; H, 5.93; N, 18.56. 
 
N'-(4-methylphenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide (AH-
3) 
White solid; mp 208-210 ˚C; 
IR (KBr): 3628, 2941, 2864, 1681, 1529, 1498, 1452, 1246, 854 cm-1; 1H NMR (400 MHz, 
DMSO): δ ppm = 12.57 (S, 1H, NH), 10.85 (S, 1H, NH), 8.31 (s, 1H, =CH), 7.75-7.62 (m, 
2H, Ar), 7.20-7.18 (m, 2H, Ar), 2.97-2.77 (m, 2H, CH2), 2.66-2.58 (m, 2H, CH2), 2.37 (s, 3H, 
CH3), 1.80-1.74 (m, 4H, CH2); MS: m/z = 282 (M+); Anal. Calcd for : C, 68.06; H, 6.43; N, 
19.84. Found: C, 68.18; H, 6.50; N, 19.77. 
 
N'-(3,4-dimethoxyphenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide 
(AH-4) 
Yellow solid; mp 220-222 ˚C; 
IR (KBr): 3628, 2905, 2847, 1681, 1554, 1428, 1221, 836 cm-1; MS: m/z = 328 (M+); Anal. 
Calcd for C17H20N4O3: C, 62.18; H, 6.14; N, 17.06. Found: C, 62.38; H, 6.29; N, 17.01. 
 
N'-(2,5-dimethoxyphenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide 
(AH-5) 
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Pale-yellow solid; mp 212-214 ˚C; 
IR (KBr): 3650, 3128, 2991, 2883, 1664, 1545, 1508, 1492, 1427, 1255, 889 cm-1; 1H NMR 
(400 MHz, DMSO): δ ppm = 12.50 (S, 1H, NH), 10.60 (S, 1H, NH), 8.61 (s, 1H, =CH), 7.57 
(t, 1H, Ar), 6.90 (t, 2H, Ar), 3.83 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 2.80 (d, 2H, CH2), 2.65 
(t, 2H, CH2), 1.81-1.74 (m, 4H, CH2); MS: m/z = 328 (M+); Anal. Calcd for C17H20N4O3: C, 
62.18; H, 6.14; N, 17.06. Found: C, 62.31; H, 6.25; N, 17.02. 
 
N'-(3-bromophenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide (AH-6) 
White solid; mp 214-216 ˚C; 
IR (KBr): 3648, 2998, 2915, 1678, 1614, 1595, 1539, 1445 cm-1; MS: m/z = 346 (M+); 
Anal. Calcd for C15H15BrN4O: C, 51.89; H, 4.35; N, 16.14. Found: C, 51.92; H, 4.17; N, 
16.53. 
 
N'-(4-hydroxyphenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide (AH-
7) 
White solid; mp 219-220 ˚C; 
MS: m/z = 284 (M+); Anal. Calcd for Calcd for C15H16N4O2: C, 63.37; H, 5.67; N, 19.71. 
Found: C, 63.64; H, 5.45; N, 19.69. 
 
N'-(2-hydroxyphenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide (AH-
8) 
White solid; mp 226-228 ˚C; 
IR (KBr): 3614, 2978, 2949, 2853, 1678, 1660, 1549, 1428 cm-1; MS: m/z = 284 (M+); 
Anal. Calcd for C15H16N4O2: C, 63.37; H, 5.67; N, 19.71. Found: C, 63.58; H, 5.51; N, 
19.80. 
 
N'-[4-(dimethylamino)phenyl]methylene}-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide 
(AH-9) 
Yellowish-orange solid; mp 208-210 ˚C; 
IR (KBr): 3614, 2998, 2989, 2850, 2828, 1680, 1441 cm-1; MS: m/z = 311 (M+); Anal. 
Calcd for C17H21N5O: C, 65.57; H, 6.80; N, 22.49. Found: C, 65.68; H, 6.69; N, 22.67. 
N'-(3-chlorophenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide (AH-
10) 
Pale-yellow solid; mp 212-214 ˚C; 
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MS: m/z = 302 (M+); Anal. Calcd for C15H15ClN4O: C, 59.51; H, 4.99; N, 18.51. Found: C, 
59.35; H, 5.17; N, 18.19. 
 
N'-(4-chlorophenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide(AH-11) 
White solid; mp 225-226 ˚C; 
MS: m/z = 302 (M+); Anal. Calcd for C15H15ClN4O: C, 59.51; H, 4.99; N, 18.51. Found: C, 
59.39; H, 5.06; N, 18.27. 
 
N'-(2-chlorophenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide(AH-12) 
Pale-yellow solid; mp 216-218 ˚C; 
IR (KBr): 3656, 3545, 3014, 2978, 2914, 2856, 1678, 1505, 1428 cm-1; MS: m/z = 302 
(M+); Anal. Calcd for C15H15ClN4O: C, 59.51; H, 4.99; N, 18.51. Found: C, 59.42; H, 4.91; 
N, 18.40. 
 
N'-(4-fluorophenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide(AH-13) 
White solid; mp 226-228 ˚C; 
IR (KBr): 3626, 2947, 1629, 1506, 1413, 1228, 829 cm-1; MS: m/z = 286 (M+); Anal. Calcd 
for C15H15FN4O: C, 62.93; H, 5.28; N, 19.57. Found: C, 62.78; H, 5.39; N, 19.55. 
 
N'-(4-nitrophenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide(AH-14) 
Yellow solid; mp 217-218 ˚C; 
MS: m/z = 313 (M+); Anal. Calcd for C15H15N5O3: C, 57.50; H, 4.83; N, 22.35. Found: 
57.29; H, 4.74; N, 22.46. 
 
N'-(3-nitrophenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide (AH-15) 
Yellow solid; mp 204-206 ˚C; 
IR (KBr): 3619, 2914, 2855, 1645, 1515, 1496, 1447, 1221 cm-1; MS: m/z = 313 (M+); 
Anal. Calcd for C15H15N5O3: C, 57.50; H, 4.83; N, 22.35. Found: C, 57.40; H, 4.99; N, 
22.21. 
N'-pyridin-3-ylmethylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide (AH-16) 
White solid; mp 228-230 ˚C; 
IR (KBr): 3641, 2927, 2894, 1675, 1589, 1528, 1456, 1205 cm-1; 1H NMR (400 MHz, 
DMSO): δ ppm = 12.61 (S, 1H, NH), 11.24 (S, 1H, NH), 8.45 (s, 1H, =CH), 8.84 (d, 1H, 
Ar), 8.57-8.55 (m, 1H, Ar), 8.17 (d, 1H, Ar), 8.38-8.35 (m, 1H, Ar), 2.97-2.77 (m, 2H, CH2), 
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2.67-2.57 (m, 2H, CH2), 1.82-1.75 (m, 4H, CH2); MS: m/z = 269 (M+); Anal. Calcd for 
C14H15N5O: C, 62.44; H, 5.61; N, 26.01. Found: C, 62.54; H, 5.38; N, 25.88. 
 
N'-2-furylmethylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide (AH-17) 
White solid; mp 214-216 ˚C; 
IR (KBr): 3629, 2974, 2889, 1692, 1606, 1519, 1468, 1427, 1221 cm-1; MS: m/z = 258 
(M+); Anal. Calcd for C13H14N4O2: C, 60.45; H, 5.46; N, 21.69. Found: C, 60.36; H, 5.36; N, 
21.61. 
 
N'-1-naphthylmethylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide (AH-18) 
White solid; mp 227-228 ˚C; 
IR (KBr): 3626, 3593, 3028, 2978, 2912, 2852, 1668, 1554, 1492, 1448, 1282 cm-1; MS: 
m/z = 318 (M+); Anal. Calcd for C19H18N4O: C, 71.68; H, 5.70; N, 17.60. Found: C, 71.78; 
H, 5.46; N, 17.51. 
 
N'-(3-hydroxyphenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide (AH-
19) 
White solid; mp 215-216 ˚C; 
 MS: m/z = 284 (M+); Anal. Calcd for C15H16N4O2: C, 63.37; H, 5.67; N, 19.71. Found: C, 
63.22; H, 5.56; N, 19.61. 
 
N'-(2-methoxyphenyl)methylene-4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide (AH-
20) 
White solid; mp 223-224 ˚C; 
 MS: m/z = 298 (M+); Anal. Calcd for C16H18N4O2: C, 64.41; H, 6.08; N, 18.78. Found: C, 
64.32; H, 5.91; N, 18.66. 
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1H NMR spectrum of AH-16:  
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Mass spectrum of AH-1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass spectrum of AH-3: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N NH
H
N
N
O
N NH
H
N
N
O
 205
Mass spectrum of AH-4:  
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IR spectrum of AP-1 
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IR spectrum of AH-3 
40060080010001200140016001800200024002800320036004000
1/cm
0
10
20
30
40
50
60
70
80
90
100
%T
36
28
.2
2
30
57
.2
7
29
41
.5
4 2
86
4.
39
28
41
.2
4
8
23
53
.2
3
39
.7
3
16
81
.9
8
15
29
.6
0
14
98
.7
4
14
52
.4
5
14
35
.0
9
13
36
.7
1
12
46
.0
6
11
72
.7
6
85
4.
49
61
5.
31
52
0.
80
49
9.
58
47
6.
43
43
2.
07
AH-4me
 
IR spectrum of AH-5 
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IR spectrum of AH-13 
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Summary 
  
The work presented in the Thesis entitled “Synthesis and pharmacological properties of 
heterocyclic analogs” can be summarized as below. 
 
Chapter 1 covers the synthesis of novel dihydropyrimidine derivatives via three 
component Biginelli reaction between n-butyl acetoacetate, aromatic aldehydes and 
thiourea. Synthesized molecules have n-butyl carboxylic ester moiety at 5th position of 
DHPM skeleton. n-butyl acetoacetate was prepared from ethyl acetoacetate by 
transesterification with the help of n-butanol and sodium methoxide as a catalyst in 
toluene as a solvent. Components of the reaction, thus prepared, were reacted in ethanol 
using catalytic con. HCl to afford corresponding DHPMs. The same molecules were 
prepared using solvent free microwave irradiation technique under Fuller’s earth as a 
solid support. As a result of this green chemistry approach, the improvement in the 
reaction time, yield and work up procedure was achived. The spectral data is presented to 
support the structure of synthesized molecules. 
 
In chapter 2, bicyclic systems are synthesized from Biginelli dihydropyrimidine 
derivatives. DHPM skeleton is very important scaffold to synthesize variety of bicyclic 
systems. n-Butyl acetoacetate, synthesized as mentioned in chapter 1, was reacted with 
thiourea and various aromatic aldehydes. The DHPMs, thus synthesized, were reacted 
with mono chloroacetone to obtain fused bicyclic thiazolo-pyrimidine system. The 
thiazolo-pyrimidine derivatives thus synthesized were studied by IR, Mass, 1H NMR and 
13C NMR spectroscopy. 
 
Chapter 3 includes application of cyclic aliphatic ketones in the formation of spiro 
pyrano[3,2-c]chromene derivatives. Cyclopentanone, cyclohexanone and cycloheptanone 
were utilized as a cyclic ketone in one-pot three component reaction with 4-hydroxy 
coumarin and malononitrile in ethanol with morpholine as a catalyst to afford spiro 2-
amino-3-cyano pyrano[3,2-c]chromene derivatives. The synthesized compounds were 
characterized by IR, Mass, 1H NMR and 13C NMR spectroscopy. 
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In chapter 4 & 5, construction of 1,2-diazete and 1,3-diazetidine ring system at 3 position 
of 4-hydroxy coumarin is demonstrated. 3-(ethoxymethylene)-2H-chromene-2,4(3H)-
dione was prepared as per literature method which on subsequent treatment with 
hydrazine hydrate gives 4-hydroxy-2-oxo-2H-cromene-3-carbaldehyde. The prepared 
hydrazone was confirmed by mass and 1H NMR spectroscopy. Thus prepared hydrazone 
was condensed with various aromatic aldehydes to afford arylmethylenehydrazone. 
Afforded arylmethylene hydrazone underwent elctrocyclic reaction and constructed 1,2-
diazete ring system. When 3-(ethoxymethylene)-2H-chromene-2,4(3H)-dione was reacted 
with substituted phenyl thiourea, 1,3-diazetidine-2-thione ring was constructed at 3 
position of 4-hydroxy coumarin. The structural elucidation of all the synthesized 
compounds was carried out by IR, Mass and NMR spectral study. Spectral data are 
consistent with the proposed structures. 
 
Chapter 6 covers a brief literature survey on indazole system, their synthesis and 
biological profile. This chapter deals with the synthesis of N’-arylmethylene-4,5,6,7-
tetrahydro-2H-indazole-3-carbohydrazide derivatives. 4,5,6,7-Tetrahydro-2H-indazole-3-
carbohydrazide was synthesized in two step, starting from cyclohexanone and diethyl 
oxalate, subsequent treatment with hydrazine hydrate. A library of N’-arylmethylene-
4,5,6,7-tetrahydro-2H-indazole-3-carbohydrazide was generated by condensation of 
hydrazide and various aromatic aldehydes. The spectral characterizations of synthesized 
compounds are reported. 
 
All the synthesized compounds are sent for their antiviral screening and results are 
awaited. 
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